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hcm = hypertrophic cardiomyopathy
la = left atrium/atrial 
lge = late Gadolinium enhancement
lv = left ventricle/ventricular
lvot = left ventricular outflow tract
mvi e-wave = early diastolic mitral valve inflow peak velocity 
mvi a-wave = late diastolic mitral valve inflow peak velocity
mybpc3 = cardiac myosin binding protein C
nt-probnp = n-terminal pro brain natriuretic peptide
pvf s-wave = (peak) systolic pulmonary venous flow velocity
pvf d-wave = (peak) early diastolic pulmonary venous flow velocity
pvf a-wave = (peak) late diastolic pulmonary venous flow velocity
sam = systolic anterior motion of the mitral valve leaflet 
ssfp = steady state free precession 
scd = sudden cardiac death
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tdi ea = peak early diastolic myocardial velocity measured with tissue Doppler imaging
tpm1 = cardiac α-tropomyosin
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Pathophysiology and clinical management of hcm
pAthophysioloGy of hypertrophic cArdiomyopAthy
I n this section, a brief introduction into the molecular genetics and genetic screening of hypertrophic cardiomyopathy (hcm) will be provided, followed by the functional 
consequences of hcm mutations and histological characteristics. The next section of 
this chapter will focus on the clinical issues of hcm, involving diastolic dysfunction, 
microvascular obstruction, atrial fibrillation and therapeutic possibilities. 
(hcm) is primary a disorder of the myocardium, causing cardiac hypertrophy of the 
left ventricle (lv) in the absence of increased loading conditions such as systemic 
hypertension or aortic valve stenosis. In North America, hcm has an estimated 
prevalence of 0.10 to 0.40 percent when diagnosed by echocardiography if maximal lv 
wall thickness exceeds 15 mm in any segment.1, 2 hcm may occur sporadic, but family 
studies have shown that hcm can also occur as a familial disease with an autosomal 
dominant pattern of inheritance. The hypertrophy in hcm predominantly involves 
the interventricular septum in Caucasian populations, but involvement of apical lv 
segments is more frequent in japanese patients. Apical hcm tends to have a more benign 
clinical course.3 Symptoms in hcm may vary from late onset heart failure to sudden 
cardiac death (scd) at a young age. 
Molecular genetics 
In almost every cell in the human body, all genes are organized in twenty-two pairs 
of autosomal chromosomes and one pair of sex determining chromosomes (x and y). 
Therefore, all autosomal genes exist in pairs (alleles). A person either has two of the 
same alleles (homozygote) or two variants of an allele (heterozygote). from each parent, 
one randomly selected allele is transmitted onto the next generation, forming a new pair 
of alleles. If a mutation in one allele is expressed in the phenotype (the characteristics 
of an organism, e.g. hcm), than that specific allele is called dominant. If a mutation 
is required to be present in both alleles to be expressed in the phenotype, the allele is 
called recessive. As a consequence, a heterozygous parent who carries an autosomal 
dominant mutation (i,e. a hcm mutation) has a 50 percent chance of transmitting the 
mutation onto the next generation, who then also will express the phenotype.
   To date, more than 400 mutations in more than 13 genes that mainly encode for 
sarcomeric proteins have been identified in hcm patients.4-6 Previously, the development 
of hcm (penetrance) was thought to be gene specific, since a penetrance of almost 
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Pathophysiology and clinical management of hcm
100 percent has been described in β-myosin heavy chain (myh7) mutation carriers, 
developing severe hcm.7 Cardiac myosin binding protein C (mybpc3) mutation carriers 
usually develop hcm only after the forth decade of life or do not develop hcm at all 
(incomplete penetrance).8 Moreover, cardiac troponin T mutations (tnnt2) have been 
associated with increased risk for scd concomitant with only mild lv hypertrophy.9 
When hcm is caused by mutations in genes that encode for non-sarcomeric proteins, it 
often conjures with other cardiac abnormalities, see table 1.5 
 However, variable mutations in the same gene have shown to also considerably vary in 
survival rates.7, 9 for example, hcm patients with a Arg403Gln mutation in the myh7 gene 
have a life expectancy of 45 years, while hcm patients with a val606Met mutation in that 
same gene have a normal life expectancy in a Caucasian population.7 
   The variable expression of disease is thought to be not solely depend on the causal 
mutation, but also on variation in expression of genes other than those that harbour the 
mutation (modifying genes). 4, 10 functional variants of modifying genes, such as the 
angiotensin converting enzyme gene, endothelin-1 gene and tumor necrosis factor-α have 
been proposed as potential modulators of the hcm phenotype.11-13 
   In addition, environmental factors, such as participation in competitive sports, systemic 
hypertension and infectious agents, may also importantly affect the clinical course of hcm.14 
In rare occasions, intrafamilial differences observed in hcm have also been described to be 
caused by homozygosity of the causal mutation or the presence of two causal mutations in 
the same gene (double heterozygosity) or in different genes (compound heterozygosity). 
usually, this aggravates the phenotype.15-17
 
Genetic screening
The familial nature of hcm has raised an urge to screen first degree relatives of hcm patients 
for asymptomatic hcm or hcm mutation carriership without manifest hcm. To identify hcm 
mutation carriers, a causal mutation first has to be found in the proband (the patient in 
whom the disease is first diagnosed). It is intuitively thought that genetic screening for a 
causal mutation should involve all possible hcm mutations, which is feasible with recently 
developed chip-based genetic screening techniques. However, this method of screening is 
very cost-inefficient and has little clinically relevant yield.18 
   Therefore, first screening for mutations in genes that have the highest likelihood to 
harbour the causal mutation is highly advocated, but acquires accurate knowledge of the 
prevalence of causal mutations within the local population.19
18 |
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   In the Netherlands, mybpc3 mutations account for approximately 40 percent of all hcm 
mutation carriers, see table 1. of all mybpc3 mutations, the 2373insG founder mutation (a 
mutation that is passed on to many generations) is found in 25 percent of mybpc3 mutation 
carriers and has the highest prevalence in the northwestern part of the Netherlands.8 myh7 
mutations account for an additional 10 percent of familial hcm patients in the Netherlands. 
Therefore, in the Netherlands, genetic screening first involves the mybpc3 gene, followed by 
screening of the myh7 gene. When no mutation is found in those genes, tnnt2 and tpm1 are 
subsequently screened, followed by all other genes known to be related to hcm íf necessary. 
Although the yield of genetic screening has increased tremendously in the past decade, 
a causal mutation is still not found in 30-40 percent of hcm patients.19 Then, screening of 
family members for possible asymptomatic hcm patients or hcm mutation carriers without 
manifest hcm is confined to electrocardiography (ecg) and echocardiography.
Cardiological evaluation of family members of hcm patients
echocardiography is widely used to screen for asymptomatic hcm patients among family 
members of the proband. However, the evaluation of the incremental value of high 
resolution imaging techniques such as cardiac magnetic resonance imaging (cmr), has 
demonstrated that cmr was capable of diagnosing hcm in 6% of patients who did not 
demonstrate hcm on echocardiography.20 
   When ecg is used for screening purposes to detect hcm mutation carriership among 
family members without hypertrophy on echocardiography, the Romhilt-estes scoring 
system for lv hypertrophy with a total score >4 has been proposed to be diagnostic for 
hcm mutation carriership. However, this screening method has shown to have a sensitivity 
of 23 percent and specificity of 95 percent, yielding a positive predictive value 70 percent 
and negative predictive value of 79 percent. 21 When tissue Doppler imaging (tdi) with 
echocardiography is used in hcm mutation carriers with borderline hypertrophy, subtle 
systolic and diastolic dysfunction can be observed.22 Whether the dysfunction is the 
result of already increased lv wall thickness and mass or can be regarded as one of the 
first initial detectable changes in myocardial mechanics that triggers the development of 
hypertrophy, is unknown. Consequently, it still needs to be determined if these subtle 
functional abnormalities can also be found in hcm mutation carriers with normal wall 
thickness, since the abnormalities found by ecg or tdi echocardiography are insufficient to 
rule-in or rule-out hcm mutation carriership when wall thickness is still normal. 
   cmr may the imaging modality of choice to further investigate this issue, since it allows 
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not only static and dynamic assessment of cardiac morphology and function, but also 
high temporal resolution assessment of regional intramyocardial deformation (strain) 
throughout the entire cardiac cycle. The cmr techniques used for this purpose are called 
balanced segmented steady state free precession (ssfp) and cmr tissue tagging respectively 
and are demonstrated in figure 1.23, 24 
The importance of presymptomatic screening in hcm
Since the ultimate phenotype of hcm is the result of a complex interplay between 
causal mutations, modifying genes and environmental factors, close monitoring and 
early diagnosis of hcm patients and identification of patients at risk to develop hcm is 
important to enable timely initiation of therapy. Asymptomatic hcm patients among 
Figure 1. cmr imaging techniques used for morphological and functional assessment. A. end-diastolic 
lv short axis ssfp cine image. B. end-systolic lv short axis ssfp cine image. The clear delineation of 
endo- and epicardial border (solid and dotted lines) enables precise volume and mass calculation. C. 
end-diastolic lv short axis tissue tagging image. D. end-systolic lv short axis tissue tagging image. By 
tracking the myocardial deformation throughout the cardiac cycle with harmonic phase (harp) analysis, 
intramyocardial deformation(strain) analysis can be performed with cmr tissue tagging in any, but 
usually circumferential direction. lv= left ventricle. rv= right ventricle.
20 |
Chapter 1
family members may be diagnosed by echocardiography and/or cmr, but identification 
of those at risk to develop hcm poses a larger clinical challenge. This may be achieved 
by genetic screening and/or cardiological evaluation, as discussed in the previous 
sections.
   Although the benefit of presymptomatic screening with respect to prevention of scd 
and development of heart failure is well recognized, data on the effect of having a 
positive carrier status on the quality of life is limited. Preliminary results from a study 
addressing this issue in children with inheritable cardiovascular disease including hcm 
are reassuring, since no differences in well-being were found in this group compared to 
a representative sample of peers.25 
   After the initial diagnosis of hcm or hcm mutation carriership, cardiological follow-
up is necessary. However, the optimal time interval of follow-up of presymptomatic 
hcm mutation carriers is debatable, since large variability in penetrance of hcm 
exists. Currently, consensus advocates that in general, hcm mutation carriers without 
hypertrophy should undergo cardiological evaluation by ecg and echocardiography/
cmr annually or biennially.When hcm has become manifest, cardiological evaluation 
should also include ambulatory ecg motoring and exercise testing.
Consequences of hcm mutations on sarcomeric function and calcium cycling
As described previously, hcm mainly results from mutations in genes encoding for 
sarcomeric proteins. Therefore, the development of hypertrophy in hcm is believed 
to be a maladaptive mechanism to compensate for deprived sarcomeric function.4, 5 A 
mutation may induce sarcomeric dysfunction in two different manners: 1. the product 
of the mutated gene is incorporated into the cellular structure and serves as a ‘poison 
peptide’, negatively affecting normal function, 2. the product of the mutated gene is not 
incorporated in the cellular structure as it is degraded by the ubiquitin-proteasome system 
and causes ‘haplo-insufficiency’.26 This means that incorporation of the total amount of 
gene product transcripted from the normal allele is insufficient to maintain normal function 
of the cellular structure (i.e. the sarcomere).
   Data on the effects of hcm mutations on sarcomeric function are to some extent conflicting 
due the differences in experimental setup, but most studies report that mutated sarcomeres 
display increased calcium sensitivity and subsequent increased contractility at baseline 
states, but consequently decreased response to β-adrenergic stimulation and sarcomeric 
lengthening, suggesting an impaired frank-Starling mechanism.27, 28
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Figure 2. Calcium cycling in the cardiomyocyte. At diastasis, calcium is stored in the sarcoplasmatic reticulum 
and bound to calsequestrin. In response to calcium sparks, which are generated by the l-type calcium channel 
in the T-tubulus in response to an action potential, calcium is released from the sarcoplasmatic reticulum 
through channels in the ryanodine receptors. As a result, cytosolic calcium concentration increases, enabling 
actin-myosin interactions and subsequent contraction of the sarcomere. At the beginning of diastole, calcium 
re-uptake into the sarcoplasmatic reticulum from the cytosol occurs by the atp requiring calcium pump 
(serca2a) occurs, thereby lowering the cytosolic calcium concentration and restoring calcium contraction 
in the sarcoplasmatic reticulum. As a result actin-myosin interaction is hindered, resulting in relaxation 
of the sarcomere. In unphosphorylated state, phospholamban inhibits serca2a. When phospholamban is 
phosphorylated through mediation of calcium and/or in response to β-adrenergic signalling by cAMP-kinase, 
serca2a is desinhibited, resulting in increased re-uptake of calcium into the sarcoplasmatic reticulum and 
subsequent increased relaxation. In hcm, calcium cycling is impaired, causing increased diastolic and decreased 
systolic calcium concentrations and subsequent decreased relaxation and contraction. sr= sarcoplasmatic 
reticulum, pln=phospholamban, pi=inorganic phosphate 
   In addition, calcium cycling in the cardiomyocyte in hcm is also impaired due to 
reduced β-adrenergic signalling and alterations in other neurohumoral receptor pathways. 
Reduced phosphorylation of phospholamban, which in its unphosphorylated state blocks 
the atp-depended calcium transporter of the sarcoplasmatic reticulum (serca2a), reduces 
the amount of calcium uptake by the sarcoplasmatic reticulum during early diastole, see 
figure 2.4 As a result, diastolic cytosolic calcium concentration is relatively high, and 
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systolic cytosolic calcium concentration relatively low, since systolic cytosolic calcium 
concentration is governed by calcium release from the sarcoplasmatic reticulum by 
channels in the ryanodine receptor.
   The increased calcium sensitivity of the sarcomeres in hcm together with the increased 
diastolic cytosolic calcium concentration enables the calcium mediated actin-myosin 
interaction during diastole, resulting in impaired relaxation.29 Moreover, the increase in 
diastolic calcium concentration has been suggested to activate the calmodulin-calcineurin 
signalling pathway that stimulates the onset of a gene programme ultimately leading 
to cellular hypertrophy and formation of interstitial fibrosis and subsequent further 
deterioration of diastolic function.29, 30
   This is in line with the findings of a hcm mouse model study, in which α-cardiac myosin 
heavy chain transgenic mouse models display prolonged lv relaxation times, reduced 
-dp/dt and left atrial (la) dilation before the development of hypertrophy compared to 
their wildtype littermates.31 Also, systolic and early diastolic myocardial velocities were 
significantly reduced and la dimensions increased in β-myosin heavy chain transgenic 
rabbits with normal lv mass.31, 32 These findings evoke sarcomeric systolic, but more 
prominently diastolic dysfunction as the impetus to develop hypertrophy in hcm.
   In human hcm mutation carriers with borderline hypertrophy, both systolic and diastolic 
dysfunction have been detected by tdi as described previously.22 However, in contrast 
to the experimental data, no la dilation was found. This may be due to the limitations of 
echocardiography to depict the la (i.e. poor acoustic window) or due the inaccuracy of the 
method to calculate la volumes, which is based on geometrical assumptions. 33, 34 Apart 
from technical limitations, these data may suggest that the development of hcm in human 
may be principally different from hcm animal models. 
   With cmr, 3d la volume measurement is feasible, thereby merely omitting the use of 
geometrical assumptions to measure la volumes.35 Therefore, cmr may be employed to 
further investigate la volumes and function in hcm mutation carriers with normal lv wall 
thickness, but the intra- and interobserver variability of this 3d method should first be 
evaluated before used for research purposes.
Histopathological findings in hcm
Histologically, hcm is characterized by disorganization of myocardial architecture such 
as disarray of myofibers, intertwined hypertrophied myocytes with bizarre shaped nuclei 
and focal and/or widespread replacement and plexiforme fibrosis, see figure 3.36-38 The 
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disarray of myofibers – also called myocyte disarray- in hcm patients is believed to 
originate from the perturbed formation of the sarcomere, but mild forms of myocyte 
disarray can also be found at the insertion points of the right ventricular free wall into 
the septum in normal controls.39-41 In hcm patients, myocyte disarray is extensive and 
may completely disrupt the circular orientation of the myofibers in the midventricular 
wall. Also, myocyte disarray is not only confined to the insertion sites in hcm, but is also 
frequently present in other segments of the lv, including the mid portion of the septum 
and anterior and inferior wall. Interestingly, the lateral free lv wall usually remains devoid 
of myocyte disarray.40, 42, 43
   Also, thickening and narrowing of intramural coronary arteries due to proliferation of 
Figure 3. Pathological images of hcm. A. Macroscopic transverse section through a normal heart. The 
interventricular septum is indicated by the white asterisk. B. Macroscopic transverse section of hcm. Note 
that total mass of the heart is larger compared to the normal heart and that the interventricular septum is 
disproportionally hypertrophied, as indicated by the white asterisk. Also the lumen of both the left ventricle 
and the right ventricle are smaller in hcm. C. on a cellular level, ‘whorling’ of cardiomyocytes (grey areas) is 
considered one of the histological hallmarks of hcm (Hematoxylin and eosin staining, original magnification 
x400). D. On an ultra-structural level, disorganization and fragmentation of the myofibrils is represented by 
the y-shaped myofibrils. (electron microscopy image, original magnification x20.000). lv= left ventricle, rv= 
right ventricle (courtesy of j.W.M. Niessen).
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medial and/or intimal components - particularly smooth muscle cells and collagen - can 
be found in up to 83 percent of hcm patients.40 Therefore, hcm patients are more prone 
to develop myocardial ischemia.37, 44 Indeed, replacement fibrosis is closely related to 
presence of narrowed, but not occluded intramural coronary arteries.37
   on macroscopical level, malformation of the mitral valve apparatus including 
elongation and increased laxity of the mitral valve leaflets and direct insertion of the 
papillary muscle into anterior mitral valve leaflet have been described as characteristic 
pathological findings in hcm.45
CLINICAL MANAGeMeNT of HyPeRTRoPHIC CARDIoMyoPATHy
Diastolic dysfunction
As indicated previously, diastolic function is importantly impaired in hcm patients, which 
has been shown to be an independent determinant of limited exercise capacity.46 Whereas 
lv wall thickness is mainly increased in the septum, early diastolic circumferential strain 
rates measured with cmr tissue tagging are also decreased in the anterior, lateral and inferior 
segments.47, 48 In addition, early diastolic longitudinal myocardial velocities, measured 
with tdi echocardiography, are reduced in hcm patients in both the septum and lateral wall, 
also indicating more generalized lv diastolic dysfunction.49
   In clinical practice, there are several parameters that are widely used to assess diastolic 
function: 1. measurement of early diastolic longitudinal myocardial velocity (ea) with 
tdi, which is thought to be a relatively load-independent parameter of lv relaxation,47 2. 
assessment of the mitral valve inflow (mvi) pattern, from which an early diastolic (e-wave) 
and late diastolic (a-wave) wave pattern can be discriminated, and 3. assessment of the 
pulmonary venous flow (pvf) pattern, in which a systolic (s-wave), early diastolic (d-
wave) and late diastolic (a-wave) wave pattern can be discerned. Indeed, the ratio of the 
mvi e-wave peak velocity and the ea (e/ea) has shown to strongly correlate with invasively 
measured lv filling pressures.47 Nevertheless, the e/ea ratio alone does not have enough 
discriminative power to be used as a single parameter of diastolic function. Therefore, 
non-invasive evaluation of diastolic function is always performed in combination with the 
evaluation of la volumes, and other parameters of diastolic function, including the mvi and 
pvf patterns, see figure 4.50 
   The physiological background of the mvi and pvf wave patterns is the following: In brief, 
the physiological diastole starts at the end of systole with rapid sarcomeric relaxation 
and release of the potential elastic energy that is build up during systole, causing early 
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diastolic elastic recoil of the lv and lv pressure decline. When lv pressure is lower than 
in the la, rapid filling of the lv starts in early diastole, and is represented by the e-wave 
on the mvi pattern. The early diastolic filling of the lv also causes rapid passive decline 
of la volume. Since the compliance of the lv is higher than of the la, blood may flow 
directly from the pulmonary veins into the lv, merely using the la as a conduit. This is 
the underlying process that results in the d-wave of the pvf pattern. At the end of diastole, 
atrial contraction further facilitates filling the lv and is reflected by the a-wave on both 
the pvf and mvi patterns.50 The a-wave of the pvf pattern reciprocates the a-wave of mvi, 
reflecting the backflow of blood into the pulmonary veins. Consequently, the duration and 
peak velocity of the a-wave of the pvf pattern increases and duration and peak velocity the 
a-wave on the mvi pattern decreases when diastolic dysfunction progresses.
   Diastolic dysfunction can be classified into four grades of severity for clinical purposes, 
as proposed by ommen et al.50 The initial abnormality of diastolic function (grade I) is 
a decrease of early diastolic velocities by impaired relaxation, which is reflected by a 
decline of the ea-wave, the mvi e-wave and pvf d-wave peak velocities, see figure 4. Also, 
the deceleration time of the mvi e-wave increases. The reduction of lv filling in early 
diastole is compensated by an increase in diastolic filling by atrial contraction, probably 
due to increased la volumes prior to contraction, since a frank-Starling mechanism has 
also been observed in the la.51 This results in increased atrial contribution to lv filling, as 
reflected by a decrease in mvi e/a ratio, see figure 4.52 filling pressures in these patients are 
normal at rest, but tend to increase during exercise due to shortening of the filling time.50
   When diastolic dysfunction progresses (grade II), lv compliance also becomes impaired, 
causing significant increase of la and lv filling pressures throughout the entire diastole, 
see figure 4. The increased la pressure causes an increase (pseudonormalization) of the 
mvi e-wave and pvf d-wave peak velocities. The reduced compliance of the lv results in 
rapid equilibration of la and lv pressure, which causes a pseudo-normalization of the 
deceleration time of the mvi e-wave, but also in reduction, again pseudonormalization of the 
peak mvi a-wave velocity. The increase of la pressures at end-diastole additionally causes 
a reduction of la filling velocities as reflected by lower pvf s-wave velocities in grade II 
diastolic dysfunction. The lower pvf s-wave velocities, together with the increased e/ea 
ratio allow to discriminate grade II diastolic dysfunction from normal diastolic function. 
When lv filling pressures are reduced, i.e. by applying the Valsalva manoeuvre, the grade 
II regresses to the grade I, see figure 4. 
   In grade III diastolic dysfunction, lv filling pressures are further increased, causing 
26 |
Chapter 1
high mvi e-wave velocities and pvf-d-wave velocities, further shortening of the mvi e-
wave deceleration time by rapid equilibration of la and lv pressures and decreased 
contribution of la contraction to lv filling, a reflected by a very small mvi a-wave, but 
very large pvf a-wave (restrictive pattern). Also, ea-wave velocities increasingly reduce, 
causing an increase of e/ea ratio. The diastolic dysfunction in an individual patient may 
vary between grade I to III, depending of filling status. However, if diastolic dysfunction 
becomes irreversible (restrictive pattern), diastolic dysfunction is classified into grade IV, 
see figure 4.
   In addition, N-terminal probnp (nt-probnp) levels can be used as a marker of diastolic 
Figure 4. Schematic overview of progression of diastolic dysfunction (adapted from ommen).50
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function in hcm.53-55 Although nt-probnp is believed to be produced by both the lv and la 
in response to wall stress, conflicting data has been reported on whether la volume or 
lv mass is strongest determinant of nt-probnp.53-55 Also, no data is available on the role 
of nt-probnp in evaluating the effect of therapy on diastolic function in hcm patients, and 
warrants further research.
Microvascular dysfunction
Microvascular dysfunction in hcm patients is thought to be the net result of narrowing 
of the intramyocardial coronary arteries, myocyte disarray, decreased density of the 
arterioles and increased diastolic pressures.56, 57 Microvascular function is evaluated by 
measuring the response of myocardial blood flow to hyperaemia by adenosin infusion, i.e. 
with positron emission tomography. In hcm patients, the hyperaemic response to adenosin 
is severely blunted, which may predispose for exercise induced ischemia. Interestingly, 
microvascular dysfunction has greatest impact in the subendocardial layer of the lv and 
correlates well with nt-probnp and lv mass, indicating that intramyocardial as well as 
extramyocardial forces affect microvascular function in hcm.57, 58
   A long term follow-up study demonstrated that the degree of microvascular dysfunction 
is an independent predictor of clinical deterioration and death. Therefore, monitoring 
hyperaemic response may facilitate clinical decision making in the treatment of hcm 
patients.58
Atrial fibrillation
Atrial fibrillation (af) is the most common arrhythmia in hcm and symptomatic af occurs 
in 20-30 percent of hcm patients.59-62 Detection of af and identification of risk factors 
associated with af in hcm patients is important, since af is associated with increased 
risk of hcm related death (heart failure and stroke), functional impairment and thrombo-
embolism.63-70
   la dilation, advanced age and congestive heart failure have been shown to be independent 
predictors of the occurrence of af in hcm.71 Interestingly, in post mortem studies, hcm 
patients with af also displayed increased amounts of lv fibrosis, but the extent of lv 
hypertrophy was not related to af.68, 72 Since lv fibrosis may be expected to cause la 
dilation through diastolic dysfunction, this might explain why lv fibrosis in an important 
determinant of af, but this needs to be further investigated.73
   With cmr, fibrosis can be detected in vivo with late gadolinium enhancement (lge) imaging 
in hcm, see figure 5.74, 75 lge imaging is based on the principle that an inert extravascular 
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Gadolinium-based contrast agent increases the signal intensity of myocardium and resides 
longer in myocardium with increased extracellular space, i.e. due to myocardial infarction 
or fibrosis.75, 76 Therefore, it may be used to further evaluate the relation between fibrosis 
and af in hcm patients.
Left ventricular outflow tract obstruction
The hallmark of progressive hcm is obstruction of the lv outflow tract (lvot). lvot 
obstruction is caused by hypertrophy of the anteroseptal lv segment and its severity 
depends on the contractile state of that particular segment and filling status of the lv. 
Therefore, the lvot obstruction is dynamic and should be discriminated from the static 
lvot obstruction due to aortic stenosis. With auscultation, the dynamic obstruction results 
in a harsh, diamond shaped systolic murmur that starts well after S1 and typically increases 
with valsalva manoeuvre. The murmur is best heard at the apex, and may radiate to the 
lower sternal border and/or axillae.
   The lvot obstruction causes an intracavital pressure gradient which probably pulls the 
Figure 5. Late Gadolinium enhancement (lge) patterns in hypertrophic cardioymyopathy (hcm). Two 
different patterns of lge can be observed in hcm patients. A. The patchy pattern, describing bright spots 
of lge that are typically located at the insertion points of the right ventricle into the septum. B. The 
confluent pattern, which describes large areas of lge, as can be observed in the anterior wall of this 
patient. Note that in this patient, also patchy enhancement is present in the inferior insertion point of 
the right ventricle into the septum. lge is indicated by the white arrowheads.
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anterior mitral valve leaflet towards the septum by the Venturi effect, resulting in typically 
mild-to-moderate, eccentric mitral regurgitation due to incomplete leaflet coaptation. 
Although subjected to controversy for years, the likelihood of severe symptoms and scd 
related to lvot obstruction did not increase as the gradient increased above the threshold of 
30 mmHg.77 Therefore, when a pressure gradient over the lvot ≥ 30 mmHg is measured, 
the lvot is deemed to be obstructed. lvot obstruction at rest is present in approximately 
25-37 percent of hcm patients. When provoked by valsalva manoeuvre or physiological 
exercise, significant lvot obstruction can be diagnosed in an additional 33 percent of 
hcm patients, underscoring the dynamic nature of this phenomenon.78 of note, measuring 
a significant lvot gradient using dobutamine stress echocardiography has limited or no 
clinical implications.79, 80 Clinically, lvot obstruction may cause exertional dizziness and 
limited exercise tolerance by reducing blood pressure increase during exercise, which can 
at least partially be treated pharmacologically.
Pharmacological treatment of heart failure
Pharmacologic symptomatic relief in hcm may be achieved by administration of 
negative intotropes such as β-adrenergic receptor antagonists (i.e.propranol, atenolol and 
metoprolol), L-type calcium channel inhibitors (e.g. diltiazem and verapamil), and/or a type 
1a anti-arrhythmicum (disopyramide).81-83 In clinical practice, the β-adrenergic receptor 
antagonist and L-type calcium channel inhibitors are generally use as first line treatment. 
The beneficial effects of β-adrenergic receptor antagonists may probably be attributed to 
the decrease of heart rate and increase of diastolic filling time and reduction of myocardial 
oxygen demand, since β-adrenergic receptor antagonist have not been reported to cause 
significant lvot gradient reduction.84
   Although the L-type calcium channel inhibitors seem to be more effective that the β -
adrenergic antagonists in reducing the lvot obstruction, their vasodilator properties may 
also result in afterload reduction and subsequent paradoxal increase the lvot obstruction.83-
85 Severely symptomatic obstructive hcm patients are preferably treated with a combination 
of disopyramide and a β-adrenergic agent.82 
Invasive treatment of heart failure 
In obstructive hcm patients with severe limiting symptoms refractory to optimal 
pharmacologic treatment, invasive treatment strategies to relieve the lvot obstruction 
should be considered, such as surgical septal myectomy (Morrow procedure) or alcohol 
septal ablation (asa). Surgical septal myectomy has been an established treatment for over 
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forty years with long term survival rates comparable to patients with non-obstructive hcm 
(10-year survival of 79-85 percent).86-89 
   The procedure involves resection of a discrete proportion of hypertrophied muscle 
from the basal anteroseptum via a transthoracic approach. When appropriate, mitral valve 
apparatus repair and other additional cardiac surgery can be performed within the same 
session. 
   In asa, a small bolus of 1-3 cc of ethanol is infused into the first septal perforator 
branches of the left anterior descending coronary artery, distal from an occluded balloon 
catheter.90 As a result, myocardial infarction and subsequent thinning and akinesis of a 
discrete portion of the septum occurs. This causes immediate and long term relief of the 
dynamic lvot gradient, decrease of mitral valve regurgitation, and subsequently reduction 
of la size and improvement of symptoms.91 
   Although la size is important to monitor the effect of lvot obstruction, it is currently 
unknown to what extent reduction of mitral regurgitation, lv mass and/or diastolic 
dysfunction attribute to reduction of la volume.92 This would yield more insight in the 
salutary effects of lvot reduction and may help to further refine the treatment of hcm.
   As an alternative to septal myectomy and asa, dual-chamber pacing has shown to 
induce significant lvot gradient reduction by optimizing the atrio-ventricular conduction 
interval.93 However, in a randomized trail, no incremental symptomatic benefit from ddd-
pacing compared to placebo was observed. Therefore the effectiveness of this therapy is 
debatable, but should not be entirely regarded as an obsolete treatment for obstructive 
hcm.93 In a selective (elderly) obstructive hcm patient group, unsuitable for surgery and 
asa, ddd-pacing with dedicated optimization of atrio-ventricular intervals may still be of 
additional benefit.
Risk stratification and management of sudden cardiac death 
Apart from the development of heart failure, hcm patients are at increased risk for scd, 
especially the young and often asymptomatic hcm patients. Indeed, scd may be the first 
symptom of underlying disease.94-96 Although the incidence of scd among hcm patients 
is highest before the age of 35, it also occurs at advanced age. scd most often occurs 
during mild exercise or sedentary state (70 percent), but also during vigorous exercise (16 
percent).97 In athletes, hcm accounts for 9-36 percent of cases of scd, and has been related 
to development of ischemia, which may trigger the onset of potentially life threatening 
ventricular arrhythmias.37, 38, 95, 96
   Annual mortality rates of scd in general hcm population has been reported to be lower 
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than 1%, but clinical risk factors increasing the risk of scd have been identified, see 
table 2.77, 98-100 When hcm patients have ≥ 2 major risk factors, 6-year survival have been 
shown to be significantly decreased from 95±4% to 82±14% and justifies implantable 
cardioverter/defibrillator (icd) implantation.98
Interestingly, one cmr study in hcm patients reported that mean extent of lge was higher 
in hcm patients with ≥ 2 major risk factors for scd compared to hcm patients with ≤1 risk 
factor for scd.101 This relation may be explained by the association between the extent 
of lge and ventricular tachycardias, which likely fibrosis.102 Therefore, an increasing 
number of clinicians are inclined to consider the presence and extent of lge in their 
decision to implant an icd if ambiguity remains after assessment of conventional clinical 
risk factors.
   implantation of icd’s has proven to effectively terminate potentially life threatening 
ventricular arrhythmias when implanted for secondary and/or primary prevention in hcm 
patients.103 However, no specific major risk factor was associated with an increased risk of 
icd intervention. Based on retrospective data, it has also been proposed that hcm patients 
with a single risk factor of scd should have an icd implanted.104 However, the benefits 
of icd implantation should be netted against the risk of lead failure and inappropriate 
discharges, which have been reported in up to 25 percent of hcm patients with implanted 
icd´s. 
Table 2. Clinical risk factors for sudden cardiac death in hcm patients
major risk factors minor risk factors 
cardiac arrest (ventricular fibrillation) atrial fibrillation
family history of premature sudden death myocardial ischemia
spontaneous sustained vt lv outflow tract obstruction
non-sustained vt (Holter) high risk mutation
lv wall thickness ≥ 30mm intense (competitive) physical exertion
unexplained syncope
blunted response to exercise (pts ≤ 40 yrs)*
*=defined as <25 mmHg increase from baseline blood pressure. vt= ventricular tachycardia, lv= left 
ventricular
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Summary 
Since its first description by Teare in 1958, the clinical burden of hcm has been largely 
elucidated.105 Although genetic research in the past decades has enabled to detect patients 
at increased risk to develop manifest hcm, more diagnostic tools are necessary for early 
identification of the disease. The presymptomatic diagnosis of disease allows to study 
the morphological and pathophysiological cardiac alterations in hcm mutation carriers 
that ultimately lead to manifest hcm. This would enable to develop treatment strategies 
that may delay or completely prevent the development of manifest hcm. 
outline of thesis
▪ The second chapter of this thesis discusses the potential of the cmr tissue tagging 
technique to quantify regional deformation of myocardium throughout the cardiac 
cycle and reviews the clinical application of this technique.
▪ In the third chapter, the emerging role of cmr in determining the aetiology of non-
ischemic cardiomyopathies is reviewed, specially focussing on the use of ssfp cine 
imaging and lge imaging for this purpose.
▪ In the forth chapter, the effect of normal ageing on left atrio-ventricular coupling 
is evaluated using 3d la volumes and function measurement. The accuracy of this 
technique is validated against other techniques to measure la volumes.
▪  In the fifth chapter, the morphology of hcm mutation carriers without lv hypertrophy 
is evaluated with cmr ssfp cine imaging and compared with the morphological findings 
by echocardiography. Subsequently, the importance of using high resolution imaging 
techniques for assessing cardiac morphology is discussed in a letter.
▪ The sixth chapter concerns the evaluation of regional systolic and diastolic function 
in hcm mutation carriers with normal lv wall thickness. for this purpose, cmr tissue 
tagging was used.
▪ In the seventh chapter, the effects of lvot obstruction reduction on la volume and 
function in relation with quantitatively measured mitral regurgitation, diastolic 
function and nt-probnp levels is evaluated in obstructive hcm patients.
▪ In chapter eight, the relation between lge, la volume and af in hcm is evaluated in a 
multicenter study.
▪ Chapter nine summarizes the findings of this thesis and discusses clinical implications 
and directions for further research in english and Dutch.
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AbSTrACT
Accurate quantification and timing of regional myocardial function allows early 
identification of dysfunction and therefore becomes increasingly important for clinical 
risk assessment, patient management and to evaluate therapeutic efficacy. 
for this purpose, the application of tissue Doppler echocardiography has rapidly increased. 
However, echocardiography has some major inherent limitations. 
Cardiovascular magnetic resonance (cmr) imaging with tissue tagging provides highly 
reproducible data of myocardial function, not only in longitudinal and radial direction, but 
also in the circumferential direction. Due to the development of faster imaging protocols, 
improved temporal resolution, less time-consuming post-processing procedures and the 
potential of quantifying myocardial deformation in three dimensions at any point in the 
heart, this technique may serve as an alternative for tissue Doppler echocardiography and 
is now ready for more widespread clinical use.
This review discusses the clinical use of cmr tissue tagging for quantitative assessment of 
regional myocardial function, thereby underlining the specific features and emerging role 
of this technique.
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M ethods for accurate quantification of regional myocardial function have been urged by the clinical need to predict contractile recovery in patients with ischemic heart 
disease and recently developed novel therapeutic options for improving local function, 
such stem cell therapy in patients with heart failure, and percutaneous transluminal septal 
myocardial ablation in patients with hypertrophic obstructive cardiomyopathy.1-3 Timing 
of regional myocardial function is essential to optimize selection of candidates for cardiac 
resynchronization therapy (crt).4
Strain analysis allows a direct assessment of the degree of regional myocardial deformation 
and its timing during the cardiac cycle. Strain is expressed as the percentage of shortening 
or lengthening of a small element of myocardium in relation to its original length. 
   Both echocardiography with tissue Doppler imaging and cardiovascular magnetic 
resonance (cmr) tissue tagging are imaging techniques capable of measuring myocardial 
strain. 5-9
The use of tissue Doppler echocardiography for strain quantification has rapidly increased, 
especially in the setting of resynchronization therapy.10-11 echo-Doppler derived parameters 
are predominantly based on longitudinal and radial motion data. However, myocardial 
contraction is principally circumferential, and thus echo-based Doppler methods do not 
allow the most accurate evaluation of myocardial function. cmr imaging provides highly 
reproducible data of myocardial deformation, not only in longitudinal and radial direction, 
but also in the circumferential direction.12,13 Due to the development of faster imaging 
protocols and improved temporal resolution, less time-consuming post-processing 
procedures and the potential of quantifying myocardial deformation in three dimensions 
at any point in the heart, cmr tissue tagging has become a powerful tool for basic research, 
and seems ready for more widespread clinical use.14-17
   Several studies have been published in the past using cmr tissue tagging. In this review 
we focus on the clinical applications of cmr tissue tagging for evaluation of normal and 
diseased myocardium, thereby underlining the specific features and emerging role of this 
technique for assessment of regional myocardial function. 
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Cmr TiSSuE TAggiNg
In 1988, Zerhouni et al. [8] introduced a new cmr technique to magnetically label or 
tag different regions within the heart wall. The basic idea was to create non-invasive 
markers within the heartwall by applying saturation planes perpendicular to the imaging 
plane at the eCG trigger signal, prior to image acquisition. During the subsequent image 
acquisition, reduced signal is obtained from the saturated tissue. Therefore the cut line 
of the image plane and the saturated plane appears as a hypo-intense or black line on the 
images, see figure 1. 
   A fast way to generate a tagging pattern was introduced by Axel and Dougherty in 1989.9 
This method is known as Spatial Modulation of Magnetization (spamm). Since spamm is 
fast, it can be applied twice, in two orthogonal directions, yielding a grid pattern. With 
spamm either sharper stripes or a sinusoidal intensity variation can be obtained.18
Figure 1. cmr tissue tagging. The schematic drawing indicates the short-axis image planes and the 
magnetically saturated planes perpendicular to the imaging plane (A). During subsequent image 
acquisition, reduced signal is obtained from the saturated tissue. This results in black lines on the 
images (B).
   Because the magnetization is a property of the tissue, the tag lines move along with the 
tissue in which they are created. When created at end-diastole, see figure 2a, the lines will 
deform with the myocardium during contraction, see figure 2b, and become undeformed 
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again during subsequent relaxation, see figure 2c and 2d.
   From this it can be recognized that the deformed tag pattern reflects the underlying 
motion of the heart wall. By tracking the motion of the tag lines throughout the cardiac 
cycle, the intramural myocardial deformation can be quantified, see figure 3. 
The tags gradually will fade during the cardiac cycle, see figure 2, due to tissue T1 
relaxation and the imaging rf pulses. This fading may hamper assessment of regional 
myocardial function, especially the analysis of the relaxation of the heart during diastole. 
To improve the tag contrast relative to the background of the relaxed, non-tagged signal, 
fischer et al. introduced the use of complementary spatial modulation of magnetization 
Figure 3. An example of a short-axis images with deformed tagging grid on end systole is shown (A). 
Tagging is achieved by the application of spatial modulation of magnetization (spamm). The tag-tag 
distance is 7 mm. using the spammvu software package, the intersection points of the tagging grid can 
be marked (B) and tracked throughout the cardiac cycle (C). The displacement of these points can be 
measured and subsequently the intramural myocardial deformation can be quantified.
Figure 2. example of tagged images. Typically, tagging is applied just before contraction starts (end-
diastole (A). Because the taglines are a temporary property of the tissue, taglines move along with the 
tissue in which they are created. The lines will deform if the myocardium contracts (B), and become 
undeformed during relaxation (C). Due to T1 relaxation, the contrast between tagged (dark) and non-
tagged (bright) myocardium will gradually disappear during subsequent image acquisition (D).
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(cspamm). 19
   With cspamm, the tagging signal is separated from the relaxed signal by subtracting two 
measurements, one with a positive and one with a negative tagging pattern. A disadvantage 
of cspamm is the increased image acquisition time. further improvement can be obtained 
by choosing imaging sequences like echo planar imaging (epi) or balanced steady state free 
precession.20-22 for a complete overview and evaluation of the different pulse sequences 
that can be used in combination with tagging, we refer to the excellent review of Axel et 
al.2
Tagged image analysis 
The analysis method used to extract information on myocardial function from the tagged 
images depends on the clinical purpose for which it is applied. 
   visual assessment requires tags which can be easily followed by eye, and therefore the 
tag lines should be as sharp as possible. for this purpose image quality is essential while 
temporal resolution and the applicability of semiautomatic post-processing become less 
important. This means for the image acquisition that a rectangular intensity profile of the 
tag lines is preferred, and that grid-tagged images are presented to the observer. spamm 
with a sharp grid is one of the most widely used techniques for this purpose.
   for quantitative assessment of myocardial deformation with (semi)automated analysis 
methods, however, other types of tagging images may be more suitable. Basically, three 
types of analysis methods can be discerned. The first type of methods aims at the detection 
and tracking of the tag lines in the images. Software programs like findtags and spammvu 
are based on methods of this type.24-25
   The second type is based on optical flow, a method originating from machine vision 
applications, which determines the motion of the object in the image by assessing temporal 
and spatial changes in image intensity. The third type is the harmonic phase (harp) analysis 
[26]. The harp method calculates for each pixel the spatial phase in the periodic tagging 
pattern. This phase can be used to track the points through the cardiac cycle, or to calculate 
the deformation directly, by calculating the regional spatial frequency of the tagging 
pattern and comparing it with the undeformed frequency. for a more in-depth review and 
further references on image analysis, we refer again to reference 23.
   Due to its almost fully automated nature, harp is currently the most widely used analysis 
method. It has been shown that the use of cspamm yields significantly better strain results, 
when harp analysis is used.27 Although traditionally the harp method is optimized for high 
temporal resolution and low spatial resolution, and displacement-encoded imaging with 
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Figure 4. Interpretation of myocardial 
strain (i.e. deformation) depends on the 
used coordinate system. for clinical 
purposes, description of strain in the 
radial/circumferential/longi-tudinal 
(rcl) system is preferable. Radial strain 
(R) indicates deformation of the heart 
in the radial direction. Positive radial 
strain during systole reflects the local 
contribution of the myocardium to 
wall thickening. Circumferential strain 
(C) reflects intramural circumferential 
shortening. A negative value is related to 
myocyte contraction. Longitudinal strain 
(L) reflects the regional longitudinal 
shortening from base to apex.
stimulated echoes (dense) for low temporal resolution and high spatial resolution, this is 
not an essential difference intrinsic to the either method.
Strain Analysis
Strain analysis describes the change of shape of material (i.e. myocardium) resulting from 
deformation. Strain is independent of rigid body motion (translation and/or rotation) and 
does not necessarily need an external reference system. 
Principal and normal strains
In literature, principal strains as well as normal strains are used to present regional 
myocardial function. The principal or maximum strains provide the maximum deformation 
in three orthogonal directions, irrespective to the geometry of the heart.28,29 for a meaningful 
clinical interpretation, the orientation of the maximum stretch should also be taken into 
account. 
for interpretation of normal strains a coordinate system is required. Two different, 
coordinate systems, the radial/fiber/cross fiber (rfx) system and the radial/circumferential 
/longitudinal (rcl) system are used for this purpose.30-33 for the rfx systems the fiber 
orientation is required. for clinical purposes, description of strain in the rcl system is 
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preferable. using this coordinate system, myocardial deformation can be described in a 
more intuitive way, see figure 4: 1) Radial strain, representing deformation of the heart in 
the radial direction (i.e. towards the center of the ventricle). Positive radial strain during 
systole reflects the local contribution of the myocardium to wall thickening, negative 
radial strain during systole implies local wall thinning (dyskinesia); 2) Circumferential 
strain, reflecting intramural circumferential shortening. A negative value is related to 
myocyte contraction; A positive value indicates systolic bulging; and 3) Longitudinal 
strain, reflecting the regional amount of myocardial shortening from base to apex (negative 
value).
Strain rate
The strain rate can be derived from the different strain measures by dividing strain by the 
time information (T) from each time frame:
Time derivative of strain is the strain rate (1/s) and is of importance to assess the relaxation 
of the ventricle. Quantification of the strain rate allows detailed evaluation of lv diastolic 
function.34,35
Shear strains
In addition to the normal strains, three shear angles can be calculated: the radial-
circumferential shear angle αrc, the radial-longitudinal shear angle αrl, and the 
circumferential-longitudinal shear angle αcl. The cl-shear angle is the most interesting 
shear angle: it describes the twisting motion of the heart and is closely related to torsion 
of the left ventricle. 
Torsion
cmr tissue tagging offers also the opportunity to quantify myocardial torsion. The twisting 
motion of the lv stores potential elastic energy by straining the extracellular matrix, which 
is released during early diastole, and therefore probably contributes to early diastolic 
suction.36 In the lv, torsion and untwisting is the result of contraction and relaxation of 
the spiraling myofibers.37 Several different definitions are used to describe torsion.38,39 
Strainrate =
Strain (t1)-Strain (t2)
         ( t2-t1)
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Figure 5. Torsion and untwisting are the result of contraction and relaxation of the spiraling subepicardial 
and subendocardial myofibers. The net ventricular torsion is the result of the subepicardial contraction 
and subendocardial counterbalancing contraction.
However, the most widely used definition is the CL shear on the epicardial surface between 
two short-axis slices, see figure 5. 
STudiES iN ThE NOrmAl lV
Myocardial strain in the healthy 
In the normal heart, the end-systolic circumferential and longitudinal strains (shortening) 
gradually increased from base towards the apex, and from epicardium towards the 
endocardium. for the end-systolic radial strain (representing the local contribution to wall 
thickening), significant differences between slices were not found.
   However, this finding on radial strain may be partly a consequence of the lowest spatial 
density of tag data in the radial direction, and thereby a less accurate measurement of 
strain in the radial direction.40 
In another study, the circumferential, longitudinal and radial strains increased from base 
to apex. Also between segments differences were found: the highest absolute values were 
found for radial strains in the anterior and septal regions, and for circumferential and 
longitudinal strains in the posterior and lateral walls. Despite the high radial strains in 
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the anterior and septal regions, the regional ejection fraction in this area was smaller, 
probably as a result of the lower circumferential and longitudinal strains in this part.41 
These observed regional differences in strain are probably related to regional differences 
in regional lv architecture, function and local stress.
   When tagged images are obtained with high temporal resolution (14 ms), strain analysis 
allows detailed mapping and timing of myocardial deformation. In healthy subjects, both 
the onset time of circumferential shortening (Tonset) in early systole, and the time of peak 
circumferential shortening (Tpeak) at end-systole, were studied. The onset of shortening 
width (time needed for 20-90percent of the left ventricle to start shortening) was small 
(35±9 ms). A distinct spatial pattern for Tonset was found, with earliest onset in the lateral 
wall and latest onset in the septum (p<0.001). Compared to Tonset, the Tpeak had a larger 
width (121±22 ms) and an opposite spatial pattern, with peak shortening occurring earlier 
in the septum than in the lateral wall (p<0.001). These maps may serve as reference in 
detecting mechanical asynchrony due to intraventricular conduction delays or ischemia.42 
Myocardial strain in relation to age
Three-dimensional cmr tissue tagging was applied by fonseca and oxenham to 
determine the effects of aging on regional lv myocardial contraction and relaxation.43,43 
Strain analysis was performed in 15 younger (age 19-26 years) and 16 older (age 60-
74 years) healthy volunteers.In the older group, peak apical rotation and torsion were 
increased during systole and persisted longer. The peak rate of untwisting was reduced 
in older subjects (74±16 vs. 91 ± 15 degrees/s, p<0.01) and this reduction of untwisting 
rate was larger at the base than at the apex (p<0.05). These observations demonstrate 
that patterns of regional nonuniformity of diastolic myocardial function (including 
prolonged systolic torsion and reduced untwisting rate) are associated with aging.
STudiES iN ThE impAirEd lV
Coronary artery disease 
After transmural myocardial infarction, changes in intramural myocardial function will 
occur. Independent of localization, intramural deformation was found to be reduced in the 
infarcted myocardium. Therefore, the infarct area can be recognized by a specific spatial 
pattern of intramural deformation, including reduced and more circumferentially oriented 
systolic stretch (local systolic dilatation or bulging). Regional differences in intramural 
deformation between infarcted and non-infarcted (remote) myocardium were larger in the 
left anterior descending coronary artery related infarcts than circumflex or right coronary 
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artery related infarcts of enzymatically the same size.45 This finding may be one of the 
mechanical explanations why anterior myocardial infarction seems more prone to post-
infarct remodeling.46 
   In a direct comparison between strain and wall thickening analysis, strain analysis was 
found to be superior in discriminating infarct from remote myocardium. In this study, the 
perfusion territory of the culprit vessel was considered the infarct region. for detecting 
dysfunctional myocardium, wall thickening analysis had a sensitivity of 69 percent and a 
specificity of 92 percent, whereas strain analysis demonstrated a sensitivity of 92 percent 
and a specificity of 99 percent. The global ejection fraction correlated better with averaged 
myocardial strain (r=0.89, p< 0.001) than with wall thickening (r=0.76, p< 0.005).47 
   Some controversy exists about myocardial function in non-infarcted, remote myocardium. 
In one study performed within 10 days after infarction, dysfunctional regions (infarcted 
myocardium), regions with normal function (adjacent myocardium), and regions with 
hypercontractile function (remote myocardium) were observed.48
Another study however, demonstrated that patients with single-vessel disease had reduced 
intramyocardial circumferential shortening throughout the lv, including the remote non-
infarcted regions on day 5 after first anterior infarction.49 one explanation for these 
different findings might be the difference in definition of remote areas. 
Eight weeks after first anterior infarction, strains remained reduced not only at the infarct 
area, but in the remote myocardium of the non-infarcted basal segment as well.50 This 
persistent dysfunction in infarcted and non-infarcted areas may be one of the first indicators 
of progressive remodeling and the occurrence of heart failure late after myocardial 
infarction. 
   Ischemia also affects lv torsion and untwisting. In animal experiments, ischemia induced by 
a short period of coronary artery occlusion resulted in increased counterclockwise rotation. 
A probable explanation is the loss of counter action of contraction of subendocardial, 
clockwise oriented fibers due to subendocardial ischemia. When the occlusion persisted, 
the torsion pattern showed a form of pseudonormalization and finally was globally 
decreased, because contractility of subepicardial fibers also decreased.51 A decrease in 
torsion was also observed in patients after myocardial infarction.52 This reduction of 
torsion was related to the extent of the asynergic area and to a decrease of global ejection 
fraction. 
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CAD and response to dobutamine stress 
Dobutamine stress echocardiography (dse) is an established technique to study the presence 
of viability and ischemia.53 Several studies have demonstrated that dobutamine cmr tissue 
tagging is as safe and effective in detection of wall motion abnormalities, and therefore is 
a good alternative for dse. 
A comparison between low-dose dse and cmr tissue tagging (infusion of 5 and 10 μg/
kg/min dobutamine) was performed by Kramer et al..54 The authors demonstrated that 
both techniques are sensitive and accurate for the prediction of functional improvement 
after reperfused myocardial infarction. using a 5percent increase in intramyocardial 
circumferential shortening at peak response to dobutamine as evidence of normal 
contractile reserve.55 The sensitivity and specificity of dobutamine cmr tissue tagging were 
82 percent and 69 percent, respectively, with an overall accuracy of 76 percent. using 
the same threshold for response of dysfunctional myocardium to dobutamine, functional 
recovery 8 weeks after myocardial infarction could be predicted (p<0.04). Dysfunctional 
myocardium that does not respond normal to peak dobutamine did not show functional 
improvement.56 
   In a study by Kuijpers et al. more than 200 patients with chest pain were studied with high-
dose dobutamine cmr tissue tagging.57 This study demonstrated that high-dose dobutamine 
cmr tissue tagging detected more new wall motion abnormalities (68/211 patients) than 
dobutamine cmr studies without tagging (58/211 patients, p<0.01). Coronary angiography 
confirmed the presence of coronary artery disease, defined as a diameter reduction of >50 
percent in one or more major epicardial coronary arteries, in 65 (96 percent) of the 68 
patients identified by cmr tissue tagging of which 62 patients needed revascularization. 
The sensitivity of dobutamine cmr tissue tagging for detecting significant coronary artery 
disease was 92 percent and specificity was 98percent.
Dilated cardiomyopathy 
In patients with non-ischemic dilated cardiomyopathy (dcm) a consistent pattern of 
marked regional heterogeneity in myocardial function was found. In the septum, systolic 
lengthening (in both circumferential and longitudinal direction) instead of shortening 
was found during systole, while in the lateral wall relatively normal systolic shortening 
occurred (p<0.001 lateral vs. septal walls). Reduced function in the septal region may 
be related to increased wall stress, leading to relative hypoperfusion and subsequently 
myocardial dysfunction.58 
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   In general, subendocardial hypoperfusion and concomitant reduced contraction 
in the subendocardium will lead to limited counteraction of clockwise rotation of the 
subepicardial fibers. This results in an increased net ventricular torsion. Importantly, 
decreased contractility and associated increased torsion as a result of hypoperfusion may 
occur far before irreversible tissue damage including increased collagen content and 
altered architecture becomes present, and thus may serve as early indicators of (reversible) 
cardiac abnormalities in patients prone to the development of structural cardiac damage 
and dysfunction.59-61
   Another factor contributing to heterogeneity in regional myocardial function in these 
patients might be the presence of conduction abnormalities. Dilated cardiomyopathy is 
often complicated by intraventricular conduction delay (~25 percent), usually manifested 
as a left bundle branch block (lbbb).62 The presence of a lbbb is associated with an 
asynchronous contraction pattern and worse outcome.63 In a large population of patients 
with congestive heart failure, the presence of a lbbb yielded a hr of 1.36 (1.15-1.61 
p<0.001) for all cause mortality.
   Recently, crt has emerged as a new treatment strategy for this subgroup of heart failure 
patients.64 However, approximately one third of the patients eligible for crt do not respond 
to this therapy, which raised the demand for adequate patient selection.65 
As shown by Nelson et al., mechanical dyssynchrony is a key predictor for crt efficacy 
in these patients.66 They quantified circumferential myocardial strain using cmr tissue 
tagging in 7 healthy subjects and 8 patients with dcm and conduction delay prior to crt, and 
measured the change in dP/dtmax during crt. Circumferential shortening was significantly 
reduced in dcm hearts compared to controls (-5.3 ± 2.1% vs. –18.6 ± 2.9%, p<0.001), 
consistent with depressed myocardial function. In addition, a high variance in strain was 
observed in these patients (201.4 ± 84.3percent vs. 28.0 ± 7.1percent, p<0.001), indicating 
a greater dispersion or heterogeneity of regional peak systolic strain. This indicator of 
mechanical dyssynchrony showed a good correlation with the change in dP/dtmax during 
crt (r=0.85, p<0.008). 
   A study by Zwanenburg et al. using cmr tissue tagging with high temporal resolution (14 
ms) demonstrated that in general the onset of circumferential shortening in dcm patients 
propagated from the septum to lateral wall, which is opposite to the direction as found in 
normal subjects. However, in patients with non-ischemic dcm this pattern of mechanical 
activation was quite uniform, while in ischemic dcm a wide range of directions of activation 
were found. As a consequence, the location of the area with delayed activation may vary 
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as well, and this may be one of the mechanical explanations why crt is less effective in 
ischemic dcm.67
Mechanical lv function after partial left ventriculectomy 
Partial left ventriculectomy (plv) was developed as an alternative therapy for end-stage 
heart failure, but results were variable and good predictors of outcome were not available. 
In a study by Setser et al., circumferential shortening was calculated at three short-axis 
levels in 24 dcm patients before plv, and 3 and 12 months after surgery.68 Before surgery, 
the septum did not show shortening but was stretched during systole. At follow-up after 
surgery, lv mass and volume decreased (p<0.01). Circumferential shortening especially 
in the septum improved significantly at both postsurgical time points. In addition, it 
was found that stretch (dyskinesia) of the basal septum prior to surgery increased the 
probability of event-free survival after 6 months. The lv torsion was further reduced 
after ventriculotomy, probably as a result of normalization of wall stress, resulting in 
better myocardial perfusion and subsequently improved subendocardial contraction, 
counterbalancing the subepicardial contraction.69
Hypertrophic cardiomyopathy
In general, global lv function is preserved in patients with asymmetric septal hypertrophic 
cardiomyopathy (hcm). However, strain analysis by cmr tissue tagging revealed that 
the amount of regional myocardial contraction and the strain rate are both impaired 
in hypertrophied as well as in non-hypertrophied regions. In these patients, also an 
asynchronous contraction pattern is observed, indicated by a larger dispersion in time 
to peak strain for different regions.70 Compared to control subjects, the maximum 
circumferential shortening occurs earlier in systole in hcm patients, especially within 
the hypertrophied septum. The heterogeneity of regional myocardial mechanics in hcm 
patients may reflect the regional variation in the myocardial disarray and fibrosis that is 
characteristic of this disorder.
Probably as a result of the -subendocardial- depressed circumferential strain, lv torsion 
(counterclockwise rotation of the apex around the long axis relative to the base) was 
greater in hcm patients compared to controls (19.9 ± 2.4° versus 14.6 ± 2.7°, p<0.01) as 
shown by young et al..71 
In patients with left ventricular hypertrophy due to other causes than a genetic disorder, 
diastolic function represented by strain-rate is impaired while systolic function is preserved. 
A recently published study by edvardsen et al. demonstrated in participants of the Multi-
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ethnic Study of Atherosclerosis study a direct relationship between regional diastolic 
dysfunction and increasing lv mass.35 Regional diastolic strain-rate was significantly 
reduced in patients with hypertrophy (1.5± 1.1∙s-1) compared with subjects without 
hypertrophy (2.2±1.1∙s∙-1, p<0.001). 
Studies in valvular heart disease
The chronic pressure overload in patients with aortic stenosis induces lv hypertrophy 
and may cause ventricular dilatation later in the disease process. As a consequence of 
severe hypertrophy, diastolic dysfunction is likely to occur. Coronary flow is reduced 
in hypertrophied ventricles as well, and more in subendocardial regions compared to 
subepicardial regions.38 
Importantly, decreased contractility and concomitant increased torsion as a result of 
hypoperfusion may occur far before irreversible tissue damage including increased collagen 
content and altered architecture is present.59-61 Therefore, decreased subendocardial 
contraction and/or increased torsion may serve as early indicators of (reversible) cardiac 
abnormalities in patients prone to the development of cardiac dysfunction.
   Nagel et al. and Stuber et al. have shown that during systole a wringing motion is performed 
by the normal lv with clockwise rotation at the base (-4.4±1.6°) and counterclockwise 
rotation at the apex (+6.8±2.5°) when viewed from the apex.72-73 untwisting occurs mainly 
during the iso-volumetric relaxation period and is completed before diastolic filling 
starts. 
   In patients with aortic valve stenosis, systolic rotation at the base was reduced (-2.9° 
before aortic valve replacement versus -4.2° in controls) while apical rotation was increased 
(22.2° before aortic valve replacement versus 10.3° in controls).74 Maximum systolic 
torsion was increased in patients with aortic stenosis before valve replacement (25.1±6.6° 
versus 14.5±3.7°). one year after valve replacement, torsion decreased to almost normal 
values, although basal rotation remained decreased.
FuTurE dirECTiONS
The unique features provided by cmr tissue tagging allows for detailed evaluation of regional 
systolic and diastolic myocardial function in three-dimensions. This is of great advantage 
for evaluation of patients with heart failure due to different etiologies. As demonstrated, 
myocardial strain and torsion are sensitive measures for -subendocardial- contraction and 
global untwisting (relaxation) of the heart under different pathophysiological conditions. 
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Alterations in diastolic function are the very first sign in developing cardiomyopathy. 
Quantification of torsion, untwisting (-rate) and diastolic strainrate with cmr tissue 
tagging opens the prospect of early detection of cardiac disease in patients prone to the 
development of cardiomyopathy. 
   Today, a major limitation remains the impossibility to study routinely patients with a 
pacemaker and/or implantable cardioverter/defibrillator (icd). However, several individual 
cases and a limited number of animal and human studies have been published reporting on 
the effects and safety of cmr and devices.75,76 only under strict conditions, when special 
precautions are made regarding the functioning of the pacemaker, and when an appropriate 
imaging strategy is used, a cmr study can be performed relatively safely in these patients.75 
However, the risk of thermogenic damage and loss of capture remains present and cannot 
be overstated.77 In addition, the effects of cmr on leads placed in the coronary sinus are 
currently unknown, and icd’s are an absolute contraindication. Therefore, only when cmr 
compatible pacemaker systems become available, in-vivo and follow-up studies can be 
initiated, providing better insight in the relationship between electrical and mechanical 
activation.
Conclusion
As demonstrated, cmr tissue tagging is an excellent non-invasive tool to study myocardial 
function in detail with high spatial and temporal resolution. In contrast to other imaging 
modalities it offers the possibility to quantify regional, intramural myocardial function 
in three dimensions at every site of the heart, and provides detailed data not only on 
contraction, but also on relaxation of the heart. In addition, cmr is capable in providing 
accurate data on global ventricular function geometry and tissue characteristics (presence 
of fibrosis) as well.
offering these -unique- features, cmr seems to be the non-invasive imaging modality of 
choice to fulfill the needs required for fundamental science and to study function, geometry 
and tissue characteristics in relation to impaired cardiac function and advanced therapies 
in-vivo.
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Determining the aetiology of non-ischemic cardiomyopathy
I n the majority of patients, lv dysfunction results from ischemic cardiomyopathy that is caused by coronary artery disease and subsequent ischemia and myocardial infarction. 
However, normal coronary arteries are found in a substantial proportion of patients with 
lv dysfunction. While a patient is inevitably exposed to a small but considerable risk when 
performing a coronary angiogram, research has focused on seeking non-invasive methods 
to differentiate ischemic from non-ischemic cardiomyopathy (nicm), which requires an 
importantly different therapeutic approach than ischemic cardiomyopathy. Moreover, nicm 
has a heterogeneous aetiology resulting from a complex interplay between predisposed 
genetic constitution and the detrimental effects of infectious and/or toxic agents on the 
function of myocardium. Consequently, further optimisation of treatment in nicm patients 
warrants determining of the underlying cause(s) of nicm.
   In the last decade, important progress has been made in determining the aetiology 
of cardiomyopathies by using cardiac magnetic resonance imaging (cmr). cmr allows 
a comprehensive, non-invasive assessment of cardiac function, morphology and tissue 
characterisation within a 45 minutes timeframe. 
   Since an introduction to cmr techniques has recently been published in the section 
of education in Heart ‘the use of cmr in the evaluation of heart failure’, we herewith 
will restrict the description of cmr techniques to a brief summary of their role in tissue 
differentiation and determination of the aetiology of cardiomyopathies, see table 1. 
   Although a classification based on genetic interrogation of cardiomyopathies has been 
advocated, we will classify nicm according to the World Health organization (who) 
Table 1. Appearance of tissue involved in ischemic and non-ischemic cardiomyopathy 
with different cmr imaging techniques
tissue type gradient echo (cine imaging)
T1-weighted 
spin echo
T2-weighted      
spin echo lge imaging
Myocardium grey grey grey black
fat white white white white
Blood white black black black
oedema white black white white
Scar tissue grey grey grey white
fibrosis grey grey grey white
lge=late gadolinium enhancement
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into hypertrophic cardiomyopathy (hcm), restrictive cardiomyopathy (rcm) dilated 
cardiomyopathy (dcm), arrhythmogenic right ventricular cardiomyopathy (arvc) and 
unclassified cardiomyopathy, in order to concur with clinical practice.
hypErTrOphiC CArdiOmyOpAThy
Differentiating physiological from pathological hypertrophy
lv hypertrophy is diagnosed when lv mass exceeds the normal range, which is 85-181 
gram or 46-83 g∙m-2 for males and 66-114 gram or 37-67 g∙m-2 for females with ssfp cine 
imaging.1 lv hypertrophy can be physiological, as in an athlete’s heart, or adaptive to 
systemic hypertension or aortic valve stenosis. In addition, lv hypertrophy may be the 
result of infiltrative systemic disease (amyloidosis), or lysosomal storage diseases, such 
as Anderson-fabry disease. Another important cause of lv hypertrophy is familial hcm, 
which is quite common with an estimated prevalence of 1:500 in general population and 
is mainly caused by mutations in genes that encode for sarcomeric proteins that have an 
autosomal dominant pattern of inheritance. Importantly, hcm is one of the major causes of 
sudden death in young athletes. 
   Therefore, distinction between physiological and pathological forms of lv hypertrophy 
is critical see figure 1. One study demonstrated that physiological lv hypertrophy as 
observed in competitive endurance athletes could not be distinguished from hcm and 
adaptive lv hypertrophy based on lv mass alone. 2 However, the diastolic wall-to-volume 
ratio, calculated by dividing maximal end-diastolic wall thickness by indexed lv end-
diastolic volume, yielded a positive predictive value of 95 percent and a negative predictive 
value of 94 percent when using a cut-off value of 0.15 mm/mL∙m-2. No contrast induced 
hyperenhancement is found in physiological lv hypertrophy. of notice, patients with 
hcm, aortic stenosis and systemic hypertension had considerable overlap in lv geometry 
as determined with ssfp imaging, as might also be expected with athletes involved in 
isometric sports. 
Familial hypertrophic cardiomyopathy
Although hcm is generally diagnosed with 2D-echocardiography, there are certain 
technical limitations of echocardiography that may affect adequate measurement of lv wall 
thickness. first, delineation of the lv wall depends on the acoustic window of a patient. 
Second, the echocardiographic transducer is situated on a fixed point on the anterior chest 
wall when acquiring cross-sectional images of the lv wall, which are therefore prone to be 
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obtained with obliquity and affect absolute geometric measurements.
   While image plane selection with cmr can be applied from every angle, the image planes 
can always be planned perpendicular to the lv wall. A direct comparison between cmr ssfp 
cine imaging and 2d-echocardiography evaluating their diagnostic accuracy to identify 
hcm patients among a group of patients suspected with hcm, showed that cmr identified 
hypertrophied areas, typically of the anterolateral wall, in 6 percent of patients who would 
otherwise remain undetected by 2d-echocardiography.3 In addition, echocardiography 
underestimated the magnitude of hypertrophy in the basal anterolateral wall by 20±6 
percent, and the presence of extreme hypertrophy (≥30mm) in 10 percent of patients, which 
is a risk factor for sudden death. Therefore, evaluation of lv wall thickness in suspicion 
of hcm should ideally be performed with cmr, especially when discrepancy exists between 
echocardiographic and electrocardiographic findings.
   In hcm patients, two different patterns of hyperenhancement can also be recognized: 
Patchy and confluent hyperenhancement, see figure 1. Both types of hyperenhancement 
may occur in every segment of the lv in hcm patients, but predominantly occur at the 
anterior and inferior insertion points of the right ventricular free wall into the septum, 
where myocyte disarray is most prominent. Although myocyte disarray was believed to 
cause the hyperenhancement, so far hyperenhancement has only been related to increased 
collagen deposition and oedema, but not with myocyte disarray.
   The extent of hyperenhancement has also been related to the occurrence of ventricular 
arrhythmia’s and increased number of clinical risk factors for sudden death.4, 5 However, 
the prognostic value of the presence and extent of hyperenhancement in hcm patients is 
still unknown and the results of ongoing studies are awaited.
   In addition, typical crypt formation in the inferoseptum has recently been found in 
81 percent of presymptomatic hcm mutation carriers without lv hypertrophy.6 Possibly, 
these crypts represent myocyte disarray and mild forms of crypt formation have also 
occasionally been observed in a referral based population. Nevertheless, awareness of 
their high prevalence in hcm mutation carriers is important while patients with prominent 
crypt formation may be misdiagnosed as having non-compaction cardiomyopathy with 
echocardiography. However, distinction between these two entities is clinically important 
is quite straightforward with ssfp imaging, as illustrated in figure 3.
70 |
Chapter 3
rESTriCTiVE CArdiOmyOpAThy
Despite the considerable overlap that exists between hcm and rcm, we will discuss in this 
section the value of cmr in the diagnosis of amyloidosis, Anderson-fabry disease, iron 
overload, endomyocardial fibrosis and constrictive pericarditis. Constrictive pericarditis 
itself is not considered a rcm; however, distinction of this disease from rcm has critical 
clinical implications. Therefore, we will discuss this disease also in this section.
Amyloidosis
Cardiac involvement of amyloidosis displays a characteristic pattern of hyperenhancement, 
when lge images are acquired 4 minutes after injection of a gadolinium based contrast 
agent (gd-ca).7 Notably, gd-ca is more rapidly washed out of amyloid depositions 
than scar tissue, resulting from increased distributive volume due to systemic amyloid 
deposition. Cardiac amyloidosis typically shows an ill defined global subendocardial 
pattern of hyperenhancement, matching the distribution of the amyloid deposition.7 This 
hyperenhancement pattern is very characteristic for cardiac involvement of amyloidosis 
and can therefore be used to discriminate this disease from other forms of restrictive or 
hypertrophic cardiomyopathies, see figure 1.
   Although most profound in the subendocardial layer of myocardium, amyloid deposition 
occurs throughout the entire myocardium, causing the entire myocardium to have a higher 
signal on lge images than normal myocardium. Therefore, ‘nulling’ of myocardium can 
be extremely difficult when amyloidosis is present.
   The typical pattern of hyperenhancement, together with the increased T1 signal of 
myocardium, yields a diagnostic accuracy of 97 percent in patients with biopsy proven 
amyloidosis.7 However, cardiac involvement in this study was defined by echocardiography, 
so the additional value of lge imaging compared to echocardiography still needs to be 
evaluated. Nevertheless, other typical signs of amyloidosis can be observed with ssfp cine 
imaging, such as bi-atrial enlargement, hypertrophy of the atrial walls, left ventricular 
systolic dysfunction in the longitudinal but not in the radial direction of the ventricles, and 
pleural effusion.
Anderson-Fabry disease
Anderson-fabry disease is the second most prevalent inheritable lysosomal storage disease 
resulting from an X-linked recessive disorder of glycosphingolipid metabolism. Cardiac 
involvement is common, resulting from glycosphingolipid within the cardiomyocytes, 
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valves and vascular endothelium, ultimately resulting in often concentric lv hypertrophy. 
Although generally believed to be a rare disorder, recent studies on the prevalence of this 
treatable cause of lv hypertrophy showed that Anderson-fabry disease was found in 3-6 
percent of middle aged patients suspected of having hcm. 
   Histological studies on cardiac involvement mainly report intra-cardiomyocytal 
inclusions within the lysosomes with typical concentric lamellar configuration, but 
hyperenhancement typically occurs in the basal inferolateral wall in 92 percent of patients.8 
This hyperenhancement was mainly present in the midventricular and epicardial layers 
of myocardium and likely reflects replacement scarring.8 The pattern of replacement 
scarring, however, was more ill defined than scarring found after myocardial infarction 
and can also be used to differentiate cardiac involvement of Anderson-fabry disease from 
familial hcm and cardiac amyloidosis.
Iron overload
In patients with iron overload from any cause, heart failure is the most common cause of 
death. Cardiomyopathy probably results from the toxic effects of non-transferrin bound iron 
on the mitochondrial respiratory chain when the cardiac iron storage capacity is exhausted. 
This form of cardiomyopathy is reversible with chelate therapy, provided that therapy is 
initiated before the development of heart failure.9 However, the diagnosis of cardiac iron 
overload is often delayed due the relatively late onset of symptoms, echocardiographic 
abnormalities and unpredictable course. 
   While the local magnetic field is influenced by the presence of iron particles, decreased 
t2* (t2 star)-relaxation times <20 ms found in patients with cardiac iron overload strongly 
relates to decreased lv ejection fraction.9, 10 A decrease in t2*-time results in more rapid 
decay of signal intensity on t2*-weighted images and is not related to the extent of iron 
deposition in the liver, which is generally measured to determine the extent of systemic 
iron deposition, see figure 1.9 Therefore, routinely measurement of t2*-time of the heart, 
preferably the septum, allows timely initiation of chelate therapy in those patients with 
iron overload at risk to develop heart failure.
Endomyocardial disease
In hypereosinophilic syndrome, eosinophil mediated endomyocardial fibrosis and 
subsequent rcm evolves through three stages; an acute necrotic stage which develops five 
to six weeks after the onset of illness, an intermediate stage in which thrombus formation 
along necrotic endocardium occurs in often asymptomatic patients, and a fibrotic stage. In 
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the fibrotic stage, lv wall thickening as a result of endomyocardial replacement scarring 
and thrombus formation and warrants anti-coagulation therapy. Also, this form of lv wall 
thickening can be discriminated from lv myocardial hypertrophy using lge imaging, which 
reveals thickening of the endocardium and increased signal intensity, accompanied by lv 
cavity thrombus formation as indicated by black spots aligning the endocardium. However, 
only very limited data on the role of cmr in endomyocardial fibrosis is available. 
Constrictive pericarditis
The hallmark of constrictive pericarditis is a thickened, fibrotic and/or calcified 
pericardium, constricting the heart and impairing cardiac filling. The wide field of view 
of cmr enables to accurately visualize the pericardium having a low signal intensity on 
t1- and t2-weighted imaging. Pericardial thickness < 2mm is considered normal, and a 
thickness > 4 mm suggests pericardial constriction, see figure 1. However, the diagnosis 
of constrictive pericarditis cannot be made based on the anatomical images alone; the 
constrictive hemodynamic physiology must confirm the diagnosis. With real time ssfp cine 
imaging, paradoxal septal movement during inspiration can be observed, and constrictive 
inflow patterns in the caval veins can be measured with phase encoded flow velocity 
imaging.
Figure 1. The use of cmr to differentiate between non-dilated cardiomyopathies of different aetiologies. 
ssfp cine images (A, C, E) and lge images (B, D, F) of 4 chamber views can be used to differentiate 
between physiological hypertrophy in an endurance athlete’s heart (A, B) hypertrophic cardiomyopathy 
(C,D) and cardiac involvement in amyloidosis (E, F). A. In the athletes heart, concentric hypertrophy is 
present without left atrial dilation. B. No hyperenhancement is present. C. In hypertrophic cardiomyopathy, 
asymmetric hypertrophy is present, predominantly of the septum. Also, hypertrophy of the trabeculae 
and left atrial dilation can be visualized with ssfp cine imaging. D. A patchy hyperenhancement pattern 
in hypertrophied areas of myocardium, as indicated by the red arrowheads, is typical for the phenotype 
of familial hypertrophic cardiomyopathy. E. Cardiac involvement in amyloidosis is characterized 
by biventricular hypertrophy and biatrial dilation. Note that also wall thickening of the atria can be 
observed, indicated by the green arrowheads. F. The ventricular hypertrophy in amyloidosis is not caused 
by myocyte hypertrophy, but mainly by amyloid deposition throughout the entire heart. The amyloid 
deposition occurs predominantly in the subendocardium, but can also occur in the interatrial septum or 
atrial walls, as indicated by the blue arrowheads. G. Short axis view of T2* weighted image of both the 
heart and the liver (indicated by the pink and white asterisk). Note that the extent of iron deposition in the 
heart is not paralleled by iron deposition in the liver, as indicated by the difference in signal intensities 
of both organs. H. on a 4-chamber view T1-weighted image, the pericardial thickening that causes 
constrictive hemodynamics is easily visualized with cmr, as indicated by the yellow arrowheads.
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dilATEd CArdiOmyOpAThy
Differentiating ischemic from non-ischemic cardiomyopathy 
lv dilation is diagnosed with cmr ssfp cine imaging when lv end diastolic volume exceeds 
235 mL or 112 mL.m-2 in males and 174 or 99 mL.m-2 in females.1 The high spatial 
resolution of ssfp cine imaging allows detailed qualitative and quantitative assessment 
of regional wall thickness and wall thickening to detect ischemic myocardial areas. As 
described previously, ischemic cardiomyopathy is the most common cause of dcm, and 
cmr has shown to be an accurate tool to quantify the extent of myocardial infarction and to 
assess the viability of myocardium with lge imaging. In advanced ischemic heart disease, 
when lv remodelling with subsequent lv dilation has developed, ischemic cardiomyopathy 
can be differentiated from nicm using the following criteria: 1. With ssfp cine imaging 
regional wall motion abnormalities and reduction of wall thickness can be observed 
in ischemic cardiomyopathy, whereas in nicm, global hypokinesis is more frequent; 2. 
hyperenhancement in ischemic cardiomyopathy characteristically spreads from the 
subendocardium up to the epicardium and is confined to the perfusion territories of the 
coronary arteries, see figure 2. 
The specificity of the hyperenhancement pattern in ischemic cardiomyopathy is further 
underscored by several studies, in which cmr and subsequent coronary angiography 
were performed in consecutive groups of patients with systolic dysfunction of unknown 
origin.11 These studies report that the ischemic pattern of hyperenhancement was found in 
81-100 percent of patients with confirmed coronary artery disease. In the patients without 
coronary artery disease, no hyperenhancement was found in 59-88 percent of patients 
and another pattern of hyperenhancement, which was described as a mid-ventricular rim 
of hyperenhancement that predominantly involves the septum, see figure 2, was found in 
9-28percent of patients and probably reflects patchy areas of replacement fibrosis. The 
presence of this particular hyperenhancement pattern has shown to be an independent 
predictor of all cause mortality and the onset of potentially life threatening ventricular 
arrhythmias.12 Also, the ischemic pattern was described in patients with no obstructive 
coronary artery disease. It was postulated that this may be the result from transient 
occlusion due to a non-obstructive, unstable plaque or vasoconstriction. The presence 
of an area with hyperenhancement with the ischemic pattern in patients without prior, or 
unrecognized, myocardial infarction is found to have an at least 7-fold increased risk to 
develop major cardiac events. Although the diagnostic capabilities of cmr in acute and 
chronic ischemic cardiomyopathies are far more extensive than discussed above, we refer 
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to others for further reading on that topic.13 When ischemic cardiomyopathy is excluded in 
dcm, other causes such as Chagas’ disease, sarcoidosis, and myocarditis can be identified 
with cmr.
Chagas’ disease
Infection of the heart by Trypanosoma Cruzi causes Chagas’ disease, in which cardiac 
involvement develops sometimes decades after first infection in 30-40 percent of patients, 
and is endemic in the Latin Americas.14 The clinical course of disease can be subdivided 
into three stages, an acute stage, with fever and headache, an indeterminate phase, in which 
patients are asymptomatic, and a chronic phase, in which the heart is the most frequently 
affected organ resulting in heart failure and the onset of potentially life threatening 
ventricular arrhythmias.14 Localized aneurysm formation can be detected with ssfp cine 
imaging with predilection sites at the apex and basal inferolateral wall, which are difficult 
to evaluate with echocardiography, see figure 2. In addition, areas of hyperenhancement, 
indistinguishable from the ischemic pattern, can also be observed within these regions. 
These predilection sites are thought to be terminal portions of the microcirculation, which 
are most vulnerable to become ischemic in recurrent episodes of inflammatory disease and 
subsequent vasodilatation.14 Another advantage of cmr in evaluating Chagas’ disease is its 
capability to visualize potential thrombus that may develop within these aneurysms. Also, 
hyperenhancement can be detected in patients in the indeterminate stage, which could 
enable timely therapy.
Sarcoidosis
Sarcoidosis is a systemic immunological disorder characterized by multiple non-
caseating granulomas. Cardiac involvement occurs in 20-60 percent of patients, of which 
approximately 30 percent will develop lv dilation and concomitant symptoms of heart 
failure, (supra)ventricular arrhythmias and/or conduction disorders.15 While the non-
caseating granulomas within the myocardium implicate an increase of extra-cellular space, 
hyperenhancement on lge imaging is likely to occur. 
   Although data is limited, one study reports that hyperenhancement was present in 100 
percent of patients (n=19) who had confirmed sarcoidosis, demonstrating large areas of 
confluent transmural areas of hyperenhancement predominantly located in the basal and 
lateral lv segments, see figure 3.15 Interestingly, the areas of hyperenhancement were 
also present in patients with no lv dilation, indicating that cmr may help preventing the 
development of heart failure by early detection of cardiac involvement, which accounts 
for up to 85 percent total of mortality in this patient group.
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Figure 2. The use of cmr to differentiate between ischemic and non-ischemic dilated cardiomyopathies. 
ssfp cine images (A, C, E) and corresponding lge images (B, D, F) are used to differentiate between 
ischemic dcm (A, B), idiopathic dcm (C, D) and Chagas’ disease (E, F) A. end-diastolic 2-chamber 
ssfp cine image of an ischemic dcm. Note the regional wall thinning of the apical anterior wall and 
the apex (yellow dotted line) and a thrombus within the apex (yellow asterisk). B. note the rim of 
hyperenhancement originating for the subendocardium indicating scarring in the apical anterior wall 
and apex, typical for ischemic dcm. The thrombus observed on the ssfp cine appears black on lge 
images. C. Short axis ssfp cine of idiopathic dcm. Note the global wall thinning of the left ventricle. 
D. With lge imaging, a mid ventricular rim of hyperenhancement indicating fibrosis, typical for 
idiopathic dcm can be visualized (blue arrowheads). E. 2-chamber ssfp cine image of a patient with 
Chagas’ disease. Note the dispersed aneurysm formation, putatively originating from local ischemia 
due the inflammatory process (red asterisks). F. on lge images, scarring appears to occur within some 
aneurysms (red arrowheads) and represents an increased risk to develop heart failure and/or ventricular 
arrhythmias. 
Myocarditis 
Myocarditis increases the risk of SCD in young adults during sports, and accounts for 
approximately 10 percent of SCD in macroscopically normal hearts. endomyocardial 
biopsy using the Dallas criteria still is considered gold standard to diagnose myocarditis. 
However, this method has limited sensitivity inherent to the focal nature of myocarditis. 
Several cmr studies demonstrated that hyperenhancement can be found in at least 85 
percent of patients with acute myocarditis evolving within the first two weeks after the 
onset of symptoms.16 The pattern of hyperenhancement in the acute phase of myocarditis 
typically describes multiple foci within the lateral wall of the lv, originating primarily 
from the epicardium, see figure 3. When still present 4 weeks after the onset of acute 
myocarditis, this pattern of hyperenhancement has shown some, but limited prognostic 
value in patients with myocarditis.17
   Histologically, islets of necrotic, oedematous myocardium are dispersed throughout the 
hyperenhanced areas.18 Myocardial oedema in the acute phase of myocarditis can also be 
discerned with T2-weighted imaging, in which areas of increased signal intensity match 
the areas of hyperenhancement, see figure 3. Due to its susceptibility to movement, T2-
weighted imaging is less sensitive in diagnosing acute myocarditis, than lge imaging. 
   After healing, lv ejection fractions and dimensions often restore and the areas of 
hyperenhancement almost completely resolve.19 In similarity with myocardial infarct size 
shrinkage in the chronic phase, shrinkage of the islets of fibrotic areas to sizes smaller 
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than the dimensions of a voxel has been suggested as an underlying mechanism of this 
phenomenon. However, in patients in whom lv dysfunction and dilation persist, the mid 
ventricular ‘non-ischemic’ hyperenhancement pattern can be visualized. Whether the 
presence of replacement fibrosis can be attributed to an inflammatory process, or is part of 
non-specific lv remodelling, remains unknown. 
   Importantly, these studies have lead cmr to challenge the Dallas criteria as gold standard 
for the diagnosis of myocarditis, but further research on its prognostic value is still 
desirable. 
ArrhyThmOgENiC righT VENTriCulAr CArdiOmyOpAThy
arvc is histologically characterized by myocardial atrophy and gradual replacement of 
myocytes by adipose and fibrous tissue, and has an estimated prevalence of 1:5000 in 
general population. Genetic and/or infectious aetiology have been proposed. one study 
evaluated the diagnostic accuracy of cmr in a genotyped family of arvc patients. In total, 
cmr had a positive and negative predictive value of 93 percent and 88 percent respectively.20 
Most discriminative information was obtained from the lge and ssfp images. lge imaging 
had a sensitivity of 100 percent and specificity of 67 percent and hyperenhancement was 
shown in the left ventricle in 70-100 percent of patients, see figure 3. Also, detection of 
segmental right ventricular wall motion abnormalities, dilation or aneurysm formation 
had a sensitivity of 69 percent and specificity of 100 percent as observed with ssfp 
cine imaging, see figure 3. Even in this highly selected patient group, the detection of 
intramyocardial fat with T1-weighted spin echo imaging had a disappointing sensitivity of 
65 percent and specificity of 89 percent. The low sensitivity of both criteria indicates that a 
substantial proportion of arvc mutation carriers without overt arvc and other patients with 
milder forms of arvc still pose a high diagnostic challenge and can be missed with cmr. 
Therefore, the cmr evaluation of arvc should only be performed in dedicated, experienced 
cmr centers.
   Although cmr can be considered the most valuable imaging tool available in the diagnostic 
workup for arvc, its diagnostic accuracy, as well as its interobserver variability is not 
sufficient to definitively rule in or rule out arvc.
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uNClASSiFiEd CArdiOmyOpAThiES
Left ventricular non-compaction cardiomyopathy
lv non-compaction cardiomyopathy is an unclassified cardiomyopathy, characterized by 
an extensive layer of non-compacted myocardium aligning a compact layer of myocardium 
and is typically located in the apical and lateral regions of the lv, see figure 3.21 A familial 
occurrence of disease has been reported in up to 44 percent of patients and is strongly 
related to myopathies. While high-resolution imaging techniques often detect profound 
trabeculation at the apical and lateral regions of the lv in otherwise normal myocardium a 
non-compacted/compacted ratio >2.3 in end-diastole has been proposed to diagnose non-
compaction cardiomyopathy with cmr, yielding a sensitivity of 86 percent and specificity 
of 99 percent. However, in our experience, measuring non-compacted/compacted ratios 
>2.3 are also frequently found in other cardiomyopathies, such as ischemic dcm and hcm 
and even in healthy volunteers. Therefore, further refinement of the criteria to diagnose lv 
non-compaction cardiomyopathy with cmr is necessary. of note, no hyperenhancement 
has been reported in this particular patient group.
FuTurE pErSpECTiVES
   cmr can be considered the non-invasive gold standard for evaluation of cardiomyopathies, 
since it has the possibility to apply a broad spectrum of different imaging techniques for 
tissue characterisation, and combines a wide field of view with a high spatial and temporal 
resolution.
   Whereas the use of cmr has gained impressive diagnostic progress in nicm by identifying 
fibrosis, inflammation, infiltrative disease and iron deposition, these discoveries represent 
an important research challenge to gain more insight in its prognostic value. 
   In an era where the human genome has been fully sequenced and new pathogenic 
mutations are frequently identified, there may be a key role for cmr to detect early 
pathophysiological changes in asymptomatic patients at risk to develop cardiomyopathies, 
which is likely to become important in preventing the development of heart failure and 
onset of potentially life threatening arrhythmias. 
Also, with the development of cmr compatible pacemakers, cmr holds promising 
possibilities to refine the selection of candidates and optimization of resynchronization 
therapy. Finally, the diagnostic potential of high-field mri scanners and their implementation 
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in cardiac imaging, has not fully been explored and may become useful to more precisely 
evaluate left and right ventricular morphology.
   In summary, the relentless efforts put in cmr research in the past decades has resulted in 
cmr to play a pivotal role in non-invasive detection and determination of the aetiology of 
cardiomyopathies, and recent developments hold promise for the future.
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Figure 3. Identifying cardiac involvement in sarcoidosis (A, B, C), acute myocarditis (D, E, F), arvc 
(g, H, I), non-compaction cardiomyopathy (J, K) and hcm mutation carriership (I) using different 
cmr techniques. Applied techniques are: 4-chamber view ssfp cine imaging (A, D, G, J), 4 chamber 
view lge imaging (B, E, H). Short axis lge imaging (C), 4 chamber view T2-weighted spin echo 
imaging (F), axial T1-weighted imaging (I), Short axis and two chamber ssfp cine imaging (K, L). A. 
no specific cardiac abnormalities can be noted on the ssfp cine image of an asymptomatic patient with 
sarcoidosis. B, C. The lge images demonstrate extensive areas of sometimes transmural granulomas 
(yellow arrowheads). The absence of any areas of hyperenhancement in a patient with sarcoidosis 
almost excludes cardiac involvement in the disease. D. Cine image of a patient with typical chest 
pain and elevated troponin levels. No cardiac abnormalities are seen on the ssfp cine image. E. In the 
epicardium of the lateral wall, focal areas of hyperenhancement can be observed, indicating recent or 
acute myocarditis. F. The T2-weighted image shows oedematous focal areas within the myocardium 
corresponding with the focal areas of hyperenhancement. This indicates that this patient has acute 
myocarditis. G. This ssfp cine images shows mild right ventricular dilation, which is a minor criterion 
for arvc. Also, small areas of the right ventricular free wall appear to be bulging in diastole (yellow 
arrowheads), which is also one minor criterion for arvc. H. A focal area of hyperenhancement is 
identified in the septum (an indication of arvc with a very high positive predictive value) I. Also high 
signal intensity on T1-weighted image of the Rv wall near the apex can be noted, indicating fatty 
infiltration of the right ventricular free wall. However, fatty infiltration can be difficult to discriminate 
from epical fat overlying the right ventricle. Therefore, this sign of arvc has a low sensitivity and 
specificity. J. The diagnosis of non-compaction can be made with ssfp cine images only. Note the 
meshwork of trabeculae almost covering half the area of the left and right ventricle, as indicated by 
the white asterisks. K. A non-compacted to compacted ratio >2.3 measured on a short axis (not apex) 
in end-diastole is highly suggestive for isolated non-compaction cardiomyopathy. L. Crypts in a hcm 
mutation carrier, which are typically localized in the basal and mid inferoseptum (green arrowheads) and 
can penetrate compact myocardium up to the epicardium. (green dotted lines indicates border between 
right and left ventricle). This can be clearly distinguished from non-compaction cardiomyopathy.
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AbSTrACT
Background 
Biplane measurement allows rapid assessment of la volumes, however, the accuracy is 
debatable when the la dilates. In this study, the accuracy of several echocardiographic 
and cardiac magnetic resonance imaging (cmr) biplane la volume measurement methods 
is validated against 3d cmr la volume measurement.
Methods 
In 19 patients with hypertrophic cardiomyopathy and la dilation, la volumes were assessed 
with biplane echocardiography, using the area-length and Simpson’s summation of discs 
method. Subsequently, la volumes were measured with cmr, using the biplane area-length 
method and a 3d volume measurement method. The accuracy of the biplane methods 
to estimate 3d cmr la volume was determined with the Bland-Altman measurement of 
agreement method.
Results 
All biplane methods increasingly underestimated 3d cmr la volume in dilated la , but the 
mean measure of underestimation was larger with the echocardiographic methods than 
with cmr(47±18 mL and 58±23 mL, p<0.01, versus 17±28 mL, p=ns). The precision of all 
biplane methods was comparable, regardless of imaging modality. Inter- and intraobserver 
agreement was best with 3d cmr la volume measurement(1.6±2.3 percent and 0.5±2.4 
percent). Again, inter- and intraobserver agreement was comparable between all biplane 
methods.
Conclusion 
la volume measurement with biplane methods using echocardiographic and cmr yield 
different volumes but have comparable precision and inter- and intraobserver variabilities. 
Thus, repetitive biplane la volume measurements should be performed by a single imaging 
modality. 3d cmr la volume measurement provides optimal observer agreement in dilated 
la, and is therefore preferred to determine la volumes for research purposes.
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T he volume of the left atrium (la) has important prognostic value in ischemic and non-ischemic cardiac disease.1-7 In hypertrophic cardiomyopathy (hcm), dilation results 
from left ventricular (lv) diastolic dysfunction and mitral regurgitation and as such is an 
independent predictor of the development of atrial fibrillation and functional capacity. 
Also, la volume can be used to monitor the efficacy of therapeutic interventions.8-10 Several 
methods have been designed with echocardiography to calculate la volume from the areas 
of the la on two image planes (biplane methods). for calculation of la volume by the 
biplane methods, certain geometrical assumptions of the la are made, which include an 
ellipsoid shape of the longitudinal cross-section of the la in the biplane area-length method, 
and sphericity in the lv short axis orientation for the biplane Simpson’s summation of 
discs method. These two biplane methods are widely used in clinical practice, and their 
reproducibility and accuracy has been well validated in normal or minimally dilated la.11-
14 When the la dilates, its shape adapts to the surrounding anatomical structures including 
the aorta, the pulmonary arteries, and the spine. These structures affect the sphericity 
of the la, and may therefore reduce the accuracy of biplane methods.15 In addition, 
defining the posterior border of the la with 2D echocardiography is often difficult when 
la dilation occurs. Due to its superior tomographical qualities than echocardiography, 
biplane methods by cmr to be more accurate than echocardiography. on the other hand 
errors from calculations based on geometrical assumptions in dilated atria may offset this 
expectation. We therefore assessed the accuracy of two biplane volume measurement 
methods commonly used by echocardiography and of one biplane method by cmr, and 
validated their accuracy against 3d cmr la volume measurements. 
mEThOdS
Patient selection
Patients with hcm, defined as a left ventricular (lv) wall thickness >15 mm on M-mode 
echocardiography without the presence of increased external afterload (i.e. hypertension, 
aortic valve stenosis), were selected for this study. Patients gave written informed consent 
to participate, according to the declaration of Helsinki. Patients with claustrophobia or 
with an implanted non cmr-compatible device, were excluded from the study.
cmr image acquisition was performed in all patients, immediately preceded or followed 
by echocardiography. Images were analysed by two independent operators (T.G. and 
P.A.D.).
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Echocardiographic la volume measurement
echocardiography was performed on a vivid-7 machine, (General electrics vingmed 
ultrasound, Horten, Norway). The la anteroposterior dimension was derived from M-
mode registration obtained in the parasternal long axis view at end-systole. Apical 2- and 
4-chamber views were recorded during three consecutive heartbeats for biplane la volume 
measurements in end-systole. The two biplane la volume measurement methods that were 
evaluated in this study were: 1. the area-length method , see figure 1a and 1b and 2. the 
Simpson’s summation of disc method, see figure 1c.16 for the area-length method, the 
following equation was used to calculate la volume :
 8 * (area 4-chamber view * area 2 chamber view)
3π * (l1+l2)/2
la volume (mL) =
of the la appendage is excluded from analysis. C. Biplane Simpson’s summation of discs method. 
from every disc, a diameter on a 2- and 4-chamber view is determined (d2 and d4). from these two 
diameters, the area of a spherical lv short axis oriented disc of the la is determined. All areas of discs 
are summed and multiplied by the distance between the discs to calculated la volume. D. 3d cmr 
la volume measurement. on an end-systolic 2-chamber view, a stack of transversely oriented image 
planes is planned on the inferior leading edge of the mitral valve annulus. on every image plane, the 
area of the la is determined, and multiplied by the slice distance to calculate la volume. Pulmonary 
veins and the la appendage are excluded from the analysis. cmr= cardiac magnetic resonance imaging, 
la=left atrial, lv=left ventricular
Figure 1. 
schematic representation of 
biplane la volume and 3d cmr 
volume measurements.
A. and B. biplane area-length 
method. The dashed areas on 
the 2-chamber view (A) and 4-
chamber view (B) are used in 
the biplane area length method 
for calculation of la volume, 
together with l2 and l4, that 
indicate maximal longitudinal 
lengths of the la on a 2-
chamber and 4-chamber view 
respectively. Note that the area 
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l1 and l2 are the maximum longitudinal length of the la on a 4-chamber view and 2-
chamber view respectively. for the Simpson’s summation of disc method, the area of 
the short axis la disc was defined by the diameter of the la on a 2-chamber (d2) and a 
4-Chamber view (d4). The number of short axis la discs that were used to fully cover the 
la depended on the length of the la. la volumes were calculated by summation of the 
areas of the lv short axis la discs, multiplied by the slice distance between the discs. The 
pulmonary veins and la appendage were excluded from volume measurement, and the lv 
was delineated from the la by drawing a straight line between the leading edges of the 
mitral valve annulus.
cmr la volume measurement
cmr studies were performed on a 1.5-Tesla whole body scanner (Magnetom Sonata, 
Siemens, erlangen, Germany), using a six-channel phased-array body coil. After survey 
scans, a retro-triggered, balanced, steady-state free precession gradient-echo sequence 
was used for cine imaging. Image parameters were: slice thickness 5 mm, slice gap 5 
mm, temporal resolution <50ms, repetition time 3.2 ms, echo time 1.54 ms, flip angle 60 
degrees and a typical in-plane image resolution of 1.3*1.6 mm. The number of phases 
within the cardiac cycle was set at twenty. first, 4-, 3-, and 2-chamber cine views were 
acquired. A 3d la dataset was obtained by acquiring a stack of 6-10 transversely oriented 
slices planned on an end-systolic 2-chamber view starting form the lower leading edge 
of the mitral valve annulus see figure 1d. Images where analyzed off-line. For 3d cmr la 
volume measurement, endocardial contours were manually drawn on la data sets using 
mass analysis software (Medis medical imaging systems b.v., Leiden, The Netherlands). 
The la appendix and pulmonary veins were excluded from la volume analysis. A straight 
line was drawn between the leading edges of the mitral valve annulus to delineate the la 
and lv. The la volume was calculated using summation of la areas on transverse image 
planes in end-systole, multiplied by the slice distance of 10 mm. Biplane measurement 
was performed according to the area-length method, as described above, using Centricity 
Radiology ra600 Diagnostic version 6.1 (ge Medical Systems, Milwaukee, usa).
   To evaluate intraobserver agreement for all methods, one observer (T.G) repeated the 
la volume analysis in 10 randomly chosen patients, minimally one month after the first 
measurement. In addition, la volume analysis was performed by a second independent 
observer (P.A.D) to evaluate interobserver agreement.
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Statistical Analysis
A one-way between-groups anova was performed to compare means of la dimensions 
and volumes between echocardiography and cmr. Tukey’s post-hoc test was performed 
for pair wise comparison of the means. Pearson’s correlation test was used to determine 
the following correlations with 3d cmr la volumes: 1. the echocardiographically derived 
la anteroposterior dimension, 2. la volume measured with the biplane area-length method 
by echocardiography, 3, la volume measured with the Simpson’s summation of discs 
method by echocardiography, and 4. la volume measured with the biplane area-length 
method with cmr. In addition, Pearson’s correlation was used to determine the correlation 
between the echocardiographic and cmr derived biplane area-length la volumes. The 
Bland-Altman method for agreement analysis was used to evaluate the agreement between 
echocardiographic and cmr biplane la volume measurements and 3d cmr la volume, and 
to measure inter- and intraobserver agreement of all methods.17 Also, the coefficient of 
variability was calculated by dividing the standard deviation of two measurements by 
their mean. A p-value <0.05 was considered statistically significant. Data are presented as 
mean value ± standard deviation when appropriate. Limits of agreement were calculated 
as mean ± 2·standard deviation.
Table 1. Baseline characteristics
Variables  
Age 52±11
Heart rate (/min) 58±7
Systolic bloodpressure (mmHg) 126±13
Diastolic bloodpressure (mmHg) 78±6
Left ventricular mass (g∙m-2)* 105±36
Left ventricular end diastolic volume (mL∙m-2)* 93±14
Left ventricular end systolic volume (mL∙m-2)* 35±8
Left ventricular ejection fraction (%)* 63±6
Intraventricular septal wall thickness (mm)** 17±5
Lateral left ventricular wall thickness (mm)** 12±2
Left ventricular outflow tract gradient (mmHg)** 47±34
* cardiac magnetic resonance imaging derived variables ** echocardiography derived variables
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rESulTS
Nineteen patients were included in the study (mean age 52±11 years, 9 males). Baseline 
characteristics are presented in table 1. With echocardiography, the la anteroposterior 
dimension was 48±8 mm. The biplane area-length method yielded a mean la volume of 97±50 
mL, and the Simpson’s summation of discs method 86±44 mL. With cmr, the biplane la volume 
was 127±44 mL, which was not significantly different from the echocardiographic volumes. 
Figure 2. correlations between la anteroposterior dimension and biplane la volume measurement 
methods with 3d cmr la volume. Dashed line indicates the line of equality A. correlation between 
la anteroposterior dimension measurement and 3d cmr la volume. B. correlation between biplane 
Simpson la volume measured with echocardiography and 3d cmr la volume. Note that the line of 
equality shows that the biplane method increasingly underestimates 3d cmr la volume when la volume 
increases. C. Correlation between biplane area-length la volume measured with echocardiography 
and 3d cmr la volume. Parallel to biplane area-length la volume measured with echocardiography, 
relatively small 3d cmr la volumes are well estimated by biplane area length la volume measured 
with cmr, but underestimated when la volume increases. D. Correlation between biplane area-length 
la volume with cmr and 3d cmr la volume. Again, this biplane la volume measurement methods 
increasingly underestimates 3d cmr la volumes when la volume increases. ap= anteroposterior, cmr= 
cardiac magnetic resonance imaging, la=left atrial
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3d cmr la volume was 144±60 mL which was significantly larger than the la volumes derived 
from both biplane echocardiographic methods, p<0.01, but not from biplane cmr la volume.
   The la anteroposterior dimension correlated moderately with 3d cmr la volume, r=0.51, 
p<0.05, see figure 2a. 3d cmr la volume correlated strongly with the echocardiographic 
biplane area-length la volume, r=0.86, p<0.0001, biplane Simpson’s method la volume, 
r=0.93, p<0.0001, and biplane cmr la volume, r=0.88, p<0.0001 , see figure 2b,c,d. 
However, the lines of equality indicate that all biplane methods substantially underestimate 
la volumes when la volume increases, regardless of imaging modality, see figure 2.
   Bland-Altman analysis showed that best agreement was obtained between the biplane 
cmr la volumes and 3d cmr la volume, with a large range of the limits of agreement (-39 
mL to 74 mL), see figure 3. Although the biplane methods used with echocardiography 
underestimated 3d cmr la volumes more than the biplane method used with cmr, the 
precision of the echocardiographic biplane methods was comparable with the biplane cmr 
Figure 3. Bland-Altman analysis of agreement between 3d cmr la volume and A. biplane Simpson’s 
la volume measured with echocardiography, B. biplane area-length la volume measured with 
echocardiography and C. biplane area-length la volume measured with cmr. Note that the best 
agreement is between biplane area-length la volume measured with cmr and 3d cmr la volume (solid 
lines), but that the quality of the estimates, represented by range between the upper and lower limits of 
agreement (dashed lines) between the three biplane la volume measurement methods is comparable. 
cmr= cardiac magnetic resonance imaging, la=left atrial
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Table 2. Inter- and intraobserver variability of different methods to measure la volumes
Measurement method interobserver variability intraobserver variability
mean diff. 
(mL±s.d)
mean diff. 
(%±s.d)
Cov. 
(%)
mean diff. 
(mL±s.d)
mean diff. 
(%±s.d)
Cov. 
(%)
Biplane Simpson’s echo 0.6±6.6 1.4±11.0 8.1 2.8±9.7 1.1±11.3 11.5
Biplane area-length echo 1.3±15.0 0.3±21.6 16.6 0.0±14.8 2.2±21.9 17.5
Biplane area-length cmr 5.7±7.5 10.9±13.8 11.1 1.5±4.9 2.9±10.5 7.8
3d cmr 1.3±3.8 0.5±2.4† 2.8 2.0±2.2 1.6±2.3 1.7
diff.=difference, S.D.= standard deviation, cmr = cardiac magnetic resonance imaging, Cov.= 
coefficient of variability, † p<0.001 compared to biplane area-length cmr
method, with limits of agreement ranging from 11 mL to 83 mL with the biplane area-
length method and from 12 mL to 107 mL with the Simpson’s summation of discs method.
   Inter-and intraobserver agreement of all la volume measurement methods presented 
in table 2 showed that the smallest inter- and intraobserver limits of agreement was 
achieved with the 3d cmr la volume measurement, ranging from -3.0 percent to +6.2 
percent for the inter observer variability and for the intraobserver variability and -4.3 
percent to 5.3 percent. Also, the biplane Simpson’s summation of discs method seemed 
to be more precise than the area-length method, see table 2. Coefficient of variability was 
lowest in the 3d cmr la volume measurement compared to the biplane methods. Biplane 
area-length method revealed to have the largest coefficient of variability, see table 2.
diSCuSSiON
We assessed the accuracy of biplane volume measurement methods with echocardiography 
and cmr in hcm patients with dilated la by using 3d cmr la volumes measured as 
reference. All biplane la volume measurements increasingly underestimated la volumes 
when la dilation occurred, regardless of imaging modality. Despite a larger systematic 
underestimation of la volumes, biplane la volume measurement with echocardiography 
provided similar precision as biplane la volume measurement with cmr. Nevertheless, 
biplane la volume measured with cmr tended to be larger than with echocardiography. As a 
consequence, biplane echocardiography and cmr methods can not be used interchangeably 
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during the follow-up of a patient. 
   The smallest limits of inter- and intraobserver agreement were achieved with the 3d 
cmr method. This advocates the use of the 3d cmr method for repetitive la volume 
measurements, when small changes in volume have important implications, for example 
to evaluate the effect of therapy, or for research purposes. Despite these advantages, the 
acquisition and post-processing analysis are relatively time-consuming, the latter calling 
for the development of faster post-processing analysis techniques. Alternatively, real-
time 3d echocardiography may serve as a candidate for fast and accurate 3d la volume 
measurement, however only limited data is available comparing the accuracy of real-
time 3d echocardiography with 3d cmr and warrants further research.18 until then, the 
clinical applicability of the 3d method is limited and the faster biplane methods are more 
appropriate for clinical la volume measurement. 
   However, several considerations should be taken into account when using biplane methods 
to determine la volume: Biplane methods have large intraobserver limits of agreement 
which should be reckoned with when interpreting changes in la volumes. The difficult 
delineation between the body of the la, the pulmonary veins, the la appendage and the lv 
may importantly account for this relatively large intraobserver agreement. This effect may 
be reduced by averaging multiple measurements of one la volume by a single observer to 
define the la volume. However, this would offset its advantage of shorter analysis time 
compared to 3d cmr. In addition, biplane methods rely on limited measurements, which 
are multiplied in a formula. As a consequence, small variances in these measurements may 
lead to large errors of calculated volumes. As such, the Simpson’s summation of discs method 
is expected to be less sensitive to variances in measurements than the area-length method, as 
indicated in this report, see table 2, and may therefore be the biplane method of choice for 
clinical purposes. Thirdly, biplane methods are susceptible to inter- and intraoperator variability 
in determining the orientation of the 2- and 4-chamber views. This may not only interfere with 
accurate repetitive la volume measurement, but also explain the large limits of agreement 
between biplane la volumes and 3d cmr la volumes found in this study. Positioning of the two 
imaging planes at small offsets from the center of the la may lead to substantial underestimation 
of the volume. The 3d cmr la volume measurement in this study was performed on a la dataset 
that was constructed from strictly transversely oriented image planes, and therefore less likely to 
be subject to inter- and intraoperator variability, but this still needs to be further investigated. 
   Sievers and colleagues, who evaluated several cmr methods to measure la volume in healthy 
volunteers and in patients with atrial fibrillation found better agreement between biplane volume 
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measurement and 3d cmr measurement.11 Indeed, la volumes in their patient population were 
smaller, which is in line with the finding in this report that a biplane volume measurement 
becomes less accurate in dilated la, as illustrated in figure 2d.
Limitations
This was a single center study in a relatively small sample size. We evaluated a random sample 
of our hcm patient population, without selection criteria for image quality either on echo or 
cmr. Selecting hcm patients also based on image quality, probably would have improved the 
accuracy of la volume measurements. 
   With cmr, we did not evaluate the biplane Simpson’s summation of discs method, since no 
commercially available software is available yet to use this method on cmr images. However, 
as can be inferred form this report, it may be the optimal trade-off between accuracy and time 
consumption for clinical la volume measurement with cmr. We only evaluated la volumes in 
hcm patients, but results from this study are likely to be also applicable to other cardiac diseases 
in which la are dilated. 
Conclusion
Biplane la volume measurement with echocardiography and cmr have comparable precision, 
but increasingly underestimate 3d cmr la volume when the la dilates. Biplane la volumes 
using Simpson’s method of discs may be most suitable for daily clinical purposes. The 3d cmr 
la volume measurement has the highest level of agreement, and is therefore the technique of 
choice to measure la volumes for research purposes.
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AbSTrACT
Introduction 
Left ventricular (lv) filling results from diastolic suction of the lv and passive left atrial 
(la) emptying at early-diastole, and la contraction at end-diastole. The effects of ageing 
on la and lv geometry and function, and its consequences for lv filling are incompletely 
understood. Insight in these effects may increase our understanding of diastolic function. 
We used cardiac magnetic resonance imaging (cmr) to study the effects of ageing on left 
atrio-ventricular coupling and lv filling. 
Methods and Results
forty healthy volunteers underwent cmr and were subdivided into 2 age-groups: 20-40 
years (younger group). and 40-65 years (older group). for the older group, la volumes 
were larger (p<0.05), lv volumes - including stroke volumes - were smaller (p<0.05), 
whereas ejection fraction (ef) remained constant. The la-to-lv-volume ratios were larger 
(0.27±0.06 versus 0.19±0.03, p<0.001) and correlated with lv mass-to-volume ratio 
(r=0.42, p<0.01). The older group also had smaller la passive emptying (15±3.0 versus 
19±4.8 mL·m-2, p<0.05), and larger la active emptying volumes (13±3.1 versus 11±3.9 
mL∙m-2, p<0.05). for both groups, the conduit volume contributed most to lv filling, but 
was lower in the older group (21±5.1 mL versus 27±9.0 mL, p<0.05).
Conclusion
Changes in la volume and function are age-dependent and related to changes in lv mass-
to-volume ratio. The conduit volume contributes most to lv filling, and decreases with 
age, suggesting to be an indicator of diastolic function.
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With ageing, left atrial (la) volumes and function and filling of the left ventricle (lv) change.1-3 However, it is currently incompletely understood whether these 
age dependent changes in la volumes and function result from isolated alterations 
of la physiological properties, or from an altered left atrio-ventricular coupling. 
understanding these interactions and their age-dependency may lead to an increased 
insight in the mechanical aspects of diastolic function of the heart and possibly improve 
the evaluation of diastolic dysfunction. Cardiac magnetic resonance imaging (cmr) 
has a high spatial and temporal resolution, and can be used to accurately measure la 
and lv volumes and lvmass.4-6 Therefore, we used cmr to study the age-dependent 
changes in left atrio-ventricular coupling and lv filling.
mEThOdS
Study population
Subjects were recruited among healthcare workers in our institute. Subjects had to be 
non-smoking, free of pulmonary or cardiovascular disease, diabetes mellitus and/or 
hypertension (defined as systolic blood pressure ≥160 mmHg and/or diastolic blood 
pressure ≥90 mmHg). Subjects with a body mass index >30 kg·m-2, heart murmur, 
and/or abnormal electrocardiogram were excluded. Subjects with a heart rate <50 
beats per minute (bpm) or >80 bpm during image acquisition were excluded from 
analysis to minimize the effects of heart rate variability.4 The study population was 
subdivided into 2 age-groups: 20-40 years (younger group) and 40-65 years (older 
group). The study conformed to the principles outlined in the Declaration of Helsinki, 
was approved by the institutional review committee, and written informed consent 
was obtained from the subjects.
cmr image acquisition
cmr studies were performed on a 1.5-Tesla whole body scanner (Magnetom Sonata, 
Siemens, erlangen, Germany), using a six-channel phased-array body coil. After 
survey scans, a retro-triggered, balanced steady-state free precession gradient-echo 
sequence was used for cine imaging. Image parameters were: slice thickness 5 mm, 
slice gap 5 mm, temporal resolution <50 ms, repetition time 3.2 ms, echo time 1.54 
ms, flip angle 60 degrees and a typical image resolution of 1.3*1.6 mm. The number 
of phases within the cardiac cycle was set at 20. After the 4-, 3-, and 2-chamber view 
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cines were obtained, a stack of 6-10 transversely oriented slices was planned on an 
end-diastolic 2-chamber view at the level of the lower leading edge of the mitral valve 
annulus to cover the la, see figure 1.7 Then, a stack of 10-12 short axis slices were 
acquired for full coverage of the lv. The method of planning the image acquisition 
for lv coverage has been described previously.8 Cine images were acquired during 
one breath-hold in mild expiration.
Image post processing 
Images where analyzed off-line, using mass analysis software (Medis, Leiden, The 
Netherlands). for la volume analysis, endocardial contours were manually drawn on all 
la data sets in every phase of the cardiac cycle. The la appendix was included into the 
la volume, and pulmonary veins where excluded. A straight line was drawn between 
the leading edges of the mitral valve annulus to delineate la and lv, see figure 1. The 
Figure 1. planning of image planes. A. Planning of transverse left atrial cines on 2-chamber view in 
end-systole. Dotted lines indicate cut lines of images B to f from top to bottom. B-F. Contour drawing 
of left atrium on transverse images. The pulmonary veins are denoted by asterisks and excluded from 
left atrial volume measurement (B, C); a straight line is drawn between the leading edges of the mitral 
valve annulus to delineate left atrial and left ventricular border (D-f). Ao= Aorta, la= left atrium, laA= 
left atrial appendage, lv= left ventricle, PT= pulmonary trunk, RA= right atrium, RAA= right atrial 
appendage, Rv= right ventricle, SvC= superior vena cava.
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la volume was calculated using summation of la areas on transverse image planes, 
multiplied by slice distance. for lv volume analysis, epi– and endocardial contours were 
manually drawn on all end-diastolic and end-systolic lv short axis images. lv mass was 
automatically calculated using epi- and endocardial contours.9 Papillary muscles were 
excluded from lv volume and included in lv mass.
Analysis of la and lv volumes 
from the la datasets, minimum la volume, maximum la volume, la volume at diastasis 
and la volume prior to atrial contraction were determined, see figure 2. lv end-diastolic 
volume and lv end-systolic volume were determined from the end-diastolic and end-
systolic lv contours. Also, lv mass-to-volume ratio was calculated by dividing lv end-
diastolic mass by lv end-diastolic volume. The latter may serve as a marker for diastolic 
function.10 from the la and lv volumes, la reservoir volume, la passive emptying volume, 
la active emptying volume, la ejection function, conduit volume, lv ejection fraction and 
lv stroke volume were calculated, see table 1. of note, in some reports, the reduction of 
la volume during early diastole is called la reservoir volume.11, 12 In the present study, we 
Figure 2. Left atrial and left ventricular time-volume curves showing that the total left heart volume 
deviates from its constant volume state during systole, and is restored by generation of the conduit 
volume during early diastole. The passive motion of the left atrium from B to C, the active contraction 
of the left atrium from D to A and the conduit volume together account for left ventricular filling. *= 
isovolumetric relaxation period, A= minimum left atrial volume, B= maximum left atrial volume, C= 
left atrial volume at diastasis, D= left atrial volume prior to atrial contraction, e= left ventricular end 
diastolic volume, f= left ventricular end systolic volume.
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used the term la reservoir volume to describe the increase of the la volume during systole, 
when the la serves as a reservoir for blood from the pulmonary veins.
Statistical analysis
Based on previous studies on la volumes and function with cmr, a sample size for each 
group of 17 subjects was calculated to have a power of 80% to detect a 25% change in la 
volumes, with a 2-sided α of 0.05. We assumed that 10% of acquired datasets were not 
analysable. To maintain a power of 80 percent, the sample size of each age-group was set 
at 20 subjects. Normally distributed, continuous variables are presented as mean±standard 
deviation. A simple log transformation was performed when variables were not normally 
distributed as determined by a Kolmogorov-Smirnov test of normality. An independent, 
unpaired Students t-test was used to compare la and lv volumes and function and total 
left heart volumes between the 2 age-groups. Pearson’s correlation test was used for to 
identify correlations of la functions and la-to-lv ratios with lv mass-to-volume ratio. 
Partial correlation was used to control correlations for gender. Analysis was performed 
with Statistical Package for Social Sciences (spss for windows 12.0.1, Chicago, il). Results 
were considered statistically significant if p-values <0.05.
Table 1. Calculation of left atrial and left ventricular volumes and function
LA and LV volumes & function Equation
la reservoir volume Maximum la volume - minimum la volume
la passive emptying volume Maximum la volume – mid diastolic la plateau volume
la active emptying volume la volume prior to contraction – minimum la volume
la ejection function
(la active emptying volume / la volume prior to 
contraction)*100% 
Conduit volume lv stroke volume – la reservoir volume
lv ejection fraction (lv stroke volume / lv end diastolic volume)*100%
lv stroke volume lv end diastolic volume – lv end systolic volume
Total left heart volume la + lv volume
Maximum deviation from the 
constant volume state
End diastolic – end systolic total left heart volume
la = left atrial, lv = left ventricular
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rESulTS 
A total of 40 subjects were recruited, 20 in the younger group (11 males, mean age 29±5 
years) and 20 in the older group (12 males, mean age 51±6 years). In both groups, 1 
dataset was not analyzable, due to heart rates that exceeded limits. Thus, a total of 19 
subjects in each age group were analyzed. Body mass index, blood pressure, and heart rate 
were all comparable between both groups, see table 2. Minimum la volume was larger in 
the older group, 22±4.4 mL·m-2 versus 18±4.5 mL·m-2,p<0.01 and maximum la volume 
tended to be larger in the older group 50±6.7 mL·m-2 versus 47±9.3 mL·m-2, see figure 
3A. la passive emptying volume was smaller, p<0.05, and la active emptying volume 
was larger, p<0.05 in the older group, whereas la ejection function remained unchanged, 
see table 3. Also, conduit volume was smaller in the older group, p<0.05. lv end diastolic 
and end systolic volumes were smaller in the older group, 83±12 mL·m-2 versus 96±15 
mL∙m-2, p<0.05, and 33±7.0 mL·m-2 versus 40±7 mL·m-2, p<0.05 respectivel, see figure 
3B, while lv mass was comparable. As a result, lv mass-to-volume ratio was significantly 
larger in the older group in males, 0.7±0.14 gram·mL-1 versus 0.6±0.07 gram·mL-1, 
p<0.05, but not in females, 0.5±0.08 gram·mL-1 versus 0.5±0.05 gram·mL-1, see figure 
3C. Partial correlation showed that lv mass-to-volume ratio was positively correlated with 
Table 2. Baseline characteristics
Variable
Age group 20-40 years
(n=19)
Age group 40-65 years 
(n=19)
Mean age (years) 29±5 51±6†
Male/female ratio 11/8 10/9
Body mass index (kg∙m-2) 22.6±1.7 23.9±2.8
Systolic blood pressure (mmHg) 124±10 121±14
Diastolic blood pressure (mmHg) 72±6 70±8
Heart rate (beats∙min-1) 71±11 69±9
Cardiac index (L∙m-2) 4.8±0.7 3.6±0.6
† = p<0.001 versus baseline
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age (r=0.35, p<0.05) when controlling for gender. With bivariate correlation analysis, 
la passive emptying volume correlated with lv mass-to-volume ratio (r=-0.41, p<0.05) and 
conduit volume with lv ejection fraction (r=0.35, p<0.05).Total left sided heart volumes 
were comparable between both age-groups, however, total left heart volumes of the older 
group tended to be smaller, 105±13 mL·m-2 versus 115±18 mL·m-2 for the end diastolic 
volumes, and 83±12.1 mL·m-2 versus 86±14.3 mL·m-2 for end systolic volumes, p=ns. 
However, maximum deviation from the constant state of the left heart was smaller in the 
older group, 12±2.9 mL·m-2 versus 15±4.5 mL·m-2, p<0.05, see figure 3B, which is in line 
with the smaller conduit volume. The ratios of la-to-lv volumes in end-diastole and end-
systole were both larger in the older group, p<0.001, and correlated to lv mass-to-volume 
ratio (r=0.42, p<0.01). 
   In both groups, the conduit volume contributed most to lv filling, 47±11.6% in the 
younger group and 43±6.6% in the older group, p=ns, see figure 3d. Although passive 
emptying volume was smaller in the older group, the contribution of la passive emptying 
to filling of the lv was maintained, 31±5.5% versus 34±8.6%, p=ns. The contribution of 
Table 3. Left atrial and left ventricular volumes and function indexed to body surface area 
variable
Age group 20-40 years
(n=19)
Age group 40-65 years 
(n=19)
Left atrial reservoir volume (mL∙m-2) 29±6.7 28±3.7
Left atrial passive emptying volume (mL∙m-2) 19±4.8 15±3.0*
Left atrial active emptying volume (mL∙m-2) 11±3.9 13±3.1*
Left atrial ejection function (%) 37±7.3 38±5.8
Conduit volume (mL∙m-2) 27±9.0 21±5.1*
Left ventricular stroke volume (mL∙m-2) 57±10 50±6.5*
Left ventricular ejection fraction (%) 59±5.0 60±5.1
Left ventricular mass (g∙m-2) 59±15 53±12
Left ventricular mass-to-volume ratio 0.6±0.09 0.6±0.11
end diastolic left atrium / left ventricle ratio 0.2±0.03 0.3±0.06†
end systolic left atrium / left ventricle ratio 1.2±0.31 1.6±0.29†
* p<0.05 versus age group 20-40 years, † p<0.001 versus age group 20-40 years
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Figure 3. effect of age on volumes, function and lv mass-to-volume ratio. Minimum left atrium volumes 
and left atrial volumes at diastasis are larger in the older group (A). Also, left ventricular volumes are 
significantly lower in the older group (B). Left ventricular mass-to-volume ratio is larger in males in the 
older group, but not in females (C). The contribution of passive emptying and conduit tend to be lower 
in the older group, resulting in increased contribution of active emptying of the left atrium to filling of 
the left ventricle (D). tlhed = total left heart volume at end diastole, tlhes= total left heart volume at 
end systole, lved = left ventricular volume at end diastole, lves = left ventricular volume at end systole, 
max dev= maximum deviation from the constant state of the left heart. *=p<0.05, †=p<0.001
la active emptying volume to filling of the lv was larger in the older group, 27±5.9% 
versus 19±5.2%, p<0.001, see figure 3D.
discussion
This is the first study demonstrating that age-dependent changes in la volumes and function 
are strongly related to changes in lv volumes and lv mass-to-volume ratio, the latter being 
a marker of diastolic function.13 The age-dependent alterations of la volumes and function 
found in this cmr study comply with the results from previous echocardiographic studies 
on age-dependent changes in la volume and function.14-16 
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   We found that, whereas total left heart volume was preserved, the ratio between la and 
lv volumes was larger in the older group, due to increased la and decreased lv volumes. 
These changes can be explained by the observed increase in lv mass-to-volume ratio, 
which is in line with the age dependent myocardial alterations that occur on a cellular 
level; the number of cardiomyocytes decreases, and the remaining cardiomyocytes become 
hypertrophied.17, 18
The hypertrophy of the remaining cardiomyocytes and increase in lv mass-to-volume 
ratio is probably a physiological response of the heart to increased vascular afterload due 
to arterial stiffening.19 The increased lv mass-to-volume ratio subsequently results in a 
decreased compliance of the lv,20 which may lead to a gradual increase in la pressure. In 
response, the la may adapt by dilation, thereby restoring both la pressure and total left 
heart volume. Although serial simultaneous measurements of both la and lv volumes and 
pressures are necessary to verify this hypothesis, it may well explain why la pressures are 
found to be normal in elderly, as reported by Prasad and colleagues.21
   In addition, our results illustrate that ageing affects left atrio-ventricular coupling 
throughout the entire cardiac cycle: During systole, the amount of blood that is injected 
into the aorta, is larger than the amount of blood that enters the la, yielding a volumetric 
deficit of the total left heart volume, see figure 2. In the elder population, the maximum 
deviation of the constant volume state of the heart is reduced due to smaller lv volumes. 
The smaller lv volume results in a smaller motion of the mitral valve annulus plane 
in early diastole and thereby contributes to a smaller la passive emptying volume and 
smaller E-wave on mitral valve inflow pattern in the elder population, which reflects a 
smaller amount of blood flowing from the la into the lv.22-24 Also in early diastole, blood 
flows simultaneously from the pulmonary veins into the la, reflected by the D-wave on 
pulmonary venous flow pattern, and restores the total left heart volume and generates the 
conduit volume, see figure 2, as previously reported by Bowman and colleagues.11 In the 
older group, we found that both la passive emptying and conduit volume were reduced, 
which lead to increased importance of la contraction to filling of the lv, implying that the 
diastolic properties of the lv were reduced. Although we did not measure lv distensibility 
in this study, this in is line with the increased lv mass-to-volume ratio found in the older 
group.
   Indeed, conduit volume is the net result of diastolic properties of the lv, such as elastic 
recoil and lv distensibility, and existing pressure gradient between the pulmonary veins 
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and lv cavity. In this study, conduit volume was not strongly affected by lv mass-to-
volume ratio in the presence of presumed normal pulmonary venous pressures. However, 
when pathological increase in lv mass-to-volume ratio occurs, as in hypertrophic 
cardiomyopathy, aortic stenosis or hypertensive heart disease, the conduit volume may 
increasingly become dependent on the existing pressure gradient between the pulmonary 
veins and lv cavity. Then, conduit volume may be reduced and thus lv filling increasingly 
becomes dependent on la contraction. This may lead to increased exercise intolerance and 
symptomatic atrial fibrillation. However, to confirm this, la and lv volumes and function 
must be evaluated under physiological exercise conditions.
   Absolute lamax was not strongly affected by ageing, which is in line which previous 
reports.4, 25 When pathophysiologic changes of the heart occur, and in particular if lv 
filling is severely impaired, absolute lamax increases and as such is a strong prognostic 
marker for adverse outcome.26-29
   Maximum age in our population was 63 years. Many cardiac diseases occur in older 
populations. Therefore, further research is necessary to obtain reference cmr values of 
ratios of la-to-lv volumes and total left heart volumes in older age-groups. This study was 
powered to identify differences in la and lv volumes; however, a limited sample size may 
have caused type 2 errors in the evaluation of function. No invasive or other non-invasive 
diastolic parameters were used to investigate the role of altered diastolic lv function on 
age-dependent alterations of la and lv volumes and total left heart volumes.
   Due to the tomographical qualities of cmr, no geometrical assumptions were required 
to measure la volumes, and allowed inclusion of the la appendage into the volume 
measurement. As a result, the ‘true’ la volumes used in this study were larger than the 
reference values obtained by echocardiography and showed that changes in la volumes 
and function are age dependent and related to changes in lv volumes and lv mass-to-
volume ratio.
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AbstrAct
Objectives 
To evaluate whether structural left ventricular (lv) abnormalities can be observed in hcm 
mutation carriers, in whom no echocardiographic signs of hypertrophy have yet developed, 
by using cardiac magnetic resonance imaging (cmr).
Background 
Hypertrophic cardiomyopathy (hcm) is caused by mutations of genes encoding for 
sarcomeric proteins. Myocyte disarray and interstitial fibrosis precede the development of 
regional hypertrophy in hcm mutation carriers(carriers). No macroscopic left ventricular(lv) 
structural abnormalities have been observed in carriers without lv hypertrophy. 
Methods 
A cmr, echocardiogram and electrocardiogram(ecg) were performed in 16 carriers. Late 
Gadolinium enhancement imaging (lge) was used with cmr to detect fibrosis. In 16 age and 
gender matched controls, cmr and ecg where performed, and an echocardiogram was made 
when structural abnormalities were detected with cmr. All carriers had a lv wall thickness 
<13 millimetres in the year prior to the study, measured by echocardiography.
Results
 In 13 carriers (81%), crypts were discerned with cmr in the basal and mid inferoseptal lv 
wall, not detected by routine echocardiography and not observed in healthy volunteers. In 4 of 
the crypt-positive carriers, both the echocardiogram, and ecg were normal. Two hcm carriers 
revealed regional hypertrophy of the inferoseptum not detected by echocardiography, and in 
both carriers, focal lge was present.
Conclusions 
In carriers in whom frank hypertrophy has not developed yet, crypts can be detected with 
cmr in the inferoseptal lv wall, even when echocardiography and ecg are normal. The 
crypts may represent one of the early pathological alterations of myocardium in carriers, 
that ultimately progress into manifest hcm.
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H ypertrophic cardiomyopathy (hcm) is a common disease, with a prevalence in general population of 1:500 and is clinically diagnosed by the presence of left ventricular (lv) 
hypertrophy in the absence of a disease likely to cause this hypertrophy1.
   Hereditary hcm is caused by mutations in genes of which most encode for sarcomeric 
proteins2. Genetic screening of families of index hcm patients enables the identification of 
hcm mutation carriers, in whom echocardiographic dimensions of the left ventricle (lv) may 
still be within the normal range. It is yet unclear how mutations in sarcomeric proteins, 
that presumably affect all cardiac myocytes, give rise to the usually regional myocardial 
hypertrophy.
   Earlier studies in animals and human subjects have shown that myocyte disarray, fibrosis, 
relaxation abnormalities and concomitant left atrial enlargement precede the development 
of frank hypertrophy in mutation carriers3, 4. We hypothesized that hcm mutation carriers 
exhibit local structural abnormalities before hypertrophy can be discerned.
   Cardiac Magnetic Resonance imaging (cmr) has a high spatial resolution and is 
considered the gold standard for in-vivo determination of mass and volumes of the lv and 
enables precise quantification of wall thickness and dimensions5. Also, cmr with delayed 
contrast enhancement (lge) imaging can be used to detect foci of collagen deposition in the 
myocardium of hcm patients6.
   Therefore, we used cmr to evaluate whether structural lv abnormalities can be observed 
in hcm mutation carriers, in whom no echocardiographic signs of hypertrophy have yet 
developed.
methods 
Patient selection 
hcm mutation carriers with an lv wall thickness < 13 millimetres as measured by 2d 
echocardiography in the year prior to the study were selected. The hcm mutations carriers 
had either a 2373insG mutation in the gene encoding for cardiac myosin binding protein C 
(mybpc3), which is found in at least 25% of hcm patients in the Netherlands7, or a Glu62Gln 
missense mutation in the gene encoding for alpha-tropomyosin (tpm1)8.
Other inclusion criteria were: sinus rhythm, age between twenty and sixty-five years, no 
signs and/or symptoms of coronary artery disease and no history of a disease likely to cause 
secondary lv hypertrophy. The structure and global function of the lv of hcm mutation 
carriers were compared with those of age and gender matched healthy volunteers.
   Healthy volunteers, recruited from hospital employees, were included when having no 
history of cardiovascular disease, no heart murmur or hypertension on physical examination, 
and a normal electrocardiogram (ecg). Furthermore, first degree relatives of healthy 
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volunteers had to be free of inheritable cardiomyopathy, (aborted) sudden cardiac death 
and/or unexplained syncope.
   exclusion criteria for all participants were: an implanted pacemaker, implantable cardioverter-
defibrillator, cerebral clips, known allergy to gadolinium- diethylenetriaminepenta-acetic 
acid (gadolinium-dtpa) and/or claustrophobia.
   In all hcm mutation carriers, a cmr, echocardiogram and ecg were performed. A cmr and 
ecg were also performed in healthy volunteers. An echocardiogram was only performed in 
healthy volunteers when any abnormalities were revealed by cmr. 
The study was approved by our institutional ethics Committee. All participants gave written 
informed consent.
cmr image acquisition 
cmr studies were performed on a 1.5 Tesla whole body scanner (Magnetom Sonata, Siemens, 
erlangen, Germany), using a six-channel phased-array body coil. After survey scans, long 
axis four, three, and two chamber cines were acquired with a retro-triggered, balanced 
steady state free precession gradient-echo (truefISP) sequence.
   Scan parameters were: 5 mm slice-thickness with 5 mm gap between short axis slices, 
temporal resolution <50 ms, repetition time 3.2 ms, echo time 1.54 ms, flip angle 70 degrees 
and typical image resolution 1.3*1.6 mm. A stack of 10-12 short axis slices was used to cover 
the lv, as described previously9. Acquiring additional cine images was left to the discretion 
of the attending cardiologist, specialized in cmr.
   lge images were obtained 10 minutes after injection of 0.2 mmol/kg gadolinium-dtpa. An 
inversion recovery turbo fast Low Angle Shot (flash) sequence was used to obtain images 
with 6 mm slice thickness planned at the same position as the long and short axis cines in 
end-diastole. All images were obtained during breath-holding in mild expiration. lv volumes 
and mass were obtained as described previously9. lv volumes and mass were indexed to 
body surface area. end systolic left atrial dimensions were measured on three chamber view 
as the distance between the aortic root and posterior wall of the left atrium. The presence 
of lge and the structure of the lv were evaluated by a cardiologist, experienced in cmr 
(A.C.v.R), and blinded to the genotype.
Echocardiography
Two-dimensional and Doppler-echocardiography was performed on a vivid-7, (General 
electrics vingmed ultrasound, Horten, Norway). lv structure and function were evaluated 
on parasternal and apical views. Acquiring additional images was left to the discretion of 
the echocardiographer. lv structure and function were evaluated by a cardiologist (o.K.), 
experienced in echocardiography, and blinded to the genotype.
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Electrocardiography 
Standard twelve-lead ecg was performed. Conduction intervals were measured and lv 
hypertrophy was evaluated using the Romhilt-estes criteria10. ST-segments were defined as 
normal or abnormal, and in addition, a R-wave in v1> 3 mm was considered abnormal. ecg’s 
were analyzed by two observers blinded for the genotype (T.G., A.A.M.W.)
Genetic screening
Genomic DNA was isolated from blood samples. Sequencing protocols are given in 
references 7 and 8.
Statistical analysis
An independent student’s t test was used to compare groups. A probability value of <0.05 
was considered significant.
results
The group of hcm mutation carriers comprised of five tpm1 mutation carriers (three 
male), and eleven mybpc3 mutation carriers (three male), from 7 different families. No 
hcm mutation carriers were excluded. Sixteen age and gender matched healthy volunteers 
were included (six male).
Dimensions and global lv function
Baseline characteristics and global lv and left atrial dimensions measured with cmr did 
not differ between hcm mutation carriers and healthy volunteers, see table 1. cmr showed 
inferoseptal basal hypertrophy which was not detected previously by echocardiography in 
two carriers with a septal wall thickness of 17 and 13 mm respectively, see table 2. In all 
other hcm mutation carriers, maximum septal wall thickness, maximal lateral wall thickness, 
lv mass and la dimensions were within normal limits. In the hcm mutation carrier with 
regional hypertrophy, lv mass exceeded normal limits of 64.7±9.3 g·m-2.11
Structure
In the majority of hcm mutation carriers (13/16 ; 81%), cmr revealed an abnormal structure of 
the myocardium consisting of profound crypts in the basal and mid segment of the inferoseptal 
lv myocardium, at the junction of the right and left ventricle, see table 2. The crypts, were 
only visible at end-diastole. on lv short axis images, they appeared as triangular, blood 
containing bright spots, see figure 1. Importantly, the myocardial segments surrounding 
the crypts were considered normokinetic, both on cmr and echocardiocardiography. Best 
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visualization was obtained on subsequently acquired dedicated long axis slices, slightly 
modified from the two-chamber view, cutting through the inferior septum, see figure 1.
   In hcm mutation carriers with a lv septal wall thickness <9 millimetres, the crypts could 
be visualized within the inferoseptal lv wall up to the subepicardium, see figure 1. In those 
hcm mutation carriers with a lv wall thickness ranging from 9–12 millimetres, the crypts 
could be visualized only throughout 70 percent of the inferoseptal lv wall. The one hcm 
mutation carrier, in whom lv wall thickness was 17 millimetres, revealed only one remnant 
crypt at the border of the regionally hypertrophied segment. The three hcm mutation carriers 
in whom no crypts were discerned were all female and were mybpc3 mutation carriers. 
All healthy volunteers had normal lv myocardium without the structural abnormalities 
described above.
   focal lge within the septal wall was present in the two hcm mutation carriers with regional 
hypertrophy. lge was absent in all other hcm mutation carriers and healthy volunteers. However, 
the crypts did mimic focal lge by partial volume effects on short axis lge images, see figure 2. 
Table 1. Baseline Characteristics and dimensions measured by cmr
hcm mutation carriers 
(n=16)
Healthy volunteers 
(n=16) p-value
Mean age (yrs) 40.7 ± 12.7 40.1 ± 11.3 ns
male/female 6/10 6/10 ns
Systolic BP (mmHg) 114.8 ± 12.7 122.7 ± 12.7 ns
Diastolic BP (mmHg) 65± 9.1 70.3 ± 7.0 ns
lvedv (mL∙m-2) 92.0 ± 11.0 92.5 ± 11.0 ns
lvesv (mL∙m-2) 34.3 ± 4.9 36.3 ± 5.7 ns
lvef 62.7 ± 3.7 60.8 ± 3.2 ns
lv mass (mL∙m-2) 56.2 ± 11.0 52.3 ± 10.0 ns
swt (mm) 9 ± 2.8 7.5 ± 1.2 ns
pwt (mm) 7.3 ± 1.6 7.0 ± 1.4 ns
la dimension (mm) 28.3 ± 6.1 29.8 ± 5.2 ns
BP= blood pressure. edv= end-diastolic volume. ef= ejection fraction. esv= end-systolic volume. 
hcm= hypertrophic cardiomyopathy. la= left atrial. lv= left ventricular. pwt= maximal left ventricular 
lateral wall thickness. swt= maximal septal wall thickness
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Figure 1. Structural abnormalities in hcm mutation carriers. A. Short axis view of hcm mutation carrier. 
White arrowhead indicates triangular shaped, blood containing spot in inferoseptum. Gray cutline 
represents the image plane of images B through f. B. modified two chamber view through inferoseptum 
of healthy volunteer; no crypts can be observed. C-E. Modified two chamber view through inferoseptum 
of hcm mutation carriers with lv wall thickness less than 9 mm. white arrowheads indicate crypts 
penetrating the myocardium up to the subepicardial layer. F. Modified two chamber view through 
inferoseptum of hcm mutation carrier with lv wall thickness of 11 mm. The penetration of the crypts 
can be visualized only up to 70 percent of the myocardium, as indicated by white arrowheads. hcm = 
hypertrophic cardiomyopathy
Electrocardiography
None of the hcm mutation carriers met the criteria for left ventricular hypertrophy, see table 
2. In two (15%) crypt-positive carriers, ST-segments were abnormal. An R-wave in v1 > 3 
mm was found in 9 of the crypt-positive carriers. In total, 69% of the crypt-positive carriers 
had an abnormal ecg. of the 3 hcm mutation carriers in whom no crypts were detected, 2 had 
a normal ecg, and one had an abnormal ecg.
discussion
hcm is characterized by a large interfamilial and intrafamilial variety of clinical presentations, 
ranging from sudden cardiac death at young age to mild symptoms of heart failure at 
advanced age, even if a single mutation is involved. Therefore, research is often focused on 
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early identification of hcm mutation carriers who are at increased risk for developing heart 
failure or potentially life threatening arrhythmias12-14.
   This study is the first to report that structural abnormalities consisting of crypts can 
be detected in the lv myocardium of many asymptomatic hcm mutation carriers, in whom 
no hypertrophy has developed yet, no lge is present, and no ecg abnormalities occur. The 
crypts were best visualized in end-diastole with cmr, not with routine echocardiography. 
When lv wall thickness was less than 9 millimetres, crypt penetration could be visualized 
up to the subepicardial layer of the myocardium. The depth of crypt penetration decreased 
with the increase of lv wall thickness. In one hcm mutation carrier who had developed overt 
regional hypertrophy, only a single crypt was visible at the border of the hypertrophied area, 
Figure 2. lge images of hcm mutation carriers. A modified two chamber view of  hcm mutation car-
rier with regional hypertrophy. White arrowhead indicates focal lge, dashed line indicates the cutline 
of image plane C. B. Modified two chamber view of hcm mutation carrier without regional hyper-
trophy, dashed line indicates the cutline of image D. C. Short axis view of hcm mutation carrier with 
regional hypertrophy. White arrowhead indicates focal lge in inferoseptum, dashed line indicates 
cutline of image A. D. Short axis view of hcm mutation carrier without regional hypertrophy. Black 
arrowhead indicates partial volume effect of blood containing crypts. Dashed line indicates cutline of 
image B. lge=delayed contrast enhancement, hcm= hypertrophic cardiomyopathy
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suggesting that this might be a remnant of crypts that have been compressed by surrounding 
hypertrophied myocardium. This might also explain why crypts have never been described 
previously in pathology studies. So far, pathology studies described in detail the macroscopy, 
microscopy and histology of the myocardial structure in patients with overt hcm, but not in 
carriers without hypertrophy15, 16. furthermore, post-mortem analysed hearts always are to 
some extent in a contracted state, which makes detection of the crypts more difficult. In-vivo 
study by cmr, however, allows detailed analysis of the myocardium in the non-contracted, 
end-diastolic state. Thus, the recent availability of genetic identification of pre-symptomatic 
hcm mutation carriers, in combination with the tomographic precision provided by cmr, 
resulted in the discovery of macroscopic abnormalities in this patient group.
   Although the hcm mutation carriers in our study were asymptomatic, the crypts may 
induce regional function abnormalities and conduction disorders. If one assumes that 
crypts are the result of regional ischemia due to coronary microvascular dysfunction and/or 
myocyte disarray, both hallmarks of hcm1, then the presence of crypts might lead to loss of 
contractility within the area of myocardium where the crypts are located17. This assumption 
is in agreement with the results of a clinical study performed by Nagueh e.a., who evaluated 
myocardial function with tissue Doppler imaging in asymptomatic hcm mutation carriers18. 
They found that early diastolic myocardial velocities were reduced in hcm mutation carriers 
in whom no hypertrophy had developed yet. Thus, one might hypothesize that crypts lead 
to a loss of contractility which in turn serves as a trigger to develop hypertrophy19. However, 
we found the myocardium surrounding the crypts to be normokinetic on both cine imaging 
and routine echocardiography, which does not support this hypothesis. Whether more subtle 
systolic or diastolic abnormalities of the myocardial segments surrounding the crypts can be 
detected with more advanced functional imaging techniques such as tissue Doppler imaging 
by echocardiography or myocardial tissue tagging by cmr, needs to be further evaluated. 
   In this study, regional lge was observed within the hypertrophied region of two hcm 
mutation carriers. This is in accordance with the results of a study performed by Moon 
e.a., who found that lge was not present in carriers of troponin I mutations, in whom 
no left ventricular hypertrophy and electrocardiographic abnormalities were present20. 
Nevertheless, the location of the crypts is similar to the typical location of the lge in hcm 
patients. This suggests that crypts, as well as formation of focal replacement fibrosis, which 
is the histological counterpart of lge6, 21, may both reflect two different stages of the same 
disease process that ultimately results in manifest hcm. However, investigating the role of 
the crypts on regional myocardial function and development of regional hypertrophy with 
subsequent focal fibrosis requires a long term follow-up study with a large variety of hcm 
mutation carriers. In addition, acquiring histology of myocardium surrounding the crypts 
may enable to learn more about the histopathlogical background of the crypts.
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   We found that cmr was more sensitive in detecting structural abnormalities than routine 
echocardiography; whether the use of contrast agents might increase the sensitivity 
of echocardiography in detection of crypts has to be evaluated. furthermore, cmr 
identified regional hypertrophy in two hcm mutation carriers, which was not detected by 
echocardiography. This is consistent with a prior report22. Importantly, the crypts were 
only visualized within the basal and mid segments of the inferoseptal lv wall. Therefore, 
the awareness for the need of making dedicated modified imaging planes through the 
inferoseptum to detect the crypts may increase the sensitivity to identify hcm mutation 
carriers.
   Thus, cmr may indeed serve as a valuable additional tool to identify hcm mutation carriers 
in an early stage of disease, thereby allowing timely initiation of risk stratification and 
therapy.
Limitations
We studied two groups of common mutations in the Netherlands, and sample size was 
limited. However, whether the crypts can be found in all hcm related mutation carriers in 
whom no hypertrophy has developed, and what the role of the crypts is in the development 
of hcm, has yet to be determined. We used a gap of 5 mm between the lv short axis slices. 
Therefore, we did not cover the entire lv myocardium to screen for structural abnormalities. 
Acquiring a stack of lv short axis slices with no gap between the slices, may increase the 
sensitivity to detect crypts.
Conclusions
The integrity of the inferoseptal lv wall is interrupted by crypts in many hcm mutation 
carriers, and can be detected by cmr. The crypts are visualized in hcm mutation carriers, in 
whom lv wall thickness is within normal limits, and routine echocardiography and ecg show 
little or no abnormalities.
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Prominent crypt formation in the inferoseptum 
of a hypertrophic cardiomyopathy mutation 
carrier mimics non-compaction cardiomyopathy
v.IItjeerd Germanspieter A. dijkmansArthur A.m. Wildeotto KampAlbert c. van rossum
(Circulation 2007; 105: e610-e611)
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imAGe report
R ecently, we reported that crypts can be identified in the inferior part of the septum by cardiac magnetic resonance imaging (cmr) in the majority of carriers of hypertrophic 
cardiomyopathy mutations (hcm carriers) who have not yet developed hypertrophy.1 The 
crypts may be an early sign of maladaptive myocardial alterations that ultimately lead to 
the development of the characteristic hypertrophy in hcm patients.
   In this patient, a 30-year old asymptomatic female hcm carrier with a maximal septal 
wall thickness of 6 mm, the crypts were very prominent in the inferoseptum, see figure 
1 and as a consequence, also visible with echocardiography, see figure 2a,b. On both 
the cmr and the echocardiographic images, the crypts were identified within the basal 
inferoseptum, see figure 2a,b, and flow in the crypts was also observed, see figure 2c. No 
contrast enhancement was visible within the myocardium on delayed contrast enhanced 
cmr images.
   When crypt formation is very prominent in a hcm carrier, as in this patient, the cardiac 
image mimics the image of non-compaction cardiomyopathy on echocardiography.2 
However, crypt formation as part of the development of hcm can be distinguished from non-
compaction cardiomyopathy based on several criteria: first, non-compaction is generally 
located in the apical and/or lateral segments of the left ventricle (lv), and very rarely in 
the basal inferoseptum. Second, the crypts penetrate compact myocardium sometimes 
up to the epicardial myocardial layer, in contrast to non-compaction cardiomyopathy, in 
Figure 1. end-diastolic short axis 
cardiac magnetic resonance image of a 
hypertrophic cardiomyopathy mutation 
carrier. Note the triangular shaped, 
blood containing bright spot in the 
inferoseptum through which a dedicated 
2-chamber view is planned (dotted line).
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which a non-compacted layer of myocardium parallels a compact layer along side the 
ventricular cavity. Third, the crypt formation does not seem to affect global lv contractile 
function, while in non-compaction cardiomyopathy, patients may have a dilated and poorly 
contracting lv.3 
   Distinction between these two cardiomyopathies has import clinical therapeutic 
implications, since hcm carriers may remain asymptomatic for decades, while patient with 
non-compaction cardiomyopathy are at increased risk of thrombo-embolic events and 
supraventricular arrhythmias when heart failure is present.3 However, the only very recent 
discovery of the crypts in hcm carriers probably has caused misdiagnosis in hcm carriers 
as having some form of non-compaction cardiomyopathy in the past.
   In conclusion, if crypts are very prominent in hcm carriers, they can also be observed 
with echocardiography on a dedicated apical 2-chamber view through the inferoseptum, 
but must be carefully distinguished from non-compaction cardiomyopathy.
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Figure 2. Cardiac magnetic resonance cine of a dedicated 2-chamber view of a hypertrophic 
cardiomyopathy mutation carrier (A). The black arrowheads indicate crypts in the inferoseptum. These 
crypts can also be observed with 2d echocardiography, as indicated by the white arrowheads (B). 
Blood flow in the crypts (blue color) can be visualized with color Doppler echocardiography, see white 
arrowheads (C). 
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Non-compaction; A distinct cardiomyopathy or 
non-specific morphological trait?
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letter to the editor
W ith great interest we have read the article of Hoedemaekers et al. on linking non-compaction cardiomyopathy to hypertrophic, restrictive and dilated 
cardiomyopathies. The authors extensively describe two families in which variable 
severities of non-compaction of the myocardium segregated with mutations in the cardiac 
ß myosin heavy chain gene (myh7).1
   Although genetic heterogeneity of traditional cardiomyopathies is well recognized, the 
identification of non-compaction in patients with dilated, hypertrophic and restrictive 
cardiomyopathies suggests that non-compaction may be considered as a non-specific 
morphological trait rather than a distinct cardiomyopathy.2 In addition, not all non-
compaction associated mutations are confined to genes that encode for a specific construct 
or functional element of the cardiomyocyte, but have been described in genes that encode 
for sarcomeric, cytoskeletal and/or cell junctional proteins.1
   Also, the genetic heterogeneity of non-compaction may reflect non-specificity of 
the current criteria for its diagnosis. According to jenni et al, isolated non compaction 
cardiomyopathy is diagnosed with echocardiography when the following criteria are met: 
1. coexisting cardiac abnormalities are absent, 2. the left ventricular wall has a two-layered 
structure with a non-compacted to compact layer ratio >2 in end systole, 3. the trabecular 
non-compacted meshwork is predominantly located in the apical, lateral and inferior 
regions of the left ventricle and 4. color Doppler evidence of deep perfused intertrabecular 
recesses is present.3 While left ventricular trabeculae are more easily observed with high 
resolution imaging techniques such a cardiac magnetic resonance, Petersen et al proposed 
to use a non-compacted to compact layer ratio >2.3 in end diastole as a cut off value to 
diagnose left ventricular non-compaction cardiomyopathy.4
   In the echocardiographic study from Hoedemaekers et al., only the second and forth 
criteria of jenni et al were used to diagnose non-compaction cardiomyopathy and ‘mild’ 
forms were also noted. These modifications of diagnostic criteria will most likely have 
introduced increased susceptibility to overdiagnosis in this study. Whether the described 
mutations encode for a pure form of non-compaction cardiomyopathy is therefore 
debatable. 
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   In general, non-specific definition and/or limited imaging quality may lead to avoidable 
misinterpretation of cardiac morphology.5 When available, we advocate to use imaging 
modalities with optimal resolution for more adequate definition of cardiomyopathies in 
linkage studies, which may give an answer to the question whether non-compaction can 
be considered as a distinct cardiomyopathy or as non-specific morphological trait.
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AbstrAct
Background
The hypertrophy in hypertrophic cardiomyopathy (hcm) is believed to be a compensatory 
mechanism for impaired myocardial function induced by sarcomeric mutations. No data 
on regional function in hcm mutation carriers (carriers) with normal wall thickness is 
yet available. Cardiac magnetic resonance (cmr) was used to evaluate both regional and 
global lv function in carriers and matched controls.
Methods
28 carriers and 28, mainly genotype negative controls, were studied. Mean left ventricular 
(lv) wall thickness, lv morphology, global left atrial (la) dimensions, septal-to-lateral-
wall-thickness ratio (sl-ratio), end-diastolic (ed) wall radius, peak systolic circumferential 
strain (peak scs) and peak diastolic circumferential strain rate (peak dcsr) were determined 
by cmr cine imaging and myocardial tissue tagging.
Results
lv wall thickness was comparable between groups, but nt-probnp levels were higher 
in carriers compared to controls (115±117 versus 58±55 pmol·L-1, p<0.05). This was 
related to the larger la volumes in carriers (p<0.05). Also, sl-ratio was larger in carriers 
(p<0.001). 82% of carriers had inferoseptal crypts. ed wall radius was larger in the lateral 
wall compared to the septum for both groups (p<0.01), and comparable between groups. 
Both peak scs and peak dcsr were lower in the lateral segments in carriers compared to 
controls (-18±3% versus -20±3%, p<0.05, and 116±29%·s-1 versus 139±26%·s-1, p<0.01 
respectively) and comparable in the septum. With multivariate analysis, the response of 
peak scs and peak dcsr to ed wall radius was significantly higher in controls compared 
to carriers (p<0.05 and p<0.001). Also, when ed wall thickness was >6 mm, peak dcsr 
significantly decreased in carriers, but not in controls (p<0.001).
Conclusion
Regional systolic and diastolic dysfunction are present in carriers with normal wall 
thickness. Dysfunction is most prominent in segments with larger ed wall radius, which is 
in line with molecular studies of sarcomeric dysfunction in hcm, and it deteriorates with 
increase of wall thickness.
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H ypertrophic cardiomyopathy (hcm) is a relatively common cardiomyopathy with an estimated prevalence of 1:500 in the general population.1 The clinical course 
has a large inter- and intrafamilial heterogeneity, ranging from mild symptoms of heart 
failure late in life to the onset of sudden cardiac death at young age. over 400 mutations 
in mainly sarcomeric genes have been identified to be associated with hcm. Subsequent 
presymptomatic screening has lead to the detection of an increasing number of hcm 
mutation carriers who have not (yet) developed left ventricular (lv) hypertrophy have 
been identified.
hcm mutation carriers may remain asymptomatic for decades, and it is already known from 
an echocardiographic tissue Doppler study, that hcm mutation carriers with borderline 
hypertrophy have reduced systolic and diastolic strain rates.2 It is currently unknown 
whether these functional abnormalities result from the minor increase in lv wall thickness 
or relate to an intrinsic myocardial defect in hcm mutation carriers with normal wall 
thickness. 
   Experimental findings support the hypothesis that in hcm, the hypertrophy is merely a 
compensatory mechanism for mutant-induced impaired myocardial function.3, 4 However, 
it has never been described whether in hcm mutation carriers myocardial dysfunction is 
already present when lv wall thickness is completely normal. 5-8 
   The high spatial and temporal resolution of cardiac magnetic resonance (cmr), and its 
well developed capabilities to assess morphology and intramural myocardial function, 
make cmr an excellent tool to evaluate the structure and regional function of human hcm 
mutation carriers with normal wall thickness.9, 10
   In this study, cmr was applied to quantify systolic and diastolic myocardial function 
in hcm mutation carriers with well documented normal lv wall thickness and mainly 
genotype negative controls for comparison.
methods
Patient selection
 hcm mutation carriers were included in whom lv wall thickness was less than 10 mm 
measured by routine echocardiography within one year before inclusion.10 All hcm 
mutation carriers were free of any other systemic or cardiac disease, which might attribute 
to the development of lv hypertrophy. 
   As a control group, age and gender matched healthy volunteers were selected who 
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had no medical history, no known familial cardiac disease, no obesity, normal blood 
pressure, and who were not smoking. family members of the hcm mutation carriers 
without the pathogenic mutation, who met the inclusion criteria of healthy volunteers, 
were also included. Study participants had to be in sinus rhythm, and free from standard 
exclusion criteria for cmr. In all participants, standard physical examination, nt-probnp 
level measurement and cmr acquisition were performed.
   This study was approved by the institutional medical ethics committee and conducted 
according to the declaration of Helsinki. Written informed consent was obtained from all 
participants before entering the study. 
Cardiac Magnetic Resonance Imaging
cmr studies were performed on a 1.5-Tesla whole body scanner (Magnetom Sonata, 
Siemens, erlangen, Germany), using a six-channel phased-array body coil. All cine studies 
were acquired in a single breath hold of 8-10 seconds during mild expiration.
Cine imaging. After survey scans, a retro-triggered, balanced, steady-state free precession 
(ssfp) gradient-echo sequence was used for cine imaging. A cine dataset fully covering the 
left atrium (la) and lv was acquired as described previously.11 Image parameters were: 
slice thickness 5 mm, slice gap 5 mm, temporal resolution <50 ms, repetition time 3.2 
ms, echo time 1.54 ms, flip angle 60 degrees and a typical in-plane image resolution of 
1.3 by 1.6 mm. The number of phases within the cardiac cycle was set at 20. Also, lv 
myocardial morphology was evaluated in all subjects, especially focusing on crypts in the 
inferoseptum, using a modified 2-chamber view as described previously.10 A high temporal 
resolution (14 ms) 3-chamber cine was obtained to determine opening and closure times 
of aortic and mitral valves. Brachial blood pressure was non-invasively measured directly 
after acquisition of the high temporal resolution 3-chamber cine. 
Myocardial tissue tagging. A multiple breath-hold, retrospective triggered balanced ssfp 
myocardial sinus tagging sequence was obtained using the linearly increasing start-up 
angle (LISA) approach.9 Three lv short axis planes were positioned at 25 percent, 50 
percent and 75 percent of the distance between the mitral valve annulus and the endocardial 
border of the apex on an end-systolic lv 4-chamber view, avoiding inclusion of the lv 
outflow tract. Imaging time per slice was approximately 3-4 minutes. Image parameters 
were: 7 mm slice thickness, temporal resolution 14.1 ms, repetition time 4.7 ms, echo time 
2.3 ms, flip angle 20 degrees, and in-plane image resolution of 1.2 by 3.8 mm, with 7 mm 
tag spacing.
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Late gadolinium enhancement imaging. Late gadolinium enhanced (lge) images were 
obtained 10-15 minutes after injection of 0.2 mmol∙kg-1 gadolinium-dtpa.12 A single 
breath-hold, inversion recovery turbo fast Low Angle Shot (flash) sequence was used. 
All lge images were ecg-gated to end-diastole and planned at the same image positions as 
the long and short axis lv cines. Image parameters were: 5 mm slice thickness, repetition 
time 4.0 ms, echo time 4.4 ms, flip angle 25 degrees and typical in-plane image resolution 
1.3 by 1.3 mm.
Post processing
Cine images where analyzed off-line, using mass analysis software (Medis medical imaging 
systems, Leiden, The Netherlands). from the la cine dataset, la volumes were calculated 
from manually drawn endocardial contours in every phase of the cardiac cycle, excluding 
the pulmonary veins and including the la appendage, as described previously. la maximum 
volume (lamax), la minimum volume (lamin), la volume at diastasis and la volume prior 
to atrial contraction were determined. from these volumes, la ejection function (laef) and 
la expansion fraction (laexf) were calculated as described previously.11
   on the lv cine data set, epi- and endocardial contours were manually drawn in end-
diastole and end-systole. Global lv parameters, including lv end-diastolic volume (lvedv), 
lv end-systolic volume (lvesv), stroke volume (sv), lv ejection fraction (lvef) and lv mass 
were determined. Also, lv mass to lv volume ratio in end-diastole was determined.11 All 
volumes and mass were normalized to body surface area. Isovolumetric relaxation time 
(ivrt) was calculated by subtracting aortic valve closure time from mitral valve opening 
time, determined on the high temporal resolution 3-chamber view.
   for segmental analysis, the best corresponding basal, mid and apical lv cine slices with 
the myocardial tissue tagging slices were selected. These three slices were subdivided into 
16 segments; 6 basal and mid segments (inferoseptal, anteroseptal, anterior, anterolateral, 
inferolateral and inferior) and 4 apical segments (septal, anterior, lateral, inferior).13 Per 
lv segment, mean end-diastolic (ed) wall thickness (edwt) and mean end-systolic (es) wall 
thickness (eswt) were measured. from these parameters, wall thickening was calculated 
as (edwt-eswt)/edwt. In addition, septal-to-lateral wall thickness ratio (sl-ratio) was 
calculated by dividing the mean edwt of the 2 septal segments by the mean edwt of the 2 
lateral segments of the basal and mid slices. Mean ed wall radius per segment was calculated 
as the mean distance from the center point of the lv short axis endocardial contour to the 
endocardial border, both being automatically determined with mass software. 
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   Offline analysis of the myocardial tissue tagging images was performed with in-house 
developed software, programmed in a matlab 7.1(R14) environment (The MathWorks, 
Natick, Massachusetts, united States of America), as described previously.9 Segmental 
circumferential strain (cs) was calculated from Lagrangian strain as a percent change in 
length of a small line segment in the circumferential direction. Since myocardial fibers of 
the mid lv wall are predominantly oriented circumferentially and lie within the short axis 
image plane, cs was calculated only from the mid 50 percent of the lv wall.14
   from these segmental cs datasets, the following parameters were determined: peak 
systolic cs (peak scs), peak diastolic cs rate (peak dcsr). 
Statistical Analysis
All data are presented as mean ± standard deviation. A Kolmogorow-Smirnov test was 
used to assess the normality of distribution of scores. The unpaired Student’s t-test was 
used for comparison of normally distributed global lv and la parameters between hcm 
mutation carriers and controls. If scores of global variables were not normally distributed, 
a nonparametric Mann-Whitney u test was used.
   for segmental analysis, edwt, wall thickening, ed wall radius, peak scs and peak dcsr 
were compared between hcm mutation carriers and controls. While interdependency of 
segments was considered within slices and patients, multilevel analysis allowing random 
intercepts was performed. evaluation of within slice differences of segmental parameters 
was performed with a one-way anova, using the Bonferroni post hoc test for multiple 
comparisons. With multiple regression analysis, the effect of hcm carriership, age, gender, 
edwt and ed wall radius on wall thickening, peak scs and peak dcsr was evaluated, 
correcting for interdependency of segments. Pearson’s correlation coefficient was used to 
describe bivariate correlations between continuous variables. All regression models were 
evaluated for interaction of main effects. mlwin 2.02 (Center of MultiLevel Modelling 
(Bristol, united Kingdom) was used for multilevel analysis and Statistical Package of 
Social Sciences (spssl for windows 14.0, Chicago, Illinois, united States of America) 
for all other statistical analysis. A two-sided p-value at the <0.05 level was considered 
statistically significant. All authors had full access to the data and take responsibility for 
its integrity. All authors have read and agree to the manuscript as written.
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Table 1. Baseline characteristics
All(n=56) Carriers (n=28) Controls ( n=28) p-value
Age (years) 39±12.6 38±13.2 39±12.3 ns
Gender (male/female) 22/34 11/17 11/17 ns
Mean arterial pressure 
(mmHg)
85±9.0 83±9.8 88±7.6 ns
Heart rate (beats per minute) 65±9 63±9 67±9 ns
Body mass index (kg∙m-2) 22.8±2.6 22.9±2.6 22.7±2.6 ns
Data are presented as mean±S.D. carriers= hypertrophic cardiomyopathy mutations carriers, ns= not 
significant
Global la and lv volumes and function
Both lamin and lamax were larger in hcm mutation carriers compared to controls (p<0.05), 
see table 2. In addition, laexf was reduced (p<0.05). No differences in global lv volumes 
and mass, and ivrt between both groups were found. sl-ratio was larger in hcm mutation 
carriers compared to controls (p<0.001).
   Although within normal limits, nt-probnp levels were significantly higher in hcm mutation 
carriers compared to controls (115±117 versus 58±55 pmol·L-1, p<0.05), and correlated 
positively with lamin (r=0.49, p=0.01). Crypts located in the inferoseptum were present 
in 23 of 28 hcm mutation carriers (82%), though were absent in the control group. In both 
groups, no regional fibrosis was observed with lge imaging.
results
In total, 28 hcm mutation carriers (11 males) from nine different families were included, 
of whom 22 (79%) had a myosin binding protein C3 founder mutation (2327insG) and 6 
(21%) an α-tropomyosin mutation.15, 16 fifteen of the 28 age- and gender-matched controls 
were confirmed genotype negative family members of the hcm mutation carriers. No 
differences in baseline characteristics were observed, see table 1. All global lv and la data 
and regional lv data were comparable between genotype negative controls and selected 
healthy volunteers. In total, data from 896 segments were obtained. All segmental data 
from the cine images were analysable. Segmental cs data from 408 out of 448 (91.1%) 
segments could be used for analysis in hcm mutation carriers, and from 375 out of 448 
(83.7%) in controls. When segments were not analysable this was due to inconsistency of 
repetitive breath holding.
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Segmental analysis
End diastolic wall thickness. Averaged edwt was comparable between hcm mutation 
carriers and controls (5.9±0.9mm versus 5.1±0.9mm in the basal slice, 4.9±0.9mm versus 
4.7±0.8mm in the mid slice and 3.9±1.0mm versus 3.7±0.8mm in the apical slice, p=ns). In 
septal segments of basal and mid slices edwt was larger in hcm mutation carriers compared 
to controls (6.6±1.3mm versus 5.7±1.1mm, p<0.01 for the inferoseptal segments and 
5.8±0.7mm versus 5.3±1.0mm, p<0.05 for the anteroseptal segments), see figure 1a. Also 
the basal inferior segment had a higher edwt in hcm mutation carriers compared to controls, 
5.5±1.3mm versus 4.9±0.6mm, p<0.05). In all other segments, edwt was comparable.
   ed wall radius was comparable between hcm mutation carriers and controls. In both 
groups, ed wall radius was significantly larger in the lateral segments compared to the 
septal segments (p<0.01 in both groups), see figure 1b.
Table 2. left ventricular and left atrial volumes and function
Carriers (n=28) Controls (n=28) p-value
la min (mL.m-2) 24±6.7 20±3.9 <0.05
la max (mL.m-2) 56±11.7 51±6.4 <0.05
laexf (%) 135±28 152±32 <0.05
laef (%) 35±8.0 38±7.2 ns
lvedv (mL.m-2) 96±13.2 94±14.2 ns
lvesv (mL.m-2) 38±7.3 37±8.3 ns
sv (mL.m-2) 58±8.9 57±7.7 ns
lvef (%) 60±4.9 61±4.2 ns
lv mass (gr.m-2) 99±24.2 93±22.9 ns
lv mass/volume ratio 0.53±0.075 0.54±0.105 ns
ivrt 102±18 100±22 ns
s/l-ratio 1.3±0.21 1.1±0.13 <0.001
Data are presented as mean±S.D. All volumes are indexed to body surface area, edv=end-diastolic 
volume, esv= end-systolic volume, exf= expansion fraction, ivrt=isovolumetric relaxation time, 
la= left atrial, laef = left atrial ejection function, lv= left ventricular, lvef = left ventricular ejection 
fraction. s/l-ratio= septal-to-lateral wall thickness ratio, sv= stroke volume
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Figure 1. Segmental comparison of basal and mid left ventricular segments between hcm mutation 
carriers and controls. Data are presented as mean ± standard error of the mean as indicated by the 
solid bars (hcm mutation carriers) and open bar (controls). A. end-diastolic wall thickness is higher in 
the septal and inferior segments in hcm mutation carriers compared to controls. Also the asymmetric, 
predominantly septal distribution of increased wall thickness can be observed in the hcm mutation 
carriers. B. End-diastolic wall radius was comparable between groups, but significantly higher in the 
lateral segments compared to the septal segments. C. In controls, peak systolic circumferential strain 
is higher in the lateral wall compared to the septum, but this difference is absent in hcm mutation 
carriers. As a result, peak systolic circumferential strain is significantly higher in the lateral segments 
of controls compared to hcm mutation carriers. D. Peak diastolic circumferential strain rate is reduced 
in almost every segment in HCM carriers compared to controls. Again, the heterogeneity in peak 
diastolic circumferential strain rate found in controls is less profound in hcm mutation carriers. is= 
inferoseptal, as= anteroseptal, an= anterior, al= anterolateral, il=inferolateral, IN=inferior, peak dcsr= 
peak diastolic circumferential strain rate, peak scs= peak systolic circumferential strain, *= p<0.05, †= 
p<0.01, ‡= p<0.001
Wall thickening. Averaged wall thickening was smaller in the basal slice in hcm mutation 
carriers compared to controls, (0.79±0.17 versus 0.89±0.15, p<0.05), and comparable in 
the other slices. In both basal septal segments, wall thickening was smaller in hcm mutation 
carriers compared to controls (0.38±0.19 versus 0.62±0.22, p<0.001 for the inferoseptal 
segment and 0.61±0.25 versus 0.81±0.25, p<0.01 for the anteroseptal segment). In the 
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lateral segments, wall thickening was comparable between both groups. 
   Multilevel regression analysis showed that hcm mutation carriership (p<0.001), gender 
(p<0.001) and edwt (p<0.001), were independent determinants of wall thickening in both 
groups. Age was an independent determinant of wall thickening in hcm mutation carriers, 
but not in controls, see table 3.
Peak systolic circumferential strain. No significant differences in averaged peak scs were 
observed between hcm mutation carriers and controls. However, regional peak scs was 
lower in the lateral segments in hcm carriers compared to controls (-17.8±2.71% versus 
-19.2±3.3%, p<0.05) and tended to be higher in the inferoseptal segments (-16.8±3.0 
versus -16.3± 2.8, p=ns), see figure 1c. Interestingly, in hcm mutation carriers peak scs 
was comparable between septal and lateral segments, but it differed in controls (p<0.001), 
see figure 1c. 
   Multilevel regression analysis showed that hcm mutation carriership, (ß=0.66±0.26; 
p<0.001), gender (ß=-0.86±0.26; p<0.001) and edwt (ß=0.39±0.10; p<0.01) were all 
independent predictors of peak scs in both groups. In addition, ed wall radius was an 
independent determinant of peak scs in both groups, but regression coefficients were 
significantly different between hcm mutation carriers and controls, see table 3.
Table 3. Multilevel regression with random intercept for segmental strain parameters
Age (years) Gender edwt (mm) ed wall radius (mm)
Wall thickening (%) Carriers 0.5±0.1‡ -6.6±3.3* -15.7±1.1‡ 2.3±0.4‡
Controls 0.3±0.1† -4.2±2.4* -18.0±1.2‡ 1.8±0.3‡
Peak scs (%) Carriers 0.01±0.01 -0.80±0.36‡ 0.25± 0.13* -0.11±0.04†
Controls 0.02±0.02 -0.59±0.39 0.62± 0.18‡ -0.19±0.03‡§
Peak dcsr (%∙s-1) Carriers -0.44± 0.12‡ 13.7±3.1‡ -3.3± 1.0‡ -0.2±0.4
Controls -0.38± 0.13† 5.7± 3.6 -3.7± 1.6§ 1.6±0.4‡#
Data are presented as unstandardised regression coefficient(ß) ± standard error of the mean, carriers= 
hypertrophic cardiomyopathy mutation carriers, dcsr= diastolic circumferential strain rate, ed= end-
diastolic, scs= systolic circumferential strain, wt= wall thickness *=p<0.05, †=p<0.01, ‡=p<0.001 for 
ß, §=p<0.05, ║=p<0.01, #=p<0.001 for difference between ß’s of both groups
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Figure 2. Relation between functional parameters as different categories of edwt. Note that both 
peak scs (A) and peak dcsr (B) tend to decrease with an increase in wall thickness in hcm mutation 
carriers (solid dots), but not in controls (open dots) edwt= end-diastolic wall thickness, peak dcsr= 
peak diastolic circumferential strain rate, peak scs= peak systolic circumferential strain *= p<0.05, †= 
p<0.01, ‡= p<0.001
Peak diastolic circumferential strain rate. Averaged peak dcsr was lower in all slices in hcm 
mutation carriers, especially in the basal slice (98±18%·s-1 versus 115±17%·s-1, p<0.001). 
In addition, the difference in peak dcsr between hcm mutation carriers and controls was 
largest in the inferolateral segments (116±29%·s-1 versus 139±26%·s-1, p<0.01), see figure 
1d. In both hcm mutation carriers and controls, peak dcsr was highest in the inferolateral 
segments compared to the other segments (p<0.01).
   With multilevel regression analysis, hcm mutation carriership, (ß=-9.0±2.26; p<0.001), 
gender (ß=11.4±2.4; p<0.001) and edwt (ß=-3.5±0.9; p<0.001) were all independent 
determinants of peak dcsr in both groups. Interestingly, ed wall radius was an independent 
determinant of peak dcsr in controls (p<0.001), but not in hcm mutation carriers, see table 
3.
The effect of edwt on regional function
   The effect of edwt on segmental functional parameters is illustrated in figure 2. Mean 
peak dcsr was significantly lower in hcm mutation carriers when edwt is ≥ 6 mm and 
further decreased with increase of edwt. Also, peak scs tended to be lower in hcm mutation 
carriers than controls when edwt was >10 mm (-15.6±3.5 versus -17.6±1.6, p=0.05).
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discussion
This is the first study that evaluated global la and lv volumes and regional intramural 
myocardial function in hcm mutation carriers with normal wall thickness. The asymmetry 
in wall thickness between the septum and lateral wall, which is characteristic for hcm, 
was already present in these hcm mutation carriers with normal wall thickness. Also, 
nt-probnp levels were higher in hcm mutation carriers compared to controls, which was 
related to larger la volumes. In addition, hcm mutation carriers with normal wall thickness 
already exhibited regional systolic and diastolic dysfunction, which was most prominent 
in segments with the largest ed wall radius. Mainly the peak dcsr further deteriorated with 
increase in wall thickness.
As systolic and diastolic dysfunction were largest in the lateral segments which had normal 
eD wall thickness, our data support the hypothesis that the hypertrophy in hcm represents 
a compensatory mechanism in response to abnormal intrinsic myocardial properties (i.e. 
sarcomeric defect and/or impaired calcium handling).
   The observation in this study that ed wall radius was an independent determinant of 
peak scs in controls, but not in hcm mutation carriers suggests that the Starling curve has 
a milder slope in human hcm mutation carriers compared to controls.17 This unconfirmed 
hypothesis is supported by results from experimental studies demonstrating that 
mybpc3-c deficient as well as mutated α-tropomyosin containing cardiomyofilaments 
had higher Ca2+- sensitivity at baseline,18-20 and displayed less increase in Ca2+-sensitivity 
and subsequent increase of contractility in response to lengthening of the sarcomere (i.e. 
frank-Starling mechanism). This has also been observed in heart failure, and is known to 
induce a neurohumoral response that triggers the development of hypertrophy.21 Indeed, 
nt-probnp levels in this study were higher in hcm mutation carriers than in controls.
   Apart from this reduced length-dependent activation, altered mutant-induced Ca2+-
sensitivity of the sarcomeres is thought to be the link between sarcomere mutations and 
hcm.3 Kataoka et al. have shown that a mutant-induced enhanced myofilament Ca2+-
sensitivity in hcm will reduce peak calcium during systole and slow the calcium transient 
decay during diastole.4 The disturbed calcium transient is thought to trigger hypertrophic 
signalling routes.22 Nevertheless, it does not explain why the hypertrophy in hcm mainly 
involves the septum.23 This implies that in hcm, additional septum specific conditions such 
as increased response to shear stress in the left ventricular outflow tract may contribute to 
the development of the asymmetric hypertrophy. Although our data support that intrinsic 
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mutant-related cardiac dysfunction precedes hypertrophy, future studies are required to 
reveal if myofilament responsiveness to calcium is indeed increased in myocardium from 
HCM patients. In addition, comparison of septal and lateral Lv cardiac tissue might reveal 
secondary mechanisms responsible for asymmetric hypertrophy. 
   In addition to regional systolic dysfunction, a lower peak dcsr in almost every segment 
of hcm mutation carriers was observed. Here too, impaired myofilament responsiveness 
to calcium may at least partially explain these observations, since it has recently been 
experimentally demonstrated that due to increased calcium sensitivity, actin-myosin 
filament interaction even occurred at diastolic Ca2+ concentrations.24 
   The reduction of regional peak dcsr was further enhanced with increase in edwt. It is 
unlikely that replacement fibrosis plays an important role in the deterioration of diastolic 
function in hcm mutation carriers with increase of edwt, since no focal lge was found in 
these hcm mutation carriers.25 However, diffuse interstitial fibrosis and/or myocyte disarray 
cannot be visualized with lge imaging, so the attribution of these histological hallmarks 
of hcm on the development of diastolic dysfunction still needs to be further investigated. 5 
New promising cmr techniques have been developed that allow quantification of diffuse 
interstitial fibrosis. 23 This would enable to quantify the total fibrotic burden of the lv.7, 26 
The described effect of edwt on diastolic function may also be related to impaired energy 
metabolism and/or microvascular dysfunction, of which the latter has been found to be 
proportional to the magnitude of hypertrophy in hcm.27, 28
   In line with reduced regional peak dcsr, la volumes were found to be larger, indicating 
chronic lv diastolic dysfunction. Also a reduced laexf was shown, which may result from 
either increased distensibility of the la due to la hypertrophy or reduced longitudinal 
shortening of the lv. Although we did not measure longitudinal strain in this study, a 
previous study demonstrated reduced systolic myocardial velocities as determined by tissue 
Doppler echocardiography.2 of note, the hcm mutation carrier population in that study had 
a wall thickness of 11±1 mm, indicating advanced disease. Therefore, a straightforward 
comparison with our current data is impossible.
   The increased septal wall thickness was most prominent in the inferoseptum and associated 
with crypt formation, which was found to be present in a the majority of hcm mutation 
carriers.10 Also, peak scs of the inferoseptum tended to be higher in hcm mutation carriers 
than in controls. This might be explained by pseudo-normalization of circumferential strain, 
since crypt containing myocardium is less compact and thereby encounters less resistance 
in the circumferential direction when contracting. To further clarify the relation between 
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the crypts and myocardial function, a comparative study must be performed between hcm 
mutation carriers with and without crypts. However, in this study, the number of hcm 
mutation carriers without crypts were too small to further investigate this issue. 
   The origin of this crypt formation is still unknown, however, the crypts were mainly 
observed at the insertion points of the right ventricle into the septum. Within these areas 
of the myocardium, myocyte disarray is most prominent in hcm patients and also observed 
in normal hearts.29 These insertions points are subjected to contractile forces of both the 
right ventricular free wall and the septum, and together with the increased vulnerability 
of myocardium of hcm mutation carriers to wall stretch, we believe that these factors 
play an important role in the development of the crypts and at least partially explain why 
they are so often and extensively found in hcm mutation carriers, and rarely in a general 
population.30, 31 
   The results of this study demonstrate that with cmr, myocardial dysfunction and 
morphological abnormalities can be detected in well documented, asymptomatic hcm 
mutation carriers with normal lv wall thickness. for clinical purposes, cmr may thus be 
applied as an alternative to echocardiography and electrocardiography for cardiological 
screening for hcm mutation carriers among asymptomatic family members of hcm patients 
in whom no mutation has been found. This still occurs in approximately 40 percent of 
hcm patients.32 However, the diagnostic accuracy of these cmr parameters still needs to be 
further evaluated.
Limitations
Not all circumferential strain data were analysable. This might have introduced a selection 
bias of the results. Also, baseline diastolic blood pressure was significantly lower in hcm 
mutation carriers, which may be related to the selection of hcm mutation carriers without 
lv hypertrophy. 
Conclusions
Regional systolic and diastolic dysfunction are intrinsically present in hcm carriers with 
normal lv wall thickness which is line with molecular studies on sarcomeric dysfunction in 
hcm. Segmental dysfunction is most prominent with larger ed wall radius and deteriorates 
when wall thickness increases. 
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AbstrAct
Background
In hypertrophic cardiomyopathy (hcm), left ventricular outflow tract obstruction is related 
to mitral regurgitation (mr), left atrial (la) dilation, and diastolic dysfunction. In this 
study, the effects of lvot obstruction by alcohol septal ablation (asa) on the interrelation 
between above mentioned parameters is evaluated with cardiac magnetic resonance (cmr) 
and echocardiography. 
Methods
Global la and lv volumes and function, regional myocardial function and mr were 
quantitatively assessed in 15 controls and 16 symptomatic hcm patients before and after 
asa. cmr cine imaging, tissue tagging and tissue Doppler echocardiography were performed 
and nt-probnp levels were measured.
 
Results
In hcm patients, both peak systolic circumferential strain (peak scs) and peak diastolic 
circumferential strain rate (peak dcsr) were reduced compared to controls (-14.7±3.4 
versus -17.9±3.6%, p<0.05 and 78.7±26 versus 103±38%.s-1, p<0.001). In hcm patients, 
la volume was increased (69±15 versus 49±8 mL·m-2, p<0.01), which was independently 
determined by mr (r2=0.59, p<0.01), but not by e/ea ratio. Nt-probnp levels were elevated 
in hcm patients and independently determined by la volume (r2=0.57, p<0.01). After 
asa, peak scs was lower in all segments (p<0.001) and end-diastolic wall thickness was 
reduced from an average 9.4±3.0 to 8.6±3.0 mm (p<0.001). However, diastolic function 
only improved in the lateral lv wall, indicated by increase of peak dcsr (80±28 to 93±35 
%∙s-1, p<0.05 and reduction of lateral e/ea ratio (p<0.01). lamax also significantly reduced 
after asa, which was independently determined by the reduction of lateral e/ea ratio 
(r2=0.59, p<0.001), but not mr reduction, which decreased from 19±11 mL·m-2 to 9±8 
mL∙m-2, p<0.001). 
Conclusion
In hcm patients, both systolic and diastolic dysfunction are present, concomitant with 
increased la volume, which was an independent determinant of nt-probnp. Beside reduction 
of la volume after asa, end-diastolic wall thickness was reduced in all lv regions, but 
diastolic function only improved in the lateral lv wall. 
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H ypertrophic cardiomyopathy (hcm) is macroscopically characterized by asymmetric hypertrophy that predominantly involves the septum and is mainly caused by 
genetic mutations that mainly encode for sarcomeric proteins. The clinical course has a 
large inter- and intrafamilial heterogeneity, ranging form mild symptoms of heart failure 
late in life to the onset of sudden cardiac death at young age.1
   Heart failure in hcm patients is predominantly caused by gradual increase in left ventricular 
outflow tract obstruction (lvot obstruction) and diastolic dysfunction. lvot obstruction 
causes a pressure gradient over the lvot, resulting in systolic anterior motion of the 
anterior mitral valve leaflet (sam) and subsequent eccentric mitral valve regurgitation. Due 
to the pressure gradient over the lvot, hcm patients have a blunted blood pressure response 
during exercise, resulting in exertional dizziness and limited exercise capacity. The lvot 
obstruction can be effectively reduced pharmacologically by using calcium antagonists or 
dypiramidole, or invasively by surgical septal myectomy (Morrow procedure) or alcohol 
septal ablation (asa).2-5
   Both invasive procedures have shown to reduce lvot obstruction, which results in 
reduction of not only septal, but also lateral lv mass, improvement functional New york 
Heart Association (nyha) class and lv filling and reduction left atrial (la) volumes.6, 7 The 
latter has important clinical implications since la volumes are important determinants of 
adverse outcome in hcm patients.8-10
   However, little is known on how asa affects the interrelation between la volumes and 
function and regional lv diastolic function and mitral regurgitation. Measurement of lv 
and la volumes and function and mitral regurgitation can be optimally performed with 
a combination of cardiac magnetic resonance imaging (cmr) and echocardiographic 
techniques. Therefore, the aim of this study is to assess the effect of asa on the interrelation 
of lv and la parameters in obstructive hcm using both cmr and echocardiography.
methods
Patient selection
Sixteen symptomatic patients with obstructive hcm (functional nyha Class II or III despite 
optimal pharmacological therapy) were enrolled in the study. obstructive hcm was defined 
as the presence of lv hypertrophy in the absence of any other systemic or cardiac disease 
likely to cause this hypertrophy, as determined on 2-dimensional (2d) echocardiography 
(maximal wall thickness >15 mm in adult patients) with a resting or provoked lvot 
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gradient of > 30 mmHg documented on at least one occasion.11 The pattern of hypertrophy 
was asymmetrical septal hypertrophy in all patients. Genotype negative gender matched 
healthy volunteers served as controls. Study participants had to be in sinus rhythm and 
free from standard exclusion criteria for cmr.
   All participants underwent standard physical examination, measurement of nt-
probnp levels (Roche diagnostics, Almere, the Netherlands), a cmr examination and 
echocardiogram. The hcm patients underwent the entire study protocol within 2 weeks 
before the asa procedure and 6 months ± 2 weeks after the asa procedure. This study 
was approved by the institutional medical ethics committee and conducted according to 
the declaration of Helsinki. Written informed consent was obtained from all participants 
before entering the study.
Cardiac Magnetic Resonance Imaging
cmr studies were performed on a 1.5-Tesla whole body scanner (Magnetom Sonata, 
Siemens, erlangen, Germany), using a six-channel phased-array body coil. All cines were 
acquired in a single breath hold in mild expiration for 8-10 seconds. 
Cine imaging. After standard survey scans, a retro-triggered, balanced, steady-state free 
precession (ssfp) gradient-echo sequence was used for cine imaging. Image parameters 
were: slice thickness 5 mm, slice gap 5 mm, temporal resolution <50 ms, repetition time 
3.2 ms, echo time 1.54 ms, flip angle 60 degrees and a typical in-plane image resolution of 
1.3 by 1.6 mm. The number of phases within the cardiac cycle was set at 20. Data sets with 
full coverage of la and lv were obtained as described previously.12 Cine images where 
analyzed off-line, using mass analysis software (Medis medical imaging systems, Leiden, 
The Netherlands). 
   on the lv cine data set, epi- and endocardial contours were manually drawn in end-
diastole and end-systole. Global lv parameters, including lv end-diastolic volume (lvedv), 
lv end-systolic volume (lvesv), stroke volume (sv), lv ejection fraction (lvef) and lv mass 
were determined. Also, lv mass to lv volume ratio in end-diastole was determined.12 
   from the la cine dataset, la volumes were calculated from manually drawn endocardial 
contours in every phase of the cardiac cycle, excluding the pulmonary veins and including 
the la appendage, as described previously.12 la minimum volume (lamin), la maximum 
volume (lamax) and la volume prior to atrial contraction were determined. from these 
volumes, la passive emptying volume, la active emptying volume, la ejection function 
(laef) and la/lv ratio were calculated as described previously.12 All volumes and dimensions 
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were normalized to body surface area.
   for segmental analysis, a basal, mid and apical lv cine slice were selected best 
corresponding with slice position of three myocardial tissue tagging slices. These slices 
were subdivided into 16 segments; 6 basal and mid segments (inferoseptal, anteroseptal, 
anterior, anterolateral, inferolateral and inferior) and 4 apical segments (septal, anterior, 
lateral, inferior).13 Segments of baseline and mid slices were grouped into septal 
(inferoseptal, anteroseptal), adjacent (anterior and inferior) and lateral (anterolateral and 
inferolateral) regions. Per lv segment, mean end-diastolic wall thickness (edwt) and mean 
end-systolic wall thickness (eswt) were measured. from these parameters, relative wall 
thickening was calculated as ((eswt– edwt)/edwt)∙100%.
Myocardial tissue tagging. A multiple breath hold, retro-triggered balanced ssfp myocardial 
sinus tagging sequence was performed using the linearly increasing start-up angle (lisa) 
approach.14 Image parameters were: 7 mm slice thickness, temporal resolution 14 ms, 
repetition time 4.7 ms, echo time 2.3 ms, flip angle 20 degrees, and in-plane image resolution 
of 1.2 by 3.8 mm, with 7 mm tag spacing. Three lv short axis planes were positioned at 
25 percent, 50 percent and 75 percent of the distance between the mitral valve annulus 
and the endocardial border of the apex on an end-systolic lv 4-chamber view, avoiding 
inclusion of the lvot. Imaging time per slice was approximately 3-4 minutes. Offline 
myocardial tissue tagging analysis was performed with in-house developed software, 
programmed in a matlab 7.1(R14) environment (The MathWorks, Natick, Massachusetts, 
united States of America), as described previously.14 Segmental circumferential strain 
(cs) was calculated from Lagrangian strain as a percent change in length of a small line 
segment in the circumferential direction. Since myocardial fibers of the mid lv wall are 
predominantly oriented circumferentially and lie within the short axis image plane, cs was 
calculated only from mid 50 percent of the lv wall.15 from these segmental cs datasets, 
peak systolic cs (peak scs) and peak diastolic cs rate (peak dcsr) were determined.
Late Gadolinium enhancement imaging. Late Gadolinium enhancement (lge) images were 
obtained 10-15 minutes after injection of 0.2 mmol.kg-1 gadolinium-dtpa.16 A single breath-
hold, inversion recovery turbo fast Low Angle Shot (flash) sequence was used. Image 
parameters were: 5 mm slice thickness, repetition time 4.0 ms, echo time 4.4 ms, flip angle 
25 degrees and typical in-plane image resolution 1.3 by 1.3 mm. All lge images were ecg-
gated to end-diastole and planned at the same image positions as the long and short axis lv 
cines. The extent of lge was quantified using semi-automatic commercially available mass 
software (Medis medical imaging systems, Leiden, the Netherlands) defining a signal 
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intensity over 2 standard deviations above the mean signal intensity of a region of interest 
drawn in remote myocardium in the same slice as where the lge was present 17
Flow measurement. flow measurement in the aorta was performed with a retrospective 
triggered fast low angle shot (flash) phase-contrast technique with a velocity sensitivity 
set at 150 cm∙s-1.18 The image plane was planned perpendicular to the ascending aorta. 
Acquisition of the entire cardiac cycle was achieved by setting the acquisition window to 
120 percent of the cardiac cycle length. In order to obtain aortic sv, a region of interest was 
drawn manually on the endovascular cross-section of the aorta on the modulus images 
of the flash phase contrast sequences using flow software (Medis medical imaging 
systems, Leiden, The Netherlands). These contours were automatically transferred to the 
phase contrast images, from which sv was calculated. Quantitative mitral regurgitation 
was determined by subtracting aortic sv from lvsv. Total cmr acquisition time was 
approximately 1 hour.
Echocardiography
2d and Doppler-echocardiography was performed using a General electrics vivid-7, 
(ge vingmed ultrasound, Horten, Norway) ultrasound system. echopac (ge, Horten, 
Norway), was used for offline analysis of recordings. Values of presented parameters are 
the means of 3 recorded measurements per parameter. The echocardiogram was performed 
immediately before or after the cmr study to have comparable physiological conditions of 
the participants between both acquisitions.
Pulsed-wave Doppler recordings at the tip of the mitral leaflets were used to measure 
mitral valve inflow(mvi) peak early filling velocity (e-wave), mvi peak atrial filling velocity 
(a-wave), e/a ratio and mvi e-wave deceleration time. The peak lvot gradient was measured 
at rest using the modified Bernoulli equation on a parasternal long axis view. 
Continuous wave Doppler was used to record isovolumetric relaxation time (ivrt) on a 5 
chamber apical view, including both the lvot and lv inflow tract.
Color tissue Doppler imaging was performed on an apical 4-chamber view using a 2.5-
MHz transducer and frame rates of >80/second. Systolic (sa), early diastolic (ea) and late 
diastolic (aa) peak myocardial velocities of the septal and lateral mitral valve annulus 
were obtained by placing a 6-mm sample volume at the junction of the mitral annulus 
at septal and lateral myocardial wall. The angle of incidence between the scan lines and 
motion of the base of the heart was minimized. 
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Statistical Analysis
All data are presented as mean ± standard deviation. A Kolmogorow-Smirnov test was 
used to assess the normality of distribution of scores. The unpaired Student’s t-test was 
used for comparison of normally distributed global continuous parameters between hcm 
patients and controls. A paired Student s´ t-test was used to describe the scores of global 
parameters before and after asa. Pearson s´ correlation test was used for assessment of 
bivariate correlations between continuous variables. for segmental analysis of edwt, 
wall thickening, peak scs and peak dcsr, interdependency of segments within patients 
and slices was considered. Therefore, multilevel analysis allowing random intercepts 
per slices and patients was performed. 
   With multiple regression analysis, the effects of infarct size, lvot gradient, lv mass/
volume ratio, lateral e/ea ratio and mitral regurgitation on lamax and nt-probnp were 
determined, using stepwise entry when p-values were <0.05 in univariate analysis. The 
models were evaluated for interaction of main effects and adjusted when appropriate. 
mlwin 2.02 (Center of MultiLevel Modelling (Bristol, united Kingdom) was used for 
multilevel analysis and Statistical Package of Social Sciences (spss for windows 14.0, 
Chicago, Illinois, united States of America) for all other statistical analysis. 
   A two-sided p-value at the <0.05 level was considered statistically significant. The 
authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written.
results
of sixteen included hcm patients, one patient was lost in follow-up for cmr due to icd 
implantation for sustained ventricular tachycardia’s after asa. Controls tended to be 
younger, but this was not significant (p=0.22), see table 1. Blood pressures and heart 
rates were comparable between hcm patients and controls, but nt-probnp levels (p<0.01) 
were higher in hcm patients. Myocardial tissue tagging data of two hcm patients was not 
analysable due to inconsistency in repetitive breath holding.
Global lv and la volumes of hcm patients and controls 
lvedv, lvesv and lvef were comparable between hcm patients and controls, see table 2. lv 
mass was substantially larger in hcm patients compared to controls (97±30 versus 48±8 
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g∙m-2, p<0.001), as well as lv mass/volume ratio (p<0.001), see table 2. lvsv was comparable 
between hcm patients and controls (59±10 versus 56±7 mL·m-2, p=0.73), but aortic sv was 
significantly smaller in hcm patients compared to controls, due to the moderate mitral 
regurgitation in hcm patients (p<0.001), see table 2.
   Both lamin (p<0.01) and lamax (p<0.01) were larger in hcm patients compared to 
controls, and also the end-diastolic la/lv ratio was larger in hcm patients compared to 
controls (p<0.01), see table 2. la passive emptying volume was comparable between hcm 
patients and controls (16±5 versus 14±6 mL·m-2, p=0.42). Although la volume prior to 
atrial contraction was larger in hcm patients compared to controls (52±15 versus 34±6 
mL∙m-2, p<0.01), laef was smaller (p<0.05), see table 2. However, la active emptying 
volume was larger in hcm patients compared to controls (17±5 mL∙m-2 versus 14±3 mL·m-2, 
p<0.05).
   As a consequence, filling of lv in hcm patients was more dependent of la active emptying 
in hcm patients compared to controls (p<0.05) , see table 2. Conduit volume and subsequent 
contribution to lv filling was comparable between hcm patients and controls (30±10 versus 
28±5 mL·m-2, p=0.89), see table 2.
Table 1. Clinical parameters before and after alcohol septal ablation
Controls(n=15) Hcm before asa (n=16) Hcm after asa (n=16)
Age (years) 49±11 55±12 56±12
Gender (male/female) 10/5 10/6 10/6
Systolic bp (mmHg) 124±13 122±17 128±15
Diastolic bp (mmHg) 75±7 74±9 77±9
Heart rate (beats∙ min-1) 69±9 63±10 67±10
nt-probnp (pmol∙L-1) 58±55 563±577† 298±372*§
nyha class I 15(100%) - 10(63%)†#
II - 6(41%) 6(37%)
III - 10(59%) 0
lvot gradient (mmHg) - 50.1±35 20±16║
Data are presented as mean±S.D. asa= alcohol septal ablation, bp= blood pressure, hcm= 
hypertrophic cardiomyopathy patients, lvot = left ventricular outflow tract, nt-probnp= N-terminal 
pro brain natriuretic peptide, nyha= functional New York Heart Association class. *= p<0.05, †= 
p<0.01, ‡= p<0.001 versus controls. § = p<0.05, ║= p<0.01, # = p<0.001 versus before asa
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Table 2. Global left ventricular and left atrial parameters determined by cmr 
Controls 
(n=15)
Hcm before asa 
(n=16) Hcm after asa (n=15)
lvedv (mL∙m-2) 93±15 95±12 90±13
lvesv (mL∙m-2) 35±7 35±10 35±8
lvef (%) 61±6 63±6 62±7
lv mass/volume 0.5±0.1 1.1±0.3‡ 0.9±0.3‡║
Aortic sv (mL∙m-2) 52±7 41±10† 46±9║
Mitral regurgitation (mL∙m-2) 5±5 19±11‡ 9±8#
lge (%)     - 5±8 18±11#
la minimal volume (mL∙m-2) 20±4 37±16† 28±9†§
la maximal volume (mL∙m-2) 49±8 69±15† 55±13*§
la ejection function (%) 41±7 31±13* 34±11*
contribution to lv filling of
la passive emptying (%) 27±8 23±8 19±9*
la active emptying (%) 24±5 32±10* 29±6*
conduit volume (%) 48±5 45±11 49±16
end-diastolic la/lv ratio (%) 0.2±0.1 0.4±0.1† 0.3±0.1†
end-systolic la/lv ratio (%) 1.4±0.3 2.1±0.8† 1.7±0.5*
Data are presented as mean± standard deviation. Volumes and mass are indexed to body surface 
area. edv= end diastolic volume, esv= end systolic volume, ef=ejection fraction, hcm= hypertrophic 
cardiomyopathy patients, la= left atrial, lge= late gadolinium enhancement, lv=left ventricular, ot= 
outflow tract. *= p<0.05, †= p<0.01, ‡= p<0.001 versus controls. § = p<0.05, ║= p<0.01, # = p<0.001 
versus before asa
Flow patterns and longitudinal myocardial velocities of hcm patients and controls
ivrt was larger in hcm patients compared to controls (p<0.05) and mitral valve inflow 
e/a ratio was lower (p<0.001), see table 3. This is line with the smaller contribution of la 
passive emptying to lv filling and increased dependency on la active emptying found 
with the cmr la volume measurements, see table 2. In addition to lower peak scs and peak 
dcsr in hcm patients, the longitudinal septal and lateral myocardial velocities in systole 
(p<0.001) and early diastole (p<0.001) were significantly lower in hcm patients compared 
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to controls, see table 3. As a result, both septal (p<0.01) and lateral (p<0.01) e/ea ratios 
were increased, indicating increased lv filling pressures.
   With univariate analysis, lamax significantly correlated with lv mass/volume ratio 
(r=0.45, p<0.01, mitral regurgitation (r=0.68, p<0.001) and lateral e/ea ratio (r=0.62, 
p<0.01), but not with lvot gradient (r=0.11, p=0.67) and extent of lge (r=0.24, p=0.19). 
With multivariate analysis, mitral regurgitation (r2=0.59, p<0.01) was the only independent 
determinant of lamax. Also, increase of lamax was strongly correlated with decreased of 
laef (r=-0.80, p<0.001), see figure 1.
   With univariate analysis, nt-probnp levels were correlated with lamax (r=0.81, p<0.001), 
la ejection function (r=-0.79, p<0.001), laef (r=-0.79, p<0.001), extent of lge (r=0.49, 
p<0.01), lv mass/volume ratio (r=0.52, p<0.01), mitral regurgitation (r=0.54, p<0.001) and 
lateral e/ea ratio (r=0.61, p<0.01), but not with lvot gradient (r=0.28, p=0.31). Multivariate 
Table 3. Parameters of diastolic function determined by echocardiography 
Controls (n=15) Before asa (n=16) After asa (n=16)
ivrt (ms) 74±19 94±30* 106±32†
mvi e-wave (cm∙s-1) 86±13 98±25 81±21§
A-wave (cm∙s-1) 65±11 93±26† 99±36†
e/a ratio 1.4±0.3 1.1±0.4* 0.9±0.4†║
Deceleration time (ms) 200±37 259±84* 264±96*
Septal Sa (cm∙s-1) 9±2 7±1† 6±1‡§
ea (cm∙s-1) 10±3 6±2‡ 6±1‡
Aa (cm∙s-1) 10±2 8±2* 8±3
e/ea ratio 9±2 20±9† 19±7‡
Lateral Sa (cm∙s-1) 12±2 8±2 ‡ 7±2‡
ea (cm∙s-1) 13±3 7±2‡ 9±3‡ #
Aa (cm∙s-1) 10±2 8±3 9±3
e/ea ratio 7±2 18±11† 11±4‡║
Data are presented as mean±standard deviation. Aa= peak late diastolic myocardial velocity, A-wave 
= peak late diastolic mvi velocity, asa= alcohol septal ablation, ea = peak early-diastolic myocardial 
velocity, e-wave= peak early diastolic mvi velocity, ivrt = ivovolumetric relaxation time, mvi= mitral 
valve inflow, Sa = peak systolic myocardial velocity. *= p<0.05, †= p<0.01, ‡= p<0.001 versus controls. 
§ = p<0.05, ║= p<0.01, # = p<0.001 versus before asa
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Figure 1. Correlations between la maximum volume and la ejection function (A) and nt-probnp levels 
and la maximum volume (B). Controls are indicated by solid dots and hcm patients by open dots. After 
multivariate analysis la max was the only independent determinant of nt-probnp.
analysis showed that lamax was the only independent determinant of nt-probnp in hcm 
(r2=0.57, p<0.001), see figure 1.
Segmental lv dimensions and circumferential strain
Averaged peak septal edwt was larger in hcm patients compared to controls (15.1±3.5 
versus 7.34±1.5 mm, p<0.001). Also, mean edwt was larger in hcm patients compared 
to controls in all regions, see table 4. Wall thickening was comparable in all lv regions 
between hcm patients and controls, see table 4. However, peak scs was less. in hcm 
patients compared to controls in all regions (p<0.05), especially in the septum (p<0.01) 
and peak dcsr was significantly reduced in all regions in hcm patients compared to 
controls (p<0.001).
Effects of asa on lv and lv volumes and function
The lvot gradient and nt-probnp levels were significantly reduced after asa (p<0.01 and 
p<0.05 respectively), and nyha class improved (p<0.01), see table 1. lvedv tended to be 
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Figure 2. Correlations between change in la maximum volume and change in mitral regurgitation (A) 
and lateral e/ea ratio (B) after asa. After multivariate analysis, change in lateral e/ea ratio was the only 
independent determinant of change in la maximum volume after asa.
reduced (p=0.10) after asa, but lvesv remained unaltered (from 35±10 to 35±8 mL·m-2 , 
p=0.98). As a result, lvsv was reduced after asa (from 59±10 to 55±10 mL·m-2, p<0.05). 
Total lv mass was reduced after asa (from 97±30 to 82±33 g·m-2, p<0.05), as well as lv 
mass/volume ratio, see table 2. In contrast to lvsv, aortic sv increased after asa (p<0.05), 
due to a significant reduction of mitral regurgitation (p<0.001), see table 2.
Both lamin (p<0.05) and lamax (p<0.05) were reduced after asa, see table 2. Also, la 
volume prior to atrial contraction was reduced after asa (from 52±15 to 45±11 mL·m-2, 
p<0.05), see table 3. The contribution of la passive emptying, active emptying and conduit 
volume to filling of the lv did not change significantly, see table 2. Absolute conduit 
volume also did not increase after asa (30±10 versus 29±8, p=0.19). 
   The increase of ivrt and decrease of e/a ratio (p<0.01) after asa indicate that before 
asa, pseudonormalization of e/a ratio had occurred, see table 3. The decrease of e/a was 
the result of reduction of mvi e-wave velocities (p<0.05), and maintenance of mvi a-wave 
velocities after asa (p=0.21), see table 3. Also, a significant increase of lateral but not 
septal ea was observed after asa (p<0.001). As a consequence, lateral e/ea ratio decreased 
after asa (p<0.01) but was still higher compared to controls (p<0.001), see table 3.
   on a regional level, edwt was significantly reduced after asa, not only in the septum 
(p<0.001), but also in adjacent (p<0.001) and lateral regions (p<0.01), see table 4. 
Concomitant with the reduction of edwt, wall thickening (p<0.001) and peak scs (p<0.001) 
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Table 4. Regional left ventricular parameters before and after alcohol septal ablation
Overall
(n=512)
septum 
(n=160)
adjacent
(n=192)
lateral
(n=160)
edwt (mm) controls 5.3±1.3 5.9±1.5 4.8±1.1 5.0±1.1
hcm before asa 9.4±3.0‡ 10.9±3.8‡ 9.3±2.6‡ 8.1±1.6‡
hcm after asa 8.6±3.0‡# 9.9±3.6‡# 8.4±2.7‡# 7.4±1.8‡║
Wall thickening (%) controls 84±31 73±28 87±32 92±31
hcm before asa 81±35 57±17 77±12 94±17
hcm after asa 76±40# 39±13*# 79±21 87±20
peak scs (%) controls -17.9±3.6 -16.2±3.7 -16.2±3.2 -18.3±3.5
hcm before asa -14.7±3.4* -13.6±3.3† -14.3±3.5‡ -16.1±2.7*
hcm after asa -13.5±4.1‡# -11.9±3.0‡# -13.3±3.7‡║ -15.2±4.7‡§
peak scsr (%∙s-1) controls -102±28 -99.2±25 -104±32 -102±24
hcm before asa -89.0±19 -83.0±20‡ -89.2±19 -94.6±16
hcm after asa -95.1±27║ -83.3±25‡ -101±25║ -101±26
peak dcsr (%∙s-1) controls 103±38 100±35 101±40 108±38
hcm before asa 78.7±26‡ 75.2±23‡ 81.0±26‡ 79.7±28‡
hcm after asa 84.7±33‡ 78.5±35‡ 82.8±29† 92.8±35†§
Data are presented as mean± standard deviation. asa= alcohol septal ablation, edwt= end diastolic wall 
thickening, peak scs= peak systolic circumferential strain, peak scsr= peak systolic circumferential 
strain rate, peak dcsr= peak diastolic circumferential strain rate. *= p<0.05, †= p<0.01, ‡= p<0.001. §= 
p<0.05, versus controls ║= p<0.01, # = p<0.001 versus before asa
were reduced, see table 4. In contrast, Peak dcsr remained constant in the septum and 
adjacent regions, and was only significantly increased in the lateral regions (p<0.05). 
   With univariate analysis, change in infarct size and lvot gradient reduction did not 
significantly correlate with change in lamax, but change in lv mass/volume ratio (r=0.45, 
p<0.05), mitral regurgitation (r=0.68, p<0.01) and lateral e/ea ratio (r=0.77, p<0.01) did, see 
figure 2. With multivariate analysis, change in lateral e/ea ratio was the only independent 
determinant of change in la max after asa (r2=0.55, p<0.05).
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discussion
In the present study, it was shown that in hcm patients, both systolic and diastolic regional 
dysfunction were present not only in the septum, but in the adjacent and lateral regions of 
the lv as well. In addition, la max was increased and laef reduced. The larger lamax in 
hcm patients compared to controls was strongly related to the extent of mitral regurgitation, 
which was the strongest determinant of nt-probnp and laef in hcm. 
   After asa, lvot gradient, la max, nt-probnp levels, functional nyha class and mitral 
regurgitation were significantly reduced. lvef was preserved, but on a regional level, peak 
scs and wall thickening both decreased. Although edwt was reduced in all lv regions, e/ea 
ratio and peak dcsr only improved in the lateral lv wall. The improvement of diastolic 
function was the strongest determinant of reduction of la max after asa.
   Increased nt-probnp levels have previously been reported in clinically stable hcm patients 
and related to lv mass, functional nyha class and e/ea ratio.19-21 However, this is the first 
study that demonstrates that la max was the only independent determinant of nt-probnp 
levels in hcm. This is in line with a study performed in a population of diastolic heart failure 
patients.22 Although nt-probnp is produced by both ventricular and atrial cardiomyocytes 
in response to stretch, these data suggest that in clinically stable hcm patients, nt-probnp 
is mainly produced by atrial cardiomyocytes, since lv wall stretch is compensated by 
increased lv mass/volume ratio.
   The negative correlation of nt-probnp with laef found in this study suggests that nt-
probnp release may also probe la failure. As such, increase of nt-probnp levels may indeed 
be used as a marker to initiate recompensation therapy in hcm patients, since filling of 
the lv increasingly depends on la active emptying. Moreover, increased la volumes are 
considered a risk factor for atrial fibrillation and subsequent risk of thrombo-embolism 
and hcm related death in these patients.10, 23-25
   Interestingly, mitral regurgitation was found to be the strongest predictor of la max in 
hcm patients. In hcm, mitral regurgitation is not only caused by the sam due to the lvot 
obstruction, but also ensues from deformation of the mitral valve apparatus, which is 
often found in hcm patients. This explains the strong relation between both parameters.26 
Also, mitral regurgitation in hcm patients causes overestimation of lvef as a parameter of 
systolic function.27 As shown in this study, lvef was preserved, but aortic sv measurement 
revealed that forward sv was reduced before asa. After asa, mitral regurgitation was 
reduced and aortic sv improved.
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   Also, peak scs was less in hcm patients compared to controls. However, the lvot 
obstruction seems to cause a relative increase of peak scs in hcm patients, since peak scs 
was further reduced after asa.28 The relative increase of peak scs is probably caused by 
increased inotropy due to increased afterload, but may also result from the concomitant 
mitral regurgitation. If the peak scs would not be affected by mitral regurgitation, the 
reduction of peak scs found after asa would parallel a decrease in aortic sv. Since our 
observations reveal the contrary, mitral regurgitation indeed must to some extent affect 
regional peak scs. We only measured circumferential strain, however whether systolic 
strain in other direction is also affected by mitral regurgitation still needs to be further 
evaluated.
   Importantly, the results of this study show indirect evidence of decreased lv filling 
pressures and improvement of diastolic function; la max was significantly reduced after 
asa, lateral e/ea ratio was increased and mvi e-wave and e/a ratio were significantly reduced, 
indicating that according to ommen et al, the grade of diastolic dysfunction regresses 
from II to I after asa in this hcm population.29,30
   Despite regression of edwt in all lv regions, which has been described previously, diastolic 
function only improved in the lateral regions after asa, as confirmed by improvement 
of both peak dcsr and lateral ea.7 This discrepancy may be caused by differences in 
myocardial architecture of the myofibers between the septum and the lateral lv wall, since 
in hcm patients, myocyte disarray mainly affects the septum, but usually not the lateral 
wall.11, 31, 32 In addition, a discrete infarct in induced in the septum by asa may also have 
contributed to prevention of improvement of function despite regression of edwt. 
Clinical implications
This study demonstrates that in hcm patients, not only diastolic, but also systolic lv 
dysfunction is present, and with afterload reduction by asa, sustained reduction of lvot 
gradient, mitral regurgitation and reserve remodelling of both the lv and the la can be 
achieved, resulting in improvement of both systolic and diastolic function.
   The results suggest that afterload reduction plays a key role for improvement of lv geometry 
and function in hcm. This may be pharmacologically achieved by inhibiting the renine-
angiotensin-aldosterone system when no lvot obstruction is present, since obstructive 
hcm is still considered a contra-indication for administration of angiotensin-converting-
enzyme inhibitors or angiotensin-II-receptor antagonists. Indeed, in experimental studies, 
both spironolactone, an aldosterone antagonist, as well as candesartan, an angiotensin-II-
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receptor antagonist have been shown to reduce hypertrophy and interstitial fibrosis in hcm 
animal models.33, 34
 These agents may prove to further induce lv and la reverse remodelling or prevent relapse 
and/or lvot obstruction. Therefore, application of these agents before lvot obstruction 
occurs, or after reduction of significant lvot obstruction may yield important therapeutic 
benefits in treating hcm patients. 
   The results of this study also indicate that not only diastolic function, but also mitral 
regurgitation plays and important role in la dilation in hcm. Therefore careful evaluation 
of the extent and nature of mitral regurgitation should be considered in hcm patients – not 
only at rest, but also during exercise - while incremental therapeutic benefit from mitral 
valve repair may be expected in a selected group of hcm patients with lvot obstruction.35
Limitations
Due to the comprehensiveness of this study protocol and strict selection of controls, subject 
numbers included were limited. However, this relatively small population was sufficient 
to demonstrate significant differences between hcm patients and controls and significant 
effects of asa.
   Strain analysis is a very sensitive method to assess regional intramyocardial function, 
but in order to obtain tagging cines with a temporal resolution suitable for evaluating 
early diastolic function, a multiple breath hold acquisition setup was necessary, which 
ultimately resulted in non-analysable datasets in two hcm patients. 
Conclusions
In hcm patients, both diastolic and systolic dysfunction are present, concomitant with 
increased la volumes, which was independently determined by mitral regurgitation. 
Increase of LA max is a strong determinant of nt-probnp levels and is related to a decrease 
of laef. Despite overall reduction of edwt, diastolic function only seems to improve in the 
lateral lv regions and is an independent determinant of la max reduction.
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AbstrAct
Background
Given the association between the extent of lge with progressive ventricular dilation and 
markers of sudden death in hcm patients, we hypothesized that lge may also be associated 
with af. Therefore, the purpose of this study was to evaluate the relation between atrial 
fibrillation (af) and the extent of myocardial scarring together with left ventricular (lv) 
and left atrial (la) dimensions in patients with hypertrophic cardiomyopathy (hcm) using 
cardiac magnetic resonance (cmr).
Methods
87 hcm patients underwent cine and late gadolinium enhancement (lge) cmr. lv function 
volumes, myocardial thickness, la volume and the extent of lge were assessed and 
retrospectively related to af.
Results
episodes of af were documented in 37 patients (42%). Indexed lv volumes and mass 
were comparable between hcm patients with and without af. However, indexed la volume 
was significantly higher in hcm patients with af than in hcm patients without af (66±24 
mL∙m-2 versus 46±18 mL·m-2, p<0.001, respectively). The mean extent of lge was higher 
in hcm patients with af than those without af (12.4±14.5% versus 6.0±8.6%, p<0.05). 
When adjusting for age, gender and lv mass, lge and indexed la volume significantly 
correlated to af (r=0.34, p<0.05 and r=0.42, p<0.001 respectively). Multivariate analysis 
demonstrated that la volume was the only independent determinant of af in hcm patients 
(p<0.05).
 
Conclusions
hcm patients with af display significantly more lge than hcm patients without af. la 
dilation is the strongest determinant of af in hcm patients, and is related to the extent of 
lge in the lv, irrespective of lv mass. 
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H ypertrophic cardiomyopathy (hcm) is a complex and relatively common form of genetic heart disease and the most frequent cause of sudden death in the 
young.1 hcm is macroscopically characterized by –often asymmetrical – left ventricular 
(lv) hypertrophy in the absence of any systemic or cardiac disease likely to cause this 
hypertrophy. Histologically, myocyte disarray, scarring and microvascular dysfunction 
are the hallmarks of hcm.
   Atrial fibrillation (af) is the most common arrhythmia in hcm 2-5. In general, af is 
associated with unfavorable prognosis secondary to an increased risk of heart failure-
related mortality, thrombo-embolism and severe functional impairment 6-10. In hcm patients, 
increased left atrial (la) size, advanced age and congestive heart failure symptoms have 
been shown to be independent predictors of the occurrence of af 11. However, the effect of 
scarring on the presence of af has not been evaluated yet.
   Cardiac magnetic resonance imaging (cmr) has a high spatial resolution, is considered 
the gold standard for in vivo determination of left ventricular (lv) mass and volumes, 
and enables precise quantification of wall thickness and dimensions 12, 13. Additionally, 
late gadolinium-enhanced (lge) cmr allows visualization of myocardial scarring in hcm 
patients 14, 15.
   Given the association between the extent of lge with progressive lv dilation, ventricular 
arrhythmias and markers of sudden death in hcm patients we hypothesized that the extent 
of lge might also be associated with the presence of af 16, 17. Thus, we used cmr to evaluate 
whether the extent of lge, lv and la size were associated with af in hcm patients.
methods
Study population 
In total, 102 consecutive hcm patients referred for cmr were selected between february 2003 
and December 2006 at 2 referral centers: 1st Department of Medicine, university Hospital 
of Mannheim, Germany and the Department of Cardiology, vu university Medical Center, 
Amsterdam, the Netherlands. All hcm patients were diagnosed based on conventional 
criteria; left ventricular hypertrophy ≥ 15 mm on two-dimensional echocardiography in 
the absence of another disease that could account for the hypertrophy 18.
   of 102 hcm patients, 15 patients were excluded due to concomitant coronary artery 
disease (n = 4), previous myocardial infarction (n = 3) or implantation of a pacemaker 
or defibrillator (n= 8), yielding a total of 87 patients included in this study (54 males and 
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33 females; mean age 58 ± 13 years). This study was approved by the institutional ethics 
committees of both participating medical centers and informed consent was obtained from 
all subjects.
cmr image acquisition 
All studies were performed using a 1.5 Tesla whole body imaging system (Magnetom Sonata, 
Siemens Medical Systems, erlangen, Germany). A dedicated four-element, phased-array body 
coil was used. Images were acquired during breath-holds in mild expiration. Scout images 
(coronal, sagittal and axial planes) were obtained for planning of the final double-oblique long-
axis and short-axis views. To evaluate functional parameters, ecg-gated cine images were 
then acquired using a balanced segmented steady state free precession (truefisp) sequence. 
   Typical scan parameters were: 5 mm slice thickness with 5 mm interslice gap, temporal 
resolution 35 ms, repetition time 3.2 ms, echo time 1.2 ms, flip angle 60 degrees, and typical 
in-plane spatial resolution 1.4x1.8 mm2. After obtaining standard 4, 3 and 2 chamber long 
axis cines, a stack of 9 to 12 short-axis slices was used for full coverage of the left and 
right ventricle. 
   The lge images were obtained 10-15 min after intravenous administration of 0.2 mmol∙kg-
1 gadolinium-dtpa (Magnevist, Schering AG, Berlin, Germany), using an inversion 
recovery turbo fast Low Angle Shot (flash) sequence with 6 mm slice thickness at the 
same position as the long- and short-axis cines in end diastole 19. The inversion time was 
adjusted per patient to optimally null signal from normal myocardium typically between 
250 and 300 ms. Total acquisition time averaged 40 minutes.
Left ventricular and left atrial image analysis
lv end diastolic volumes, lv end-systolic volumes, lv stroke volume, lv ejection fraction 
and lv myocardial mass were assessed off-line from the serial short-axis true fisp cine loops 
using dedicated commercially available software (ARGuS, Siemens, erlangen, Germany). 
In addition to volumetric measurements, one-dimensional measurements of lv end diastolic 
dimensions (lvedd), posterior wall thickness (pwt) and maximum interventricular septum 
wall thickness (swt) were measured from end diastolic short-axis views at the level of the 
papillary muscles. la volumes were measured at end systole by the biplane area-length 
method on 4 and 2 chamber long axis views 20.
   The extent of lge was quantified using semi-automatic commercially available software 
(mass, Medis, Leiden, the Netherlands) defining a signal intensity over 2 standard deviations 
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above the mean signal intensity of a region of interest drawn in remote myocardium in 
the same slice as where the lge was present 14. The extent of lge was then expressed as a 
percentage of the total lv mass to enable comparison of lge burden between patients with 
different lv mass. lv and la dimension and extent of lge were measured by 2 observers 
blinded to all clinical patient details (TP; TG). 
Atrial Fibrillation
af was documented based on ecg recordings obtained when patients presented with acute 
onset of symptoms or during routine medical examination including 24 hour ambulatory 
ecg monitoring in asymptomatic patients. af was classified into paroxysmal and persistent. 
af was considered paroxysmal when self-terminating and persistent when sustained over 
7 days.
Statistical Analysis
All data are presented as a mean ± standard deviation. For comparing lv ejection fraction, 
lv end-systolic volume, la volume, lv mass, and percentage of lge between hcm patients 
with and without af, independent 2-tailed student’s t-test were used. A Chi-square test 
was used to evaluate whether the percentage of both presence of lge and symptoms were 
different between hcm patients with and without af. Additionally, independent 2-tailed 
student’s t-tests were used too assess the difference in both lv and la dimensions and the 
extent of lge between asymptomatic (nyha I) and symptomatic hcm patients (nyha II-
Iv). 
   Pearson’s correlation was used to assess the relation between the extent of lge with 
both la volume and lv mass. To correct for age, gender and lv mass, we used partial 
correlations. A stepwise multivariate logistic regression analysis was performed with the 
following variables: la volume, extent of lge and lv mass, age and gender to evaluate 
which of these variables were independent predictors of af, provided to have a p<0.10 in 
the univariate analysis. 
   Area-under-curve analysis was performed to evaluate if la volume, extent of lge and 
lv mass influences the likelihood of having af in hcm patients. Additionally, receiver-
operator-curve analysis was used to determine the optional cut-off value of la volume, 
extent of lge and lv mass to discriminate patients at increased risk of af from patients 
without. All results were considered statistically significant when p<0.05. Analyses were 
performed with Statistical Package for Social Sciences (spss for windows 14.0, Chicago, 
il, usa).
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results
In 87 of included hcm patients, af was documented in 37 hcm patients (42%) at time of 
initial diagnosis or during follow-up. Baseline characteristics are presented in table 1. af 
was classified as paroxysmal in 22 patients (60%) and persistent in 15 patients (40%).
   Age, lv ejection fraction, lv end systolic volume, and lv mass were all comparable 
between hcm patients with and without af. However, lv end systolic volume tended to 
be larger and lv ejection fraction tended to be lower in hcm patients with af, see table 
2. la volume was significantly larger in hcm patients with af than in patients without af 
(p<0.001).
   In symptomatic hcm patients, lv end systolic volume (p<0.05) la volume (p<0.05) and 
extent of lge (p<0.05) were significantly larger compared to asymptomatic hcm patients, 
see table 3. af occurred in 41% of asymptomatic hcm patients and in 43% of symptomatic 
hcm patients, which was not significantly different. In symptomatic hcm patients, the 
proportion of hcm with persistent af tended to be larger compared to asymptomatic hcm 
patients (17% versus 5%, p=0.13).
   The mean extent of lge was higher in hcm patients with af compared to those without 
Table 1. Patient demographics and baseline characteristics
hcm patients (n=87)
Age (years) 58 ± 13
Male gender 54 (61%)
nyha functional class I 41 (47%)
II 39 (44%)
III 8 (9%)
family history of hcm or sudden death 20 (23%)
Syncope 6 (7%)
Atrial fibrillation None 50(57%)
Paroxysmal 27(31%)
Persistent 10(11%)
Maximum lv wall thickness >30 mm 4 (5%)
Data are presented as the mean value ± SD or number (%) of subjects. nyha = New york Heart 
Association; hcm= hypertrophic cardiomyopathy; vt = ventricular tachycardia; vf = ventricular 
fibrillation; lv = left ventricular
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Table 2. lv and la dimensions and extent of late gadolinium enhancement in hcm patients
Atrial fibrillation 
(n=37)
No atrial fibrillation 
(n=50)
p-value
Age (years) 59±15 56±11 0.40
lv ejection fraction (%) 56±10 61±10 0.07
lv mass (gr∙m-2) 97±31 99±34 0.76
lv edd (mm) 51±7 49±8 0.51
swt (mm) 19±6 18±4 0.28
pwt (mm) 10 ±3 11±3 0.28
lvedv (mL∙m-2) 86±23 79±20 0.16
lvesv (mL∙m-2) 37±14 31±11 0.07
lvsv (mL∙m-2) 49±15 50±15 0.89
la volume (mL∙m-2) 68±27 46±18 <0.001
lge (%) 12±14 6.0±9 <0.05
Data are presented as mean ± standard deviation. Volumes are indexed to body surface area. edd=end 
diastolic dimension, edv=end diastolic volume, esv=end systolic volume, la= left atrial, lge= late 
gadolinium enhancement, lv= left ventricular, pwt=posterior wall thickness, swt=septal wall thickness
(12.4±14.5% versus 6.0±8.6%, p<0.05). However, the prevalence of af was comparable 
between hcm patients with lge to those without lge (27/59, 46% versus 10/28, 35%, 
p=ns). When adjusting for age, gender and lv mass, both the extent of lge and la volume 
moderately correlated to af (r=0.34, p<0.05 and 0.42, p<0.001 respectively). Interestingly, 
la volume moderately but significantly correlated to the extent of lge (r=0.31, p<0.05), 
irrespective of lv mass (correlation with la volume r=0.08, p=ns).
   The univariate association between the presence of af with la volume and extent of lge 
was confirmed with RoC analysis, see figure 1. The receiver-operator curve indicates that 
cut-off value for la volume of 49.8 mL∙m-2 has optimal discriminative power to predict af, 
yielding a sensitivity of 80.8% and specificity of 64.1%. With respect to the extent of lge, 
an optimal cut-off value of 3.3% was found to have a sensitivity of 76.9% and a specificity 
of 59.0%, see figure 1.
   With multivariate logistic regression analysis, a model using both the extent of lge and 
la volume to predict af in hcm patients had an r-square of 0.29, p<0.01, and revealed that 
la volume was the only parameter that was independently associated with a history of af 
in hcm patients (p<0.01). 
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discussion
The present study demonstrates with state-of-the-art cmr imaging that hcm patients with 
af had larger la volumes and displayed more lge than hcm patients without af. Indeed, 
la volume was the only independent determinant of af and moderately correlated to the 
extent of lge irrespective of lv mass. Also, in symptomatic hcm patients, lv end-systolic 
volume and la volume were larger and extent of lge was higher compared to asymptomatic 
hcm patients, which is in line with previous reports16, 21. 
   Interestingly, paroxysmal af did not seem to be more prevalent in symptomatic hcm 
patients than asymptomatic hcm patients, but persistent af tended to have a higher 
prevalence in symptomatic hcm patients compared to asymptomatic hcm patients.
Af is a commonly reported complication of HCM (2,4,8,10). established af is uncommon 
in the young, but in adults its prevalence can reach up to 30% (23,24). Remarkably, the 
prevalence of Af in our study population was higher than previously reported. This may 
in part be due to the large number of follow-up visits, ecgs and 24 hours ambulatory eCG 
recordings in the majority of patients. Since Af is considered a key determinant of HCM-
related morbidity and mortality (7,10,11,12,23), the identification of predictors of Af is of 
paramount clinical importance.
Table 3. Comparison of lv and la dimensions between asymptomatic and symptomatic 
hcm patients.
asymptomatic hcm (n=41) symptomatic hcm (n=46) p-value
Atrial fibrillation
none 24(59%) 26(57%) 0.97
paroxysmal 15(37%) 12(26%) 0.41
persistent 2(5%) 8(17%) 0.13
lvef (%) 60±10 58±9.5 0.32
lv mass (gr∙m-2) 99±30 97±34 0.84
lvesv (mL∙m-2) 29±13 37±13 <0.05
la volume (mL∙m-2) 48±21 59±23 <0.05
lge (%) 6.0±9.0 11±13 <0.05
Data are presented as mean ± stadard deviation. Volumes are indexed to body surface area. hcm= 
hypertrophic cardiomyopathy patients, ef= ejection fraction, la= left atrial, lge= late gadolinium 
enhancement, lv= left ventricular.
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Figure 1. Receiver operating characteristic (RoC) curve analysis of left ventricular mass, extent of 
late gadolinium enhancement (lge) area and left atrial volume as a predictor of af. In the panel A, 
mean area-under-curve with 95% confidence intervals are presented. In the panel B, ROC curves are 
presented of extent of lge and left atrial volume to determine optimal cut-off values. la= left atrial, 
lv= left ventricular, lge=late gadolinium enhancement
   In a community-based hcm population, olivotto et al. found that the strongest predictor 
of af was increased la volume, independent of age and functional nyha functional class 
11. In addition to la volume, Losi et al reported that la fractional shortening and age were 
independent predictors for the development of af in hcm patients 22. However, interpretation 
of these studies may be difficult, while la volume measurement may be hindered by a poor 
acoustic window which is inherent to echocardiography. By using cmr, we merely omitted 
these limitations to measure la volume, and confirmed the importance of la volume in 
relation to af in hcm patients. In this cmr study, a la volume cut-off value of 50 mL∙m-2 
had an optimal discriminative power to predict af, yielding a sensitivity of 81% and a 
specificity of 64%. This cut-off value is comparable with the results from Losi et al, who 
found a cut-off value of 44 mL∙m-2 determined with echocardiography (25). 
   The strong relation between la dilation and af in hcm patients may be explained by the 
electrical and structural remodeling that occur in the process of la dilation, including 
shortening of the atrial effective refractory period and local conduction delay 23.
   In addition, af was associated with lge in hcm patients. However, not the presence but 
the extent was shown to be indicative for af. This is in line with the findings of a necropsy 
study of hcm patients performed by yamaji et al 24, who found that the extent of lv fibrosis 
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was significantly higher in hcm patients with af (24.4 ± 0.6%) than without af (17.6 ± 
0.7%). The total fibrotic burden in the lv found by yamaji et al was higher compared to our 
findings. This difference might be explained by the fact that patients in this necropsy study 
died from progressive hcm, which has been associated with an increased fibrotic burden in 
comparison with milder forms of hcm 16. Moreover, systematic underestimation of fibrosis 
quantification is an important limitation of lge imaging, by which only focal, but not 
diffuse areas of fibrosis can be visualized and quantified. In addition, the lv must remain 
in diastasis for at least 100 ms for optimal quality of the lge images. With shorter diastasis 
duration, blurring of the lge images and subsequent difficulty in lge assessment may 
occur, eg. in patients with uncontrolled af. Therefore faster, single shot lge cmr sequences 
have been developed that can be used to qualitatively assess lge in af patients and are 
widely used for clinical purposes, but are unsuitable for quantitative lge analysis in hcm 
patients. In this study, only hcm patients with af who had acceptable rate control were 
referred for cmr, which may have introduced a selection bias into our analysis.
   The underlying mechanisms relating lv lge to af are unknown. The histological 
background of lge in hcm patients has been suggest to be myocardial scarring and/or 
interstitial fibrosis15. focal areas of myocardial scarring have been related to ventricular 
arrhythmias, but may serve as anatomical substrates for af17. Interstitial fibrosis is 
produced by fibroblasts that are activated by cardiotrophic mediators, such as angiotensin 
II. In hcm, these mediators are upregulated putatively in response to decreased myocardial 
function, causing increased interstitial fibrosis deposition as well as impaired relaxation 
of the cardiomyocyte through altered Ca2+ handling. The altered Ca2+-handling together 
with increased interstitial fibrosis may ultimately lead to diastolic dysfunction of the lv 
and subsequent la dilation and explain the relation between the extent of lge, la dilation 
and subsequent af 25, 26. This statement was supported by the moderate, but significant 
correlation between with lge with la volume found in this study, which has not been 
described previously.
   In contrast to patients with hypertension and in normal population 27, 28, lv mass did 
not correlate to la dilation in these hcm patients, see figure 2. In hcm patients, mitral 
regurgitation, originating from systolic anterior motion of the mitral valve leaflet due to 
lv outflow tract obstruction and increased interstitial fibrosis and myocardial scarring also 
importantly attribute to increase of la volume. However, no quantitative data evaluating the 
relative contribution of the extent of lge, lv diastolic dysfunction and mitral regurgitation 
to la dilation in hcm patients are yet available.
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Figure 2. hcm patients with comparable left ventricular mass and different left atrial size. A, C. end 
diastolic 4 chamber cine images. Note that the left atrium of the first patient (A) is smaller compared 
to the left atrium of the second patient (C), despite comparable lv mass. The end diastolic short 
axis lge images (B,D) reveal that the first patient (B) has no lge, while the second patient (D) has 
extensive lge of the septum, as indicated by the white arrowheads.
   If the importance of fibrosis formation in diastolic dysfunction of the lv and subsequent 
la dilation is confirmed in hcm patients, this would stress the importance to investigate 
the potential salutary effects of angiotensin II blockade, statins and aldosteron antagonists, 
which has already been demonstrated experimentally to cause regression of fibrosis, 
hypertrophy and disarray in animal hcm models 29-31. Moreover, the strong relation 
between la dilation and af may justify to use la size > 50 mL∙m-2 determined with cmr 
as an indication to initiate oral anticoagulation, while af in hcm is often asymptomatic but 
increases the risk of thrombo-embolism. 
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Limitations
for cine and lge imaging, we used a gap of 5 and 4 mm between slices for full coverage of 
the left ventricle, thereby omitting 40 to 50% of total myocardium. This may potentially 
have introduced inaccuracy of volume and mass measurement, however, in a comparative 
study performed by Hogan et al, contiguous acquisition of slices and acquisition with 4 mm 
showed comparable accuracy and yielded comparable volumes (38). Also, the retrospective 
design may have caused under reporting of af, which may affect the results from this study. 
As mentioned previously, lge imaging systemically underestimates total burden of diffuse 
fibrosis, but a recent cmr study has shown promising results to overcome this limitation 32. 
In addition, the temporal resolution of cmr cine imaging was not sufficient to adequately 
assessed lv diastolic dysfunction. While it is intuitively likely that lge and la dilation are 
both related to diastolic dysfunction, this issue warrants further research.
Conclusions
hcm patients with a history of af display significantly more lge than hcm patients without 
af. la dilation is the strongest determinant of af in hcm patients, and is related to the extent 
of lge in the lv, irrespective of lv mass.
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summAry
C ardiac magnetic resonance imaging (cmr) is an imaging modality that allows accurate assessment of mechanical function and tissue characterization with a high spatial 
resolution. In clinical practice, the diagnostic potential of cmr is employed in ischemic 
cardiomyopathy i.e. to detect ischemia and viability. In non-ischemic cardiomyopathy, cmr 
is used to determine the aetiology of non-ischemic cardiomyopathies. 
   In this thesis, the high spatial resolution of cmr and its capabilities to assess regional 
myocardial deformation by strain analysis have been applied to explore the cardiac changes 
in the development of hypertrophic cardiomyopathy (hcm), emphasizing morphology, left 
ventricular (lv) and left atrial (la) volumes and diastolic function.
 
Chapter 1
In this chapter, an update of current literature on the genetic background, pathophysiological 
mechanisms and clinical management of hcm was provided. hcm has been associated with 
mutations in genes that mainly encode for sarcomeric proteins. Although the clinical 
course of hcm seems to be mutation specific, it is strongly influenced by other genetic and 
environmental factors. Since hcm usually develops in the first decades of life and patients 
may remain asymptomatic for years, identifying a causal mutation in a hcm patient allows 
to identify asymptomatic hcm mutation carriers without lv hypertrophy among first degree 
relatives. This enables close monitoring of these patients and timely initiation of therapy 
if necessary. 
   However, mutations are found in only 60 percent of hcm patients. In the remaining 40 
percent, screening for asymptomatic hcm patients among family members is confined 
to cardiological evaluation using electrocardiography (ecg) and echocardiography. These 
diagnostic modalities have shown to only display non-specific abnormalities before the 
development of manifest hcm. Therefore, additional screening methods are warranted. 
The mutations seem to predominantly affect diastolic function in human hcm mutation 
carriers with borderline hypertrophy, but it is currently unknown whether the diastolic 
dysfunction results from the increased lv mass, or may be recognized as the trigger for the 
development of hypertrophy.
Chapter 2
cmr tissue tagging is a technique used to non-invasively assess regional deformation 
(strain) and strain rate of the myocardium, and torsion. In this chapter the underlying 
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technique and its clinical application are discussed. cmr tagging with strain analysis has 
been shown to provide highly reproducible and sensitive data, being more sensitive in 
detecting regional abnormalities than wall motion assessment. Indeed, strain analysis has 
already been shown to detect diastolic dysfunction in overt hcm patients, and may thus be 
considered an excellent tool to evaluate diastolic function in hcm mutation carriers with 
normal wall thickness.
Chapter 3 
The diagnostic value of cmr in determining the aetiology of non-ischemic cardiomyopathies 
was discussed in this chapter. cmr cine imaging allows accurate determination of lv 
structure and can be used to easily diagnose non-compaction cardiomyopathy, which is 
a cardiomyopathy that may be difficult to differentiate from hcm by echocardiography. 
Also, the use of late Gadolinium enhancement (lge) imaging and t2* measurement has 
proven to provide a unique possibility to differentiate between different causes of left 
ventricular hypertrophy, including familial hcm, amyloidosis, Anderson-fabry disease 
and cardiac iron overload.
Chapter 4.1
Since planning of the image plane with cmr is not restricted by anatomical limitations, 
several methods can be applied to measure la volume with cmr. In chapter 4.1, a 3d 
and biplane cmr method were validated and compared with several widely applied 
echocardiographic techniques to measure la volumes. The 3d la volume measurement 
method was found to have the lowest inter- and interobserver variability.
   In addition, the acquisition is most likely less operator depended compared to the biplane 
techniques. Therefore, the 3d la volume measurement method is optimal for research 
purposes when accurate measurement of la volume is warranted. However, the time 
consuming acquisition and post processing time of the 3d la volume method currently 
restrict its wider use in clinical practice.
Chapter 4.2
Before measuring la volumes and function in hcm mutation carriers, the effect of normal 
ageing on the interaction between the la and lv was evaluated in 19 younger and 19 
middle aged healthy volunteers. With normal ageing, both absolute la volumes and la 
volumes relative to lv volumes increased, while the sum of la volume and lv remained 
constant (total left heart volume). The shift of volumes of la and lv in the older age group 
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correlated with the increase in lv mass-to-volume ratio (r=0.42, p<0.01), especially in 
males. In addition, the contribution of la passive emptying to filling of the lv was lower 
in the older age group, which was compensated by a higher contribution of la active 
emptying to lv filling. However, the largest contribution to lv filling in both age groups 
was made by the conduit volume, which is defined as the amount of blood that is directly 
‘sucked’ into the lv from the pulmonary veins, thereby using the la as a conduit.1. Indeed, 
conduit volume was shown to be lower in the older age group (p<0.05), which suggested 
that diastolic suction reduces with normal ageing.
Chapter 5 
The lv structure of 16 hcm mutation carriers with normal lv wall thickness was compared 
with 16 age- and gender matched controls and described in chapter 5.1. In 13/16 (81%) of 
hcm mutation carriers, crypts could be observed in the inferoseptal basal and mid segments, 
which were discernable in end-diastole with cmr only, and not with echocardiography. 
This explains why these structural abnormalities have never been described previously 
in pathological studies, since post-mortem hearts are always contracted to some extent. 
Interestingly, the crypts were also visualized in 4 hcm mutation carriers with a normal 
ecg. 
   In an image report described in chapter 5.2 the very prominent crypts of one HCM 
mutation carrier were, although initially undetected in the study described in chapter 
5.1, shown to be visible also on echocardiography and mimicked the appearance of non-
compaction cardiomyopathy.
   Whether non-compaction cardiomyopathy is a specific cardiomyopathy or a non-specific 
morphological trait is debated in a letter described in Chapter 5.3. Non-compaction has 
been related to hcm, but also to dilated cardiomyopathies. Also, many different genetic 
mutations that do not encode for one single specific structure of the cardiomyocyte have 
been associated with non-compaction cardiomyopathy. Therefore, further research on 
whether non-compaction cardiomyopathy may be regarded as a specific cardiomyopathy 
or as a striking, but non-specific morphological trait is necessary. Ideally, this should be 
performed with high resolution imaging techniques such as cmr.
Chapter 6
Regional diastolic and systolic dysfunction and lv and la dimensions of 28 hcm mutation 
carriers with normal wall thickness, were compared with age and gender matched healthy 
volunteers. In the majority of these healthy volunteers, hcm mutation carriership was excluded. 
196 |
Chapter 9.1
Diastolic and systolic function were determined by regional peak diastolic circumferential 
strain rates and regional peak systolic circumferential strain. Also, lv morphology was 
assessed. It was found that the asymmetrical distribution of wall thickness, which is one 
of the hallmarks for hcm, was already present very early in the disease process. Systolic 
dysfunction was significant in the free lv wall, but diastolic dysfunction was present in 
almost every segment. After multivariate analysis, the magnitude of diastolic and systolic 
circumferential strain were positively related to an increase of end-diastolic wall radius 
in healthy volunteers due to the frank-Starling mechanism. However, in hcm mutation 
carriers, both diastolic and systolic circumferential strain only minimally responded to 
increase of end-diastolic wall radius, suggesting a reduced efficacy of the Frank-Starling 
mechanism. This has been confirmed previously in experimental studies. Also, higher nt-
probnp levels were found in the hcm mutation carriers compared to controls.
   Moreover, diastolic function deteriorated with increase of end-diastolic wall thickness, 
while systolic function was relatively preserved up to an end-diastolic wall thickness of 10 
mm. The reduced diastolic function was also reflected in the larger la volumes found in 
hcm mutation carriers. This study strongly suggests that in human hcm mutation carriers, 
functional abnormalities precede the development of hypertrophy, which is in line with 
the findings of experimental studies on hcm animal models. of note, crypts were found in 
23/28 hcm mutation carriers and not in controls.
Chapter 7
The effects of reduction of lv outflow tract (lvot) obstruction by alcohol septal ablation 
(asa) on the interaction between la and lv was evaluated in 16 obstructive hcm patients. It 
was found that after asa, lv mass and la volumes were significantly reduced, which was 
independently related to improvement of diastolic function, as determined by lateral e/ea 
ratio (r2=0.59, p<0.001) and peak diastolic circumferential strain rate. 
   Despite reduction of end-diastolic wall thickness in both the septum and the lateral lv 
wall, improvement of diastolic function was only observed in the lateral lv wall. The 
diminished improvement of myocardial function in the septum was probably related to 
the presence of myocyte disarray within that lv region, or results from stiffening of the 
myocardium due the induced discrete infarct by asa. Also, quantitatively assessed mitral 
regurgitation was demonstrated to be significantly reduced after asa. In addition, nt-probnp 
levels were found to strongly correlate with la volumes (r2=0.57, p<0.01) but not with lv 
mass. The importance of la volume in hcm was further illustrated in chapter 8.
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Chapter 8
The relation between lge and la volumes with atrial fibrillation (af) in hcm patients was 
assessed in a multicenter study in 87 patients. It was found that hcm patients with af 
had larger la volumes than patients without af (66±24 mL·m-2 versus 46±18 mL·m-2, 
p<0.001) and displayed more lge (12.4±14.5% versus 6.0±8.6%, p<0.05). Indeed, lge 
significantly correlated with la volume (r=0.31, p<0.05), which was the only independent 
determinant of af. Also, it was found that the extent of lge was higher in symptomatic 
than in asymptomatic hcm patients (p<0.05).
future perspectives
Clinical implications
In hcm patients in whom no mutation is found, the first degree relatives should not only be 
screened for possible hcm mutation carriership solely by using ecg and echocardiography, 
but alternatively should undergo a cmr examination. This cmr examination should be 
focused on detecting crypt formation in the inferoseptum of the lv and presence of 
hypertrophy.
   Although the positive predictive value of the crypts is presumably high, the specificity 
of the crypts to hcm mutation carriership still needs to be determined in a referral based 
population, but was found to be low among first degree relatives of hcm mutation 
carriers.
   la dilation seems to play a pivotal role in the development of atrial fibrillation in hcm 
patients and could be used to monitor the progression of disease. Moreover, la volume 
may be used in clinical decision making, i.e. to perform lvot obstruction reduction by asa, 
while this has been demonstrated to significantly reduce la volumes. As an alternative 
for la volumes, nt-probnp may also be used as a marker of progression of disease or to 
monitor the effect of therapy in hcm patients, since this biomarker strongly correlated to 
la volume.
Directions for further research
The histological background of the crypts and their role in the development of hcm is 
currently unknown. We hypothesize that their presence may be related to extensive 
myocyte disarray, which is the histological hallmark of hcm. as such, the crypts may be 
one of the early morphological alterations of the lv that ultimately lead to overt hcm. To 
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confirm this hypothesis, long-term follow-up studies comparing the clinical course of hcm 
mutation carriers with and without crypts are ongoing.
   It is unlikely that histology of the crypts can easily be obtained from human hcm mutation 
carriers, since scd rate is fortunately extremely low in most hcm mutation carriers without 
hypertrophy. As an alternative, histology of hcm mouse models which are also known to 
develop asymmetric hypertrophy may be obtained in an early stage of disease.2 first, it 
must be determined if the crypts are also detectable with cmr in these mouse models.3, 4
   Afterload reduction by asa causes reduction of lv mass in obstructive hcm patients. 
This suggests that afterload reduction by pharmacological treatment may reduce or even 
prevent the development of hcm in hcm mutation carriers without hypertrophy.5 In hcm 
mouse models, angiotensin II and spironolactone have previously been shown to reduce 
the amount of interstitial fibrosis and improve diastolic function.6, 7 Therefore, the effects 
of these agents on the development of hypertrophy in hcm mutation carriers should be 
further investigated in a randomized, double blinded, multicenter setting.
   The results of the studies performed in this thesis demonstrate that cmr provides the 
unique possibility to accurately assess lv morphology and regional myocardial function, 
as well as global lv and la volumes in hcm mutation carriers in a single acquisition. This 
indicates that cmr should be the imaging modality of choice to study the efficacy of these 
agents in preventing development of hypertrophy in hcm mutation carriers.
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sAmenvAttinG
‘nieuwe inzichten in de morfologie en pathofysiologie 
van hypertrofische cardiomyopathie met behulp van 
magnetische resonantie imaging’
D e mogelijkheden van magnetische resonantie imaging (mri) om de mechanica en weefseleigenschappen van een orgaan te visualiseren, worden in de cardiologische 
praktijk veelal toepast om de oorzaak van dysfunctie van de linker ventrikel (lv) bij 
ischemische en niet-ischemische cardiomyopathie te achterhalen. Cardiale mri is een 
beeldvormende techniek met een hoog oplossend vermogen, waarmee de morfologie en 
structuur van het hart nauwkeurig bekeken kunnen worden. Daarnaast is het mogelijk 
om met een speciale cardiale mri techniek, zogenaamde ‘myocardial tissue tagging’, de 
intrinsieke vervorming van de hartspier te meten. 
   Deze unieke eigenschappen van cardiale mri zijn in dit proefschrift gebruikt om meer 
inzicht te krijgen in de morfologische en functionele veranderingen die optreden in het 
hart van een hypertrofische cardiomyopathie (hcm) mutatie drager voordat de ziekte zich 
uiteindelijk manifesteert.
Hoofdstuk 1 
In dit hoofdstuk wordt een overzicht gegeven van de meest recente literatuur over de 
genetische achtergronden van hcm en de functionele gevolgen daarvan voor de hartspier. 
Tevens wordt de huidige stand van zaken van de cardiologische behandeling van hcm 
beschreven.
   hcm wordt voornamelijk veroorzaakt door mutaties in genen die coderen voor eiwitten 
van het sarcomeer van de cardiomyocyt. Het klinisch beloop van hcm varieert van het 
ontwikkelen van milde klachten op latere leeftijd, tot het optreden van plotse dood op 
jonge leeftijd. Hoewel deze klinische variabiliteit deels verklaard kan worden door de 
causale mutatie, wordt deze ook sterk beïnvloed door andere genetische afwijkingen en 
omgevingsfactoren. Gezien het onvoorspelbare karakter van de ziekte, is het noodzakelijk 
om hcm al in een vroeg stadium op te sporen. 
   Indien de oorzakelijke mutatie bij de hcm patiënt bekend is geworden door middel van 
genetisch onderzoek, kan door het aantonen van dezelfde mutatie bij asymptomatische 
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familieleden, de ziekte al in een vroeg stadium opgespoord en, indien noodzakelijk, 
behandeld worden. Hoewel de detectiekans de laatste jaren flink is toegenomen, wordt 
tegenwoordig slechts in 60 procent van de hcm patiënten een mutatie gevonden. In de 
resterende 40 procent is screening van familieleden nu alleen mogelijk door middel van een 
electrocardiogram (ecg) en echocardiogram, die vaak geen specifieke afwijkingen laten zien 
wanneer hcm zich nog niet heeft gemanifesteerd. er zijn dus meer screeningsmogelijkheden 
nodig en het gebruik van cardiale mri zou daarvoor een goede methode zijn.
   In dierexperimentele studies bij hcm muizenmodellen blijkt de diastolische functie al in 
een vroeg stadium gecompromitteerd te zijn. Daarom is de verwachting dat diastolische 
dysfunctie ook bij mensen al in een vroeg stadium van de ziekte te detecteren valt. enerzijds 
kan de Lv diastolische dysfunctie direct in het myocard worden gemeten, anderzijds wordt 
het ook op indirecte wijze gereflecteerd door volume en functie van het linker atrium (la). 
ook in dierexperimenten werd eerder reeds aangetoond dat LA dilatatie al in een vroeg 
stadium van de ontwikkeling van hcm aanwezig is. een van de verklaringen van deze 
vroege diastolische dysfunctie lijkt te liggen in de verstoring van de normale architectuur 
van het myocard, de zogenaamde ‘myocyte disarray’, hetgeen kenmerkend is voor hcm. 
echter, met de huidige gangbare beeldvormende technieken zijn nog nooit structurele 
afwijkingen van het hart in hcm mutatie dragers zonder hypertrofie in vivo waargenomen.
Hoofdstuk 2 
De technische achtergrond en cardiologische toepassingen van ´ cmr tissue tagging´ worden 
in dit hoofdstuk beschreven. Met ‘cmr tissue tagging’ kan de regionale myocardiale 
vormverandering (strain), de vormveranderingssnelheid (strain rate), en de torsie van het 
hart op niet-invasieve wijze worden gemeten. Het voordeel van strain analyse ten opzichte 
van meting van wandverdikking als maat voor regionale functie, is dat het een zeer 
reproduceerbare en gevoelige techniek is om veranderingen in hartspierfunctie te kunnen 
waarnemen. verder blijkt dat met strain analyse diastolische dysfunctie kan worden 
gedetecteerd bij mensen met manifeste hcm.
Hoofdstuk 3
In hoofdstuk 3 komen de mogelijkheden aan bod om met cardiale mri een aantal niet-
ischemische oorzaken van een verminderde lv functie te achterhalen. Door het hoog 
oplossend vermogen van cardiale mri kan op betrekkelijk eenvoudige manier een non-
compaction cardiomyopathie van hcm worden onderscheiden, hetgeen bij echocardiografie 
nog weleens moeilijk blijkt. De toepassing van contrastmiddelen (Gadolinium) én de 
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ontwikkeling van mri-technieken waarmee ijzerstapeling in het myocard kan worden 
bepaald, maken het mogelijk om met cardiale mri op volledig niet- invasieve wijze 
verschillende oorzaken van een onbegrepen hartspierwandverdikking van elkaar te 
onderscheiden. voorbeelden van dergelijke oorzaken zijn hcm, cardiale amyloïdose, de 
ziekte van Anderson-fabry, en cardiale ijzerstapeling.
Hoofdstuk 4.1
Alvorens la volume en functie bij hcm mutatie dragers te onderzoeken, hebben wij eerst de 
optimale methode bepaald om la volume en functie met cardiale mri te meten. Aangezien 
het la een complexe geometrie heeft en opnamen met mri in elk denkbaar vlak kunnen 
worden gemaakt, zijn in hoofdstuk 4.1 verschillende la volume meetmethoden met elkaar 
vergeleken. Daarnaast is de accuraatheid van de mri meetmethoden vergeleken met die van 
in de cardiologische praktijk veelvuldig toegepaste echocardiografische meetmethoden. 
Hoewel gemiddeld genomen geen significante verschillen tussen mri en echocardiografie 
aantoonbaar waren, voldeed de 3d cardiale mri methode het beste vanwege de geringe 
inter- en intraobserver variabiliteit. Het nadeel van de 3d methode is echter dat zowel de 
acquisitie als het achteraf meten van het la volume relatief veel tijd vergt. Daarom is deze 
3d techniek met zijn hoogwaardige metingen van het LA met name geschikt voor het doen 
van onderzoek, maar niet voor het toepassen in de dagelijkse cardiologische praktijk. 
Hoofdstuk 4.2
Met behulp van de in hoofdstuk 4.1 ontwikkelde methode is in hoofdstuk 4.2 het effect 
van veroudering onderzocht op de interactie tussen la en lv in 19 jonge en 19 middelbare 
gezonde vrijwilligers. Bij veroudering bleek het la volume niet alleen in absolute zin toe 
te nemen, maar ook relatief ten opzichte van de lv. De som van het la en lv samen bleek 
tijdens het ouder worden echter constant te blijven. De veranderingen die optreden in 
de volumetrische verhouding tussen la en lv volume bleken gerelateerd te zijn aan een 
toename in de lv massa/volume verhouding, voornamelijk bij mannen (r=0.42, p<0.001). 
De bemoeilijkte vulling van de lv tijdens het ouder worden werd weerspiegeld door een 
afname van passieve vulling van de lv in de oudere groep. Dit werd gecompenseerd door 
een toename van de actieve bijdrage van het la aan de vulling van de lv aan het eind 
van de diastolische fase. echter, vulling van het lv bleek voor het belangrijkste gedeelte 
gegenereerd te worden door het conduit volume. Dit is het bloedvolume dat direct uit de 
longvenen in de lv ‘gezogen’ wordt, waarbij het la geen actieve rol speelt, en dus alleen als 
een conduit fungeert.1 Het conduit volume zou een maat voor diastolische functie van de 
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lv kunnen zijn en in overeenstemming met die gedachte bleek het significant afgenomen 
te zijn in de gezonde oudere groep (p<0.05). echter, het is ook mogelijk dat een afname 
van de aanzuigende werking van de lv gecompenseerd wordt door een toename van de 
druk in de longvenen, waardoor pseudo-normalisatie van het conduit volume optreedt, 
terwijl de diastolische dysfunctie juist verder toeneemt. De rol van het conduit volume als 
maat voor diastolische functie moet daarom nog verder onderzocht worden. 
Hoofdstuk 5 
In hoofdstuk 5.1 werd de morfologie van de lv van 16 hcm mutatie dragers met 
normale wanddikte vergeleken met 16 gezonde vrijwilligers die qua leeftijd en geslacht 
overeenkwamen. In 13/16 (81 procent) van de hcm mutatie dragers waren er crypten te zien 
in het basale en middelste deel van het inferoseptum terwijl deze niet aanwezig waren bij 
de gezonde vrijwilligers. De crypten waren alleen zichtbaar in de eind diastolische fase 
van de hartcyclus op dynamische cardiale mri beelden, en niet op echocardiografische 
beelden. Het feit dat deze crypten nooit eerder zijn beschreven in pathologie studies valt te 
verklaren doordat de hartspier zich na het overlijden in gecontraheerde toestand bevindt, 
waardoor deze crypten moeilijker waarneembaar zijn. Bij 4 hcm mutatie dragers werden 
de crypten geobserveerd zonder dat op het ecg afwijkingen te zien waren.
   Alhoewel de crypten niet gezien werden met echocardiografie in de studie die beschreven 
wordt in hoofdstuk 5.1, blijken zij met echocardiografie toch afgebeeld te kunnen worden 
bij een hcm mutatie drager met zeer uitgesproken crypten. op de echobeelden geven de 
crypten een indruk van een non-compactie cardiomyopathie. 
   Of non-compactie cardiomyopathie een specifieke cardiomyopathie is, of dat het om 
een opvallende, maar niet specifieke morfologische variabiliteit gaat, wordt ter discussie 
gesteld in hoofdstuk 5.3. Non-compactie cardiomyopathie blijkt niet alleen gerelateerd te 
zijn aan hcm, maar ook aan gedilateerde cardiomyopathieën. Daarnaast is non-compactie 
cardiomyopathie gerelateerd aan verschillende mutaties die niet voor een bepaalde structuur 
van de cardiomyocyt coderen. Dit pleit ervoor dat non-compactie cardiomyopathie niet een 
specifieke cardiomyopathie is, maar eerder een weliswaar opvallend, maar niet specifiek 
bijverschijnsel van cardiomyopathieën. Om dit echter definitief te kunnen vast stellen is 
meer onderzoek noodzakelijk en dient dat idealiter met cardiale mri verricht te worden.
Hoofdstuk 6 
In dit hoofdstuk wordt een studie beschreven waarbij la volume en strain is gemeten 
bij 28 hcm mutatie dragers met een normale lv wanddikte en vergeleken werd met een 
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groep gezonde vrijwilligers die in leeftijd en geslacht overeenkwamen en waarvan bij 
de meerheid (n=15) hcm mutatie dragerschap was uitgesloten. Globaal over de gehele lv 
genomen verschilde de systolische strain van de hcm mutatie dragers niet van de controle 
groep, maar regionaal gemeten was de strain lager in de vrije wand van de lv. Daarentegen 
was de vroege diastolische strain rate van hcm mutatie dragers verlaagd in vrijwel alle 
segmenten van de lv. Dit verschil was het meest uitgesproken in de vrije wand van de lv.
   De eind-diastolische radius van de lv wand vertoonde bij gezonde vrijwilligers een 
positieve correlatie met toename van functie (frank-Starling mechanisme), maar bleek bij 
hcm mutatie dragers vrijwel niet te correleren met verbetering van functie. Dit suggereert 
dat het frank-Starling mechanisme bij hcm mutatie dragers minder effectief is, zoals dat 
ook in versterkte mate het geval is bij hartfalen. Deze hypothese werd ondersteund door 
de bevinding dat bij hcm mutatie dragers het nt-probnp verhoogd was ten opzichte van de 
controle groep, zij het nog binnen de normale grenzen.
   De verminderde diastolische strain rate reflecteerde zich in een groter la volume bij de 
hcm mutatie dragers. De asymmetrie in wanddikte tussen het septum en de vrije wand 
van de lv, welke zo kenmerkend is voor hcm, bleek reeds in milde vorm aanwezig te zijn 
bij deze hcm mutatie dragers met normale wanddikten. De diastolische functie van hcm 
mutatie dragers verslechterde naarmate de wanddikte toenam terwijl de systolische functie 
relatief gespaard bleef tot een lv wanddikte van 10 mm. vanaf een lv wanddikte van 
10 mm nam ook de systolische functie af. Hieruit kon worden geconcludeerd dat vooral 
diastolische dysfunctie bij hcm mutatie dragers al in een zeer vroeg stadium aanwezig is, 
zelfs bij normale lv wanddikten, hetgeen sterk suggereert dat de hypertrofie die optreedt 
in hcm zich ontwikkelt ter compensatie van verminderde functie.
Hoofdstuk 7 
In dit hoofdstuk werd het effect van alcohol septum ablatie (asa) op de interactie 
tussen la en lv bestudeerd in 16 obstructieve hcm patiënten. Na asa waren lv massa en 
mitralisklepinsufficiëntie significant afgenomen. De afname van lv massa was niet alleen 
het gevolg van het door de asa veroorzaakte discrete infarct in het septum, maar ook door 
afname van wandverdikking in alle andere regionen van de lv. ondanks dat zowel de 
wanddikte in zowel het septum als de vrije wand was afgenomen, trad er alleen verbetering 
van diastolische functie op in de laterale wand. De diastolische functie was bepaald aan de 
hand van de e/ea ratio en de vroege diastolische circumferentiële strain rate. 
   ook was het la volume afgenomen. In univariate analyse correleerde zowel de afname 
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in mitralisklepinsufficiëntie (r=0.68, p<0.01) en de toename in laterale e/ea ratio (r=0.77, 
p<0.01) sterk met deze afname in la volume, maar na multivariate analyse bleek toename 
in laterale e/ea ratio de enige onafhankelijke determinant van deze afname (r2=0.59, 
p<0.001).
   verder bleek dat de grootte van het la volume en niet de mate van lv massa in hcm 
patiënten sterk gerelateerd is aan nt-probnp waarden (r2=0.57, p<0.01). Aangezien het la 
volume bij hcm patiënten het beloop van de ziekte in enige mate voorspelt, zou nt-probnp 
als alternatief gebruikt kunnen worden als maat voor progressie van ziekte, of om het 
effect van een behandeling te meten.
 
Hoofdstuk 8
In hoofdstuk 8 wordt de relatie tussen contrast aankleuring van het Lv myocard (duidend 
op de aanwezigheid van fibrose), la volume, en atrium fibrilleren (af) beschreven. Dit 
werd onderzocht bij 87 hcm patiënten in een multi-center studie. De resultaten laten zien 
dat het la volume bij hcm patiënten met af groter is dan bij hcm patiënten zonder af 
(66±24 mL·m-2 versus 46±18 mL·m-2, p<0.001), maar ook dat de gemiddelde hoeveelheid 
contrastaankleuring hoger is bij hcm patiënten met af dan hcm patiënten zonder af 
(12.4±14.5 procent versus 6.0±8.6 procent, p<0.05). Na multivariate analyse bleek dat 
de mate van contrast aankleuring correleerde met la volume (r=0.31, p<0.05), en dat la 
volume de enige onafhankelijke determinant was van af. Tevens bleek dat symptomatische 
hcm patiënten gemiddeld meer contrastaankleuring hadden dan asymptomatische hcm 
patiënten (p<0.05).
toeKomst perspectieven
Klinische toepassing van het onderzoek 
De eerstegraads familieleden van hcm patiënten bij wie geen mutatie kan worden vastgesteld 
zouden niet zoals thans gebruikelijk is, gescreend moeten worden voor hcm mutatie 
dragerschap met slechts een ecg en echocardiogram, maar ook met cardiale mri. Hierbij 
dient, naast hypertrofie, specifiek gelet te worden op de aanwezigheid van crypten. 
   Hoewel de positief voorspellende waarde van de aanwezigheid van deze crypten voor 
hcm mutatie dragerschap naar verwachting hoog is, is de specificiteit ervan in de populatie 
patiënten die allemaal voor een cardiale mri scan verwezen worden, nog onvoldoende 
bekend. Daarom is het nog te vroeg om te stellen dat crypten die bij toeval gevonden worden 
| 209
Samenvatting en toekomst perspectieven
ook met zekerheid duiden op hcm mutatie dragerschap. Wel kwam uit dit onderzoek naar 
voren dat de familieleden bij wie mutaties waren uitgesloten geen van allen uitgebreide 
crypten hadden. 
   Daarom kan gesteld worden dat indien crypten gevonden worden bij eerstegraads 
familieleden van hcm patiënten, hcm dragerschap wel zeer aannemelijk wordt. Anderzijds 
kan op basis van de afwezigheid van crypten, hcm dragerschap niet met zekerheid worden 
uitgesloten. Waarom de meeste hcm mutatie dragers wel crypten hebben maar sommigen 
niet, dient nog te worden uitgezocht.
   la grootte blijkt een centrale rol te spelen in de ontwikkeling van af bij hcm patiënten 
en zou derhalve gebruikt kunnen worden om de progressie van de ziekte te vervolgen. 
eveneens zou de grootte van het la belangrijk kunnen zijn bij het nemen van een klinisch 
besluit, bijvoorbeeld om een asa procedure uit te voeren. Deze ingreep bewerkstelligt 
een belangrijke verkleining van het la volume, en zal daardoor naar verwachting de kans 
op het ontwikkelen van af verkleinen. Als alternatief voor het meten van het la volume 
om hcm patiënten te monitoren en het effect van de therapie te meten, zou ook nt-probnp 
gebruikt kunnen worden, aangezien deze marker sterk correleert met de grootte van het 
la.
Suggesties voor verder onderzoek
De rol die de eerder beschreven crypten spelen in de ontwikkeling van hcm is nog onbekend. 
We nemen aan dat ze een uiting zijn van de ‘myocyte disarray’, en in dat opzicht wellicht 
in bepaalde mate het beloop van hcm zouden kunnen voorspellen. om dit aan te tonen is 
een onderzoek gestart waarin hcm mutatie dragers zonder wandverdikking - zowel met als 
zonder crypten - gedurende een lange tijd (minimaal 10 jaar) vervolgd worden. 
   ook de histologische achtergrond van de crypten is tot nu toe nog onbekend. Gelukkig 
komt plotse dood bijna niet voor onder de hcm mutatie dragers zonder wandverdikking. 
echter, daardoor is de kans klein dat de histologische ontwikkeling van deze crypten op 
korte termijn achterhaald kan worden. Als alternatief kan histologie van hcm muismodellen 
verkregen worden; daarvan is bekend dat zij de voor hcm patiënten zo kenmerkende 
asymmetrische wandverdikking van de lv ontwikkelen.2 eerst moet worden onderzocht 
of deze hcm muismodellen ook crypten ontwikkelen én of deze met een speciale muizen-
mri scanner waargenomen kunnen worden.2,3
   voorts komt uit dit onderzoek naar voren dat diastolische functie afwijkingen bij hcm 
mutatie dragers al in een heel vroeg stadium optreden, zelfs als de wanddikte nog geheel 
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normaal is. ook werd duidelijk dat de diastolische functie verbeterde als de druk waartegen 
het hart moest contraheren door asa verminderd werd. Dit doet sterk vermoeden dat 
bloeddruk verlagende medicijnen wellicht de ontwikkeling van hcm kunnen vertragen of 
zelfs stoppen.4 uit eerdere studies bij hcm diermodellen is al bekend dat bepaalde bloeddruk 
verlagende medicijnen (angiotensine II antagonisten en kalium sparende diuretica) de 
hoeveelheid fibrose deden verminderen en de diastolische functie verbeterden.5,6 om te 
onderzoeken of deze medicijnen bij hcm mutatie dragers de ontwikkeling van hcm kunnen 
remmen of zelfs kunnen tegengaan, is een gerandomiseerde, multi-center studie nodig. De 
verschillende onderzoeken uit dit proefschrift laten zien dat cardiale mri de beste modaliteit 
lijkt om de effecten van deze medicijnen in hcm mutatie dragers te kunnen evalueren. In 
steeds meer cardiogenetica centra wordt cardiale mri inmiddels routinematig uitgevoerd.
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B ijna 4 jaar geleden ben ik met speciale interesse in diastolische functie en cardiale mri aan dit onderzoek begonnen met als opdracht om de diastolische functie bij 
patiënten met een hypertrofische cardiomyopathie te onderzoeken. In het bijzonder wilde 
ik met behulp van cardiale mri de diastolische functie onderzoeken van mensen die drager 
waren van een hypertrofische cardiomyopathie mutatie, maar (nog) geen hypertrofie 
ontwikkeld hadden. uiteindelijk heeft dit uitgangspunt geleid tot het schrijven van dit 
proefschrift, hetgeen mogelijk is gemaakt door de samenwerking van velen. Graag wil 
ik een aantal mensen die een bijdrage hebben geleverd aan de totstandkoming van dit 
proefschrift bedanken.
   Allereerst alle participanten die deelnamen aan een van de studies; zonder hun 
bereidwilligheid om onbaatzuchtig één of soms twee dagen lang in het vu medisch 
centrum meerdere onderzoeken te ondergaan, zouden we de kennis die we met deze studies 
hebben opgedaan niet verkregen kunnen hebben. Ik hoop dat ik met de diagnostische 
mogelijkheden die de resultaten van dit proefschrift scheppen in ieder geval een deel van 
de schuld die ik aan hen heb, kan in lossen.
   Prof. dr. A.C. van Rossum, beste Bert, de mogelijkheden die jij als promotor aan mij 
hebt geboden om eigen ideeën om te zetten in wetenschappelijk onderzoek hebben ervoor 
gezorgd dat ik aan het vumc vier zeer leerzame onderzoeksjaren heb meegemaakt. vaak 
heb je mij geholpen door kritische vragen te stellen over het onderzoek, door mee te 
denken over bepaalde problemen en nauw betrokken te zijn bij het op/herschrijven van 
manuscripten en wil je daar graag voor bedanken.
   Dr. M.j.W. Götte, beste Marco, jij bent degene geweest die mij enthousiast heeft 
gemaakt voor de cardiale mri. je hebt mij - eerst met slecht mobiel bereik al rijdend tussen 
Joure en Lelystad, maar later als staflid in het vumc – geleerd systematisch onderzoek 
te doen en mijn hersenspinsels leesbaar op papier te zetten. Bedankt voor de plezierige 
samenwerking. 
   Prof. dr. A.A.M. Wilde, beste Arthur, door het beschikbaar stellen van de database 
van ge-genotypeerde hcm patiënten en familieleden van het amc, je betrokkenheid bij het 
onderzoek en het altijd snel beantwoorden van mijn vragen, heb je een belangrijke rol 
gespeeld in het tot stand komen van dit proefschrift. Ik ben je daar zeer dankbaar voor.
   In addition to prof. dr. A.C. van Rossum, prof. dr. A.A.M. Wilde and dr. M.j.W. Götte, 
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I would like to thank Prof. dr. G. Thiene, dr. M.j. Cramer, prof. dr. W.j. Paulus, prof. dr. 
e.j. Meijers-Heijboer, and prof. dr. C. van Kuijk for their willingness to participate in the 
promotion committee.
   Mary Belderok, heel hartelijk dank voor het rekruteren van de deelnemers aan het 
onderzoek en belangrijke ondersteuning bij het uitvoeren van het onderzoek; ik weer een 
van de vele artsonderzoekers met wie je hebt samengewerkt die tijdens hun onderzoekstijd 
trouwt en kinderen krijgt en wil je graag bedanken voor de plezierige samenwerking. 
   Drs. A.M. Beek, beste Aernout, je enthousiasme voor de cardiale mri en heldere manier 
van onderwijzen werkt erg motiverend en ik heb veel van je geleerd de afgelopen jaren. 
Hartelijk dank daarvoor en voor het meedenken over het onderzoek.
   De fysici van de cardiale MRI: dr. M.B.M Hofman, dr. j.P.A. Kuijer, dr. j. T. Marcus, 
ir. M. Rolf, ir. I.K. Rüssel en dr. j.j.M. Zwanenburg, heel hartelijk dank voor jullie 
fundamentele ondersteuning van dit onderzoek. 
   De cardiale mri laboranten, met name Milan van Tuin en josé van vught, ik heb veel 
respect voor de manier waarop jullie onder begeleiding van soms wel zes artsen een mri 
acquisitie binnen het toch al strakke tijdschema weten te volbrengen. Hartelijk dank voor 
jullie collegialiteit.
   De laboranten van de pet-scanner, met name Suzette van Balen, Rob Koopmans, 
Annemarie Greve-de Wildt en femke jongsma, heel hartelijk dank voor jullie plezierige 
samenwerking en professionele manier van werken.
   De laboranten van de echocardiografie, met name Yolanda de Groot en Irma Bekkering, 
heel hartelijk dank voor het nauwkeurig verzamelen van alle echodata voor deze studie. 
   The cardiac mri fellows who came from everywhere and stayed with us for a year to 
learn to perform cardiac mri and to do research: Gerry McCann, Bodgan Marcu, Nicola 
johnston, and Simon Koestner, thank you very much for your kind cooperation and interest 
in our research.
   De artsonderzoekers van de cardiale mri, ook wel de ‘spin-doctors’ genoemd, waarmee 
ik een periode heb samengewerkt: olga Bondarenko en jan Groothuis, bedankt voor het 
‘peer teaching’ en de gezelligheid. Succes met het afronden van jullie onderzoek. Mijn 
voorganger en wederhelft van deze dubbelpromotie Willem van Dockum, het is even wat 
werk, maar dan heb je ook wat! Gefeliciteerd alvast. Robin Nijveldt, met wie ik bijna vier 
jaar lang onderzoek gedaan heb. Robin, hartelijk dank voor je collegialiteit, de plezierige 
samenwerking en het meedenken en schrijven aan dit proefschrift. Geduld is iets waar we 
elkaar niet in aanvulden, waardoor sommigen zich afvroegen of de magnetische resonantie 
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echt van geen enkele invloed op het menselijk functioneren was. veel succes met het 
verdedigen van je proefschrift eind 2008.
   De artsonderzoekers van de pet en echocardiografie met wie ik heb samengewerkt en 
allen al gepromoveerd zijn of bijna gaan promoveren: Ivo van der Bilt, jeroen van Dijk, 
Pieter Dijkmans, Paul Knaapen en Ramon van Loon, heren, bedankt voor het ‘sparren’ 
over allerlei onderwerpen. De ‘nieuwe lichting’: farshid Afsharzada, Wessel Brouwer 
Stefan de Haan, Sebastiaan Kleijn, Gerjan de Roest en jeroen Slikkerveer, allen heel veel 
succes en plezier in de komende periode. 
   De overige leden van de staf cardiologie: dr. C.P. Allaart, dr. j.e.A. Appelman, drs. K. 
de Boer, drs. S.L. Brinckman, dr. j.G.f. Bronzwaer, dr. C.C. de Cock, dr. o. Kamp, drs. 
T.C. Konings, dr. K.M.j. Marques en dr. G. veen; allen hartelijk dank voor julie bijdrage 
aan het onderzoek.
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